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 Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease which affects about 
5 to 8 million individuals in the world. Despite the high prevalence, there is currently no 
cure for IPF, and the cause of this disease is still unclear. Our laboratory and 
collaborators have shown that nudix hydrolase 21 (NUDT21, which is also known as 
cleavage factor 25, CFIm25) is a key regulator of alternative polyadenylation (APA). 
NUDT21 depletion causes 3’UTR shortening via APA leading to enhanced mRNA 
stability and protein translation. This NUDT21 reduction promotes tumor growth in 
glioblastoma by enhancing expression of oncogenes. Cancer and IPF share cellular 
features, such as enhanced expression for pathological mediators and increased cell 
proliferation. However, whether APA plays a role in lung fibrosis is not known. Our results 
reveal that NUDT21 reduction is found in lung fibroblasts isolated from IPF patients. 
Depletion of NUDT21 causes 3’UTR shortening in pro-fibrotic genes, such as Wnt and 
TGFb1, leading to robust protein expression of the pathological genes and ultimately 
worsening of pulmonary fibrosis. Additionally, we found that TGFb1 depletes NUDT21 in 
fibroblasts by transcriptionally inducing miR203 through Smad3. Modulating NUDT21 by 
overexpression or antagomiR203 attenuated NUDT21 reduction-mediated fibrosis in 
vitro. The results of this dissertation are significant in that these findings broaden our 
understanding on the role of APA in fibrosis. The knowledge discovered in this project is 
potentially beneficial as these results may lead to identification of targets for novel 
therapies which can halt the progression of IPF.   
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CHAPTER ONE 
INTRODUCTION 
IDIOPATHIC PULMONARY FIBROSIS 
Definition and Epidemiology 
 Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unclear etiology and 
unique pathophysiological characterizations, such as over-scarring of the parenchyma 
and irreversible tissue remodeling (1). IPF affects more men than women; the sex-
specific prevalence is 20.2 and 13.2 per 100,000 persons for men and female 
respectively in the United States according to the epidemiological data acquired in 1990 
(2). A recent report showed that the overall prevalence and annual incidence of IPF are 
18.2 and 7.9 per 100,000 persons affecting up to 200,000 and about 5 to 8 million 
individuals in the United States and World (3–6). IPF has been an active area of research 
and clinical care due to the increasing incidence and prevalence of the disease (7). 
Nonetheless, therapeutic options are limited for IPF, and breakthroughs in the field are 
yet to come. 
 
Presentation and Diagnosis 
Patients with IPF display unspecific respiratory symptoms of the disease at their 
initial visit, such as progressive dyspnea, non-productive cough, or shortness of breath 
which significantly lower the quality of life (8, 9). In addition, clubbed fingers and fine 
crackles predominantly in the lower posterior lung areas are often found as the general 
symptoms of IPF on medical examination (9). The initial step of diagnosis for IPF is to 
exclude known causes of other interstitial lung diseases, such as previous exposure to 
asbestos, silica powders, and bird stool, through the King's Brief Interstitial Lung Disease 
questionnaire (K-BILD). This questionnaire is utilized to determine whether the lung 
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disease is truly idiopathic (8). As a standard of diagnosis, high resolution computated 
tomography (HRCT) is generally utilized to detect the presence of usual interstitial 
pneumonia (UIP) or other UIP-related radiological features, such as ground-glass opacity 
and honey-combing in IPF patients (8, 10, 11). However, for the cases of 
probable/possible UIP or non-classifiable fibrosis, lung biopsy can be performed to 
identify the class of ILD by detecting the presence of unique UIP patterns of IPF, such 
fibroblastic foci, involvement of fibrosis in subpleural area, and patchy fibrosis, although 
lung biopsy is recommended with caution due to its invasiveness to patients (8).  
  
Risk Factors 
 There is no known cause of IPF. Nonetheless, there are environmental, genetic, 
and medical factors that are significantly associated with IPF. Cigarette smoking is the 
most strongly associated risk factor for both familiar and sporadic IPF, and about 41 to 
83% of IPF patients have a history of ever smoking (12–14). The risk of IPF is elevated 
not just in current (the odd ratio = 2.3) but also former smokers (the odd ratio = 1.9), 
suggesting that the detrimental effects of cigarettes on IPF may not completely diminish 
over time (15). Occupational exposures to metal or wood dust have been significantly 
associated with the increased risk of IPF (16, 17). 
 Genetic mutations are associated with IPF (18).  In an early report of genetic 
mutations in IPF patients, it was discovered that a heterozygous mutation in surfactant 
protein C (SPC) causes the exon 4 to be skipped and the terminal 37 amino acid to be 
deleted leading to truncated and altered sequence of SPC. This dysregulation of SPC in 
AEC ultimately leads to pulmonary fibrosis (18). Another case report was published 
where a Q188L missense mutation in SPC in a family is strongly associated with IPF 
(19), suggesting that mutation in SPC is important for pulmonary fibrosis and there is 
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more than one type of mutation for a single gene potentially contributing to IPF. A more 
comprehensive report revealed that there are six additional mutations in SPC gene 
associated with IPF (20). Later, a subsequence mechanistic study demonstrated that 
these mutations in the BRICHOS domain of SPC cause misfolding and aggregation of 
the protein leading to epithelial injuries in AEC, such as ER stress and UPR response, 
contributing to the pathogenesis of IPF (21–23). However, whether these mutations are 
the cause of IPF is controversial because SPC mutations can only account for 1% of 
sporadic cases of IPF (24, 25). 
 An innovation in genomic sequencing revealed more than 6,000 single-nucleotide 
polymorphism (SNP) associated with IPF (26). Surfactant proteins A1, A2, and D were 
identified as potential candidates for mutation-mediated pathogenesis of IPF (26, 27). 
The genes involved in telomerase complex, TERT and TERC, were also found as 
candidates responsible for familiar IPF (28, 29). Interestingly, although the mutations in 
TERT or TERC are unique features of a subset of familiar IPF where genetic 
predisposition plays important roles for the pathogenesis, dysfunctions in these 
telomerase-related genes and shortened telomere are also found in some cases of 
sporadic IPF where environmental factors have more influence on the pathogenesis (30, 
31). This result is clinically important because maintaining telomere and preventing 
telomere-mediated cellular crisis may be beneficial not just to familiar but also to sporadic 
IPF.  
In 2011, a nucleotide polymorphism in the promoter region of MUC5B was 
identified to be associated with IPF (32). This SNP was found in 38% of the patients with 
sporadic IPF and 9% of heathy controls and is associated with 37.4 times higher 
expression of MUC5B, suggesting that this SNP on the promoter leads to overexpression. 
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Collectively, these studies demonstrate that a several genetic predispositions are risk 
factors of IPF.  
 A number of medical conditions are associated with IPF. Gastro-esophageal 
reflux disease (GERD) or acid reflux is significantly associated with IPF and about 87 % 
of IPF patients present GERD (33). Although it is still controversial whether GERD is a 
contributor of IPF or just a co-morbid condition, there are widely known hypotheses for 
the cause and role of GERD. It has been proposed for the high prevalence of GERD in 
IPF patients that GERD is frequently observed in IPF patients because severe fibrosis in 
the IPF lungs alters lung compliance and increases the intrathoracic pressure to occur 
acid reflux. For the role of GERD in IPF, it has been proposed that repeated micro-
aspirations of acidic products of GERD cause chronic lung injury in epithelial cells, 
aberrant wound healing, tissue remodeling, and activation of fibroblasts ultimately 
leading to IPF. Diabetes mellitus and hypothyroidism are prevalent metabolic disorders 
found in IPF patients, but the mechanisms by which these conditions may contribute to 
the development of IPF are still unknown (34). In addition, 58 – 88% and 3 – 22% of IPF 
patients are affected by obstructive sleep apnea (OSA) and lung cancer (34). One of the 
most fatal co-morbid conditions associated with IPF is acute exacerbation which is the 
most common cause of death in the patients (35, 36). 
  
Natural History of IPF  
 IPF is a fatal disease with poor prognosis. Retrospective studies on IPF revealed 
that the mean survival from initial diagnosis is only 2 to 3 years (37). However, IPF has 
a broad spectrum for patterns of progression; a majority of IPF patients show a 
progressive and gradual decline in their lung functions while some remain stable or 
experience acute exacerbation (AE) (37, 38). The most common cause of death in IPF 
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patients is respiratory failure, and about 40% of IPF-related deaths are related to AE (39–
41). 
 Although there is no universal definition of AE for IPF, it is generally accepted that 
any lung injury which is caused by infection, pulmonary embolism, pneumothorax, and 
heart failure should be distinguished from AE (39, 42, 43). In order to be AE, there should 
be unexplained worsening of dyspnea within the past 30 days and newly formed 
honeycombing or bilateral ground-glass confirmed by high resolution CT (43). The 
incidence of AE-IPF is highly variable depending on the reported studies due to the 
variations in study design and the definition of AE-IPF. A retrospective analysis of 461 
patients with IPF revealed that a 1- and 3-year incidence of AE-IPF are 14.2% and 20.7% 
in the patients (44). Similarly, another independent analysis reported the 1- and 3-year 
incidence to be 8.6% and 23.9% (45). The average time for the initial episode of AE-IPF 
from 1st clinical visit is from 3 to 60 months according to a cohort study (46). The mean 
survival rate of AE-IPF patients is 15.5 months which is significantly shorter than 60.6 
months for other IPF patients who have not experienced AE (44). 
 A small group of IPF patients maintain stable lung functions without episodes of 
AE-IPF. These long-term survivors constitute about 25% of the entire IPF patients, and 
their mean survival rate is over 5 years without transplantation (44). According to a data 
analysis, there is a positive correlation between the mean survival rate and the duration 
of IPF; the longer IPF patients lived with the disease, the more likely they would live even 
longer (47).  
 
Treatment 
 IPF was once considered to be an inflammatory disease where chronic 
inflammation is the most critical factor of pathogenesis. Therefore, the official treatments 
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recommended by American Thoracic Society (ATS) included a number of 
immunosuppressants, such as corticosteroids, cyclophosphamide, and azathioprine (12) 
in addition to N-acetylcysteine (NAC) which reduces reactive oxygen species (ROS)  until 
2011 (48).  The first randomized double-blind trial performed for IPF was prednisone 
combined with azathioprine in 1993 where the combined therapy of prednisone and 
azathioprine did not show significant clinical advantages, such as survival rates and lung 
functions compared to prednisone alone (49). In a separate pilot study, NAC, which 
replenishes the anti-oxidant capacity of cells, was added to the traditional prednisone 
and azathioprine therapy as a triple therapy. This triple therapy significantly improved the 
lung functions of the patients with fibrosing alveolitis, which is now recognized as IPF, 
and the positive outcome validated this triple therapy to be a standard of treatment for 
IPF for the next 10 years (50). It is believed that this result was biased and was poorly 
interpreted due to the lack of significant patient size and the poor study design, which 
was not double-blinded. Another clinical trial where NAC was tested in addition to the 
two immunosuppressants demonstrated promising clinical benefits on lung functions, but 
interpretation of this study was limited by the high drop-out rate of patients and the lack 
of a true placebo arm (51). Later in a PANTHER-IPF trial, it was discovered that the triple 
combinational therapy is detrimental to IPF patients significantly lowering the survival 
rate (52). These finding resulted in a strong recommendation of ATS against the use of 
the triple therapy for IPF patients (8, 48).  
 A small pilot study on interferon gamma-1b indicated its effectiveness on IPF 
when it is combined with prednisone (53). However, later this result was disapproved by 
two independent clinical trials of interferon gamma-1b where the treatment showed no 
significant improvements on survival rates and lung functions and these negative 
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outcomes led to a recommendation against the use of interferon gamm-1b for IPF (54, 
55).  
 Pre-clinical data suggested the contribution of coagulation cascade to the 
pathogenesis of IPF which led to a number of clinical trials on anti-coagulants (56, 57). 
A randomized clinical in Japan where 56 patients with IPF were treated with prednisolone 
and an anti-coagulant showed improved survival rates compared to the patients who 
received prednisolone alone (58). However, interpretation was limited for this study due 
to the lack of a true placebo arm. A phase 3, randomized, double-blinded clinical trial for 
the use of warfarin in IPF, ACE-IPF, was terminated early due to severe mortality and 
morbidity issues (59). This failure of warfarin in IPF led to a strong recommendation 
against the use of anti-coagulants for the treatment of IPF (60). Additional post hoc 
analysis where the previous data from clinical trials on anti-coagulants suggested that 
the patients who were given anti-coagulants had significantly higher mortality rates than 
the placebo group (61). 
 Endothelin-1 is a potent vasoconstrictor which promotes epithelial-mesenchymal 
transition and, therefore, potentially contributes to IPF (62). An endothelin receptor 
antagonist, bosentan, has been approved by FDA as a treatment for pulmonary arterial 
hypertension (PAH). Due to the strong association between PAH and IPF and the reliable 
tolerance of the medication, bosentan was tested for the use in IPF in two independent 
clinical trials (63, 64). In the studies, bosentan did not improve the primary end points of 
the investigation which were a change in 6-minute walk distance (6-MWD) and worsening 
of IPF in the patients (63, 64). Another endothelin receptor antagonist, macitenatan, was 
well tolerated in IPF patients, but failed to demonstrate clinical benefits, such as improved 
FVC over 52 weeks (65). 
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 Sildenafil is a phosphodiesterase-5 inhibitor which promotes vasodilation and is 
believed to improve gas exchange in IPF patients (66, 67). A randomized, placebo-
controlled clinical trial, STEP-IPF, was performed to investigate the effectiveness of 
sildenafil on exercise tolerance, dyspnea and quality of life in IPF patients (68). 
Interestingly, despite the failure in meeting the criteria of primary endpoint, 6-MWD, the 
secondary endpoints were met, such as DLCO, dyspnea, and health-related quality of 
life assessed by the St. George’s Respiratory Questionnaire (SGRQ), suggesting that 
sildenafil may be beneficial to patients with IPF. Nonetheless, sildenafil is recommended 
only in a conditional situation according to the official guidelines of ATS (60). A recent 
clinical trial where sildenafil was investigated as a combinational medication with 
nintedanib, a new FDA-approved medication for IPF, revealed that there was no 
significant difference between nintedanib alone and the combined therapy with respect 
to improvements in SGRQ, dyspnea and shortness of breath.  
 Pirfenidone reduces fibroblast proliferation and inhibits transforming growth factor 
beta which is a potent pro-fibrotic cytokine (69). Prior to clinical trials, the efficacy of 
pirfenidone as an anti-fibrotic medication was tested in a number of animal models, such 
as mice, hamster, and rats, and pirfenidone was found to be effective for experimental 
fibrosis (70–73). More importantly, an early clinical trial on the use of pirfenidone for IPF 
suggested potential benefits on improvement in FVC, total lung capacity, and DLCO in 
the patients with IPF, which made a stepping stone for a scientific breakthrough in the 
field of IPF (74). Following this positive outcome, three independent randomized, 
placebo-controlled, Phase-III trials were performed to test the effectiveness of 
pirfenidone for IPF. Only one of the clinical trials revealed significantly reduced decline 
in FVC at week 52 by pirfenidone and the results from the other two clinical trials, 
CAPACITY 1 and 2, were conflicting; a primary endpoint, a reduced decline in FVC was 
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met only in one study (74). Additional clinical trial, ASCEND, suggested that pirfenidone 
significantly reduced decline in FVC and was well tolerated in the IPF patients (75). Later, 
a comprehensive analysis of the three clinical trials revealed that pirfenidone reduced 
not only a decline in lung functions but also all-cause mortality rate as compared to 
placebo (60, 76). Pirfenidone has been a standard of treatment for IPF since 2017 (8). 
 Nintedanib is another FDA-approved medicine for IPF. Nintedanib is believed to 
inhibit a number of signaling pathways of pro-fibrotic growth factors, such as vascular 
endothelial growth factor (VEFG), platelet-derived growth factor (PDGF), and fibroblast 
growth factor (FGF), to halt the progression of fibrosis (77–79). In the TOMORROW trial, 
nintedanib was significantly associated with a reduced decline in FVC, fewer acute 
exacerbations and improved quality of life measured by SGRQ as compared to a placebo 
(80). This positive outcome was consistently repeated in the two independent clinical 
trials, INPULSIS (81). Despite a moderate adverse event, diarrhea, most of the patients 
who received nintedanib tolerated the treatment. A comprehensive combined analysis of 
data from the TOMORROW and INPULSIS trials revealed that nintedanib lowered the 
risk of all—cause mortality compared to a placebo group (60). Nintedanib has been 
approved as a treatment for IPF since 2015 (8). Pirfenidone and nintedanib are the 
current standards of treatment for IPF. However, these treatments are not the ideal 
medications as these therapies are associated with gastrointestinal adverse effects and 
photosensitivity  (82–84). More importantly, the patients on these treatments still display 
a significant progression of the disease, suggesting that better medications are needed 
(60). 
 Lung transplant is the only cure available to IPF patients. However, lung transplant 
cannot the ideal cure for IPF as the surgery mildly increases the 5-year survival rate from 
25% to 51% (38, 85). This result suggests that clinical innovations are urgently needed 
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for IPF to improve outcome of the patients. There are a number of pharmacological 
compounds currently under clinical trials 3 or 4. Pamrevlumab is a monoclonal antibody 
targeting to inhibit connective tissue growth factor. In the PRAISE phase 2 trial, 
pamrevlumab reduced a decline in FVC as compared to a placedo, suggesting that this 
treatment may attenuate progression of IPF (86).  GLPG1690 is an autotaxin inhibitor 
which is emerging as a potential IPF treatment. In a recent phase 2a trial, FLORA, the 
patients treated with GLPG1690 had 25mL of increased FVC at week 12 although the 
placebo group showed 70mL of reduction in their FVC, suggesting that this treatment not 
just stopped the progression but improved the lung functions (87). Fentanyl Citrate is an 
opioid which has been well tolerated and shown to relieve respiratory discomfort. This 
compound is currently under phase 3 to test its effectiveness for dyspnea relief in IPF 
patients (88). 
 
Prognosis 
 Prognosis of IPF patients is determined by progression of disease which is 
generally measured by pulmonary function parameters and sometimes high-resolution 
CT. IPF patients show a restrictive pattern in pulmonary function test (PFT), especially 
in total lung capacity (TLC), force vital capacity (FVC), and the diffusion of carbon 
monoxide (DLCO) (89). These parameters and patient characteristics can be used to 
evaluate the initial severity of the disease at initial visit and utilized as a basement to 
evaluate patient prognosis. Changes in these parameters are clinically more meaningful 
than the absolute values to monitor progression of the disease. Therefore, it is 
recommended to perform PFT in the same medical laboratory to minimize environmental 
variations every 6 or 12 months (8). 
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 Among multiple lung function parameters, a decline in FVC% is the best predictor 
of mortality in IPF patients (90–93). In addition, changes in FVC and DLCO at 6- or 12-
months interval can be used to evaluate the worsening, stability, and improvement of 
IPF; greater than 10% and 15% of reductions in FVC and DLCO respectively are 
considered to define disease progression and lead to poor prognosis (12). However, 
there is no consensus on the cut-off value to define the disease pattern for IPF. Some 
authors reported that a decline in FVC greater than 5% within the 6 – 12 months follow-
up indicate a worse prognosis (37). Generally, the clinically meaningful difference in FVC 
is 2 to 6% due to the technical variation.  
 In addition to PFT, 6-MWT can be utilized to evaluate the baseline of IPF and 
predict patient prognosis (94). For actual data acquisition, oxygen saturation is measured 
by pulse oximetry (SpO2) at the beginning and end of the walk which gives a value of 
total desaturation, in addition to the total distance walked by the patient. The SpO2 less 
than 88% is strongly associated with poor prognosis (95, 96). Although SpO2 itself is a 
reliable predictor of prognosis, this value can be further used to suggest the best 
parameter to evaluate the follow-up of the patient. For example, SpO2 at the end of 6-
MWD is less than 88%, a decline greater than 15% in DLCO in 6 months is the best 
predictor or mortality. If SpO2 is greater than 88%, the best parameter is a 10% or greater 
decline in FVC. Distance in 6-MWD can be used as a predictor of prognosis; if the 
distance is less than 250m, the risk or mortality in the first year is two times greater than 
other patients. If the distance is decreased 50m or more at the follow up, the risk of 
mortality is three times greater (95, 96). 
 The presence of pulmonary hypertension at the diagnosis is a factor of poor 
prognosis for IPF, and the patient survival is inversely correlated with the mean estimated 
systolic pulmonary artery pressure (97). Therefore, echocardiography, which non-
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invasively monitors pulmonary hypertension, should be performed for patients with IPF 
at the diagnosis and follow-up. Right heart catheterization can be performed in IPF with 
caution if the patients are 1) receiving lung transplantation, 2) to show clinical 
deterioration, limited ability to exercise, a rapid decline in DLCO, disproportionate 
hypoxemia, and emphysema, 3) suspected to have precapillary pulmonary hypertension 
suggested by echocardiography and 4) to show left ventricular dysfunction with 
preserved systolic function (98, 99).  
 
Pathogenesis of IPF 
 In this section, the data obtained from IPF patients will be mainly reviewed and 
discussed. Currently, there is no animal model which reliably recapitulates the 
pathophysiological features of IPF (100, 101). The most commonly used animal model 
of fibrosis is bleomycin in C57BL/6. However, the bleomycin model lacks a several 
pathological features of IPF, such as fibroblastic foci, and honeycombing. Moreover, the 
fibrosis in the bleomycin model develops over weeks, but the fibrosis in IPF takes a 
decade. Therefore, although the bleomycin model is a useful tool to investigate the 
molecular mechanisms involved in pulmonary fibrosis, the focus of this section is to 
discuss what we have learned from the data from IPF patients. 
 The cause and exact mechanisms for pathogenesis of IPF are still elusive. 
Nonetheless, it is generally accepted that repeated epithelial injuries lead to a highly 
aberrant wound healing and activation of pathological fibroblasts which over-produce 
pro-fibrotic mediators and insoluble matrix proteins in genetically susceptible and aged 
patients (102). Repeated injuries and, thus, cell apoptosis in alveolar type I and II  
epithelial cells are common events and essential features of IPF. A number of 
mechanisms are implicated in this process, such as up-regulation of the Fas-mediated 
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cell death in type I alveolar epithelial cells (AEC) (103). Reactive oxygen species (ROS) 
may play important roles in perpetuated epithelial injuries as H2O2 secreted from 
myofibroblasts and differentiated fibroblasts induce a death signal for AEC. Moreover, 
oxidative stress on DNA is observed in the nuclei of AEC in IPF patients (104). 
Endoplasmic reticulum (ER) stress is implicated in the pathogenesis of IPF. ER is a 
cellular organelle which is responsible for production, folding, packaging, and trafficking 
of secreted and membrane proteins. ER stress occurs when there is a kinetic imbalance 
between protein production and processing (105). As a response to ER stress, cells 
undergo an unfolded protein response (UPR) which helps the cells adapt to the cellular 
stress. If the ER stress is above the cells’ capacity, the UPR activates apoptosis to 
remove the damaged cells from the tissue (105, 106). A number of studies demonstrated 
that ER stress and UPR are evident in the AEC from IPF patients as shown by the several 
markers, such as p50ATF6, IRE1a, and XBP1s (107–109). A several causes of ER 
stress have been found in IPF patients. Herpesvirus accounts for some cases of ER 
stress in IPF patients as the viral protein colocalizes with markers of UPR in AEC (108). 
Mutations in SPC and SPA causes mis-folding of these proteins leading to ER stress and 
UPR as revealed by in vivo data, suggesting that the genetic mutations in SPC and SPA 
may be the causes of ER stress in IPF patients (110–112).  
 Transforming growth factor beta (TGFb) is a pro-fibrotic cytokine which 
contributes to the pathogenesis of IPF by activating and differentiating fibroblasts, which 
will be further discussed in the next section. Among the three isoforms of TGFb, only 
TGFb1 is significantly elevated in the lungs of IPF patients (113). In normal physiology, 
TGFb1 exists as an inactive form bound to latency-associated peptide (LAP), which is 
further linked to a latent TGFb-binding protein via disulfide bond. This large latent 
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complex is bound to extracellular matrix (114, 115). During the initiation and progression 
of fibrosis, AEC overexpress integrin avb6 which can physically bind to LAP of TGFb1. 
The avb6-expressing AEC are further activated via interaction with receptors and its 
binding partners, such as phospholipids sphingosine-1-phosphate and lysophosphatidic 
acid, which promote contractile phenotype of AEC and release of TGFb1 into extra 
cellular spaces (116–118). In addition to its role as a fibroblast activator, TGFb1 inhibits 
proliferation of type II AEC and promotes mesenchymal transition of epithelial cells (119, 
120). 
 
Pulmonary Fibroblasts  
Fibroblasts in Normal Wound Healing 
 Fibroblasts are one of the major cell types in connective tissues and have a pivotal 
role in wound healing (121, 122). In normal conditions, fibroblasts regulate the turnover 
of ECM by balancing the production and degradation of the protein. However, in injured 
tissues, fibroblasts are activated and differentiated into myofibroblasts which display 
more protein-producing and contractile phenotype. This phenotypic change increases 
ECM production in myofibroblasts and leads to wound closure (123). Myofibroblasts 
appear in the early phase of injury, become proliferative in the wound healing phase, and 
progressively disappear as the wound healing process ends (123). These myofibroblasts 
are distinctive from undifferentiated fibroblasts even though both cell types are producers 
of ECM and have similar cellular functions. Myofibroblasts show extensive cell-matrix 
adhesions, abundant intracellular adhesions and gap junctions, and bundles of 
contractile microfilaments, which are also known as stress fiber (124, 125). Moreover, 
myofibroblasts express high levels of desmin, vimentin, myosin, and alpha smooth 
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muscle cell actin (αSMA), a marker of vascular smooth muscle cells as compared to 
fibroblasts (126, 127).  
 A major function of fibroblasts is to synthesize ECM proteins, predominantly 
collagen, fibronectin, glycoproteins, and proteoglycans which are required for normal 
growth, differentiation, and wound repair (127). There is a strong relationship between 
the number of fibroblasts and the amount of deposited ECM, suggesting that fibroblasts 
are responsible for synthesis and accumulation of ECM proteins (128). In addition to 
these ECM proteins, fibroblasts synthesize and excrete a number of extracellular 
proteins, such as laminin, thrombospondin, glycosaminoglycans, hyaluronic acid, 
heparan sulfate, and ECM-regulating proteins, such as matrix metalloproteinase (MMP) 
and tissue inhibitor of metalloproteinases (TIMP) (127). Another function of fibroblasts is 
to generate contractile forces which help close injured sites facilitating wound healing. 
Although fibroblasts play important roles in wound healing and re-epithelization, 
persistence and overactivation of fibroblasts lead to pathological phenotypes, such as 
fibrosis and tissue remodeling. These pathological roles of fibroblasts in aberrant would 
healing will be discussed in the next section.  
 
Fibroblasts in Pulmonary Fibrosis 
 As discussed above, repeated injuries in AEC play a central role in the 
pathogenesis of IPF, especially during the initial stage of the disease. Injured AEC and 
αSMA positive fibroblasts colocalize in IPF lungs, suggesting that these cells directly 
interact with each other for fibrogenesis (129). In vitro experiments demonstrate that 
mechanical damages in epithelial cells activate co-cultured fibroblasts via elevation of 
TGFb1 (130, 131). In addition to TGFb1, there are other pro-fibrotic mediators which 
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activate fibroblasts, such as connective tissue growth factor (CTGF) and sonic hedgehog 
(Shh) (113, 132, 133). As previously discussed, the elevation of TGFb1, following 
epithelial injuries, activates and differentiates fibroblasts into myofibroblasts. The 
pathological hallmarks of IPF are over-proliferation and accumulation of fibroblasts, 
which are the main source of the extracellular matrix (ECM) in the fibroblastic areas (134). 
Fibroblasts are one of the main producers of extracellular matrix (ECM) that can be found 
in the fibroblastic foci of IPF patients, which is negatively associated with patient 
prognosis (135, 136). These cells actively produce pro-fibrotic mediators promoting the 
establishment of profibrotic microenvironments for self-sustaining fibrogenesis (137–
139). The uncontrolled protein expression in fibroblasts has been extensively studied in 
the perspective of transcriptional regulations (140). However, it remains unclear whether 
fibroblasts overexpress profibrotic mediators and ECM proteins through post-
transcriptional regulations. Therefore, in this project, a novel post-transcriptional 
regulation, alternative polyadenylation, was investigated whether this mRNA processing 
leads to protein overexpression for pro-fibrotic mediators and ECM proteins in fibroblasts 
leading to the pathogenesis of pulmonary fibrosis. 
  
RNA Metabolism 
 Gene expression is controlled at multiple levels in cells from transcription to 
translation where many regulatory mechanisms are involved as a network. The network 
of regulatory mechanisms for gene expression is sensitive to internal and external stimuli 
and induces cellular responses to specific conditions (141). In eukaryotic cells, precursor 
mRNAs, which are derived from DNA, undergo a series of mRNA processing and 
modifications to become mature and, therefore, to be used as a template for protein 
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expression. mRNA maturation includes the addition of 5’-cap, splicing of RNA, cleavage 
of 3’ untranslated regions (3’UTRs), and addition of a polyadenylated tail to the 3’UTR 
(142–144). The length and sequence of 3’UTR is determined by the polyadenylation 
process as an endonuclease in the polyadenylation machinery truncates an unprocessed 
3’UTR followed by addition of polyA tail during the process (145). 
 RNA transcription has been extensively investigated as a critical step of gene 
expression because transcription of gene is one of the initial steps in the network of gene 
regulation. These studies revealed how transcription factors are recruited and activated 
at protomer sites and how these interactions lead to transcription of certain genes in 
response to cellular stimuli. However, as the knowledge in transcription and RNA 
metabolism progressively grows, other important RNA regulatory pathways are 
additionally discovered and characterized. For example, 5’ and 3’UTR of mRNAs had 
been neglected due to their lack of ability to encode a protein, but it has been identified 
that these non-coding sequences include important regulatory elements directly 
impacting on gene expression via post-transcriptional regulations (146). In short, 3’UTRs 
affect mRNA stability, RNA export to cytoplasm, localization, and translation efficacy by 
interacting with RNA-binding proteins (147).  
 3’UTRs are evolutionally conserved through species in general, suggesting that 
3’UTR is potentially beneficial to survival by adding additional regulatory points for gene 
expression. There are two types of regulatory elements in 3’UTR, cis- and trans-acting 
elements. Cis-acting elements refer to regulatory elements within the same mRNA. The 
adenylate uridylate (AU-rich) element (ARE) is one of the most common types of cis-
acting element in 3’UTR of mRNA. ARE is one of the strongest regulators of mRNA for 
translational repression and destabilization although not all mRNAs have these elements. 
The presence of ARE, typically repeats of AUUUA, is associated with short half-life of 
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mRNAs and the length of the ARE repeats is proportional to mRNA instability (147). 
Therefore, ARE is usually found in the genes that require transient gene expression, 
including cytokines and chemokines (148). ARE mediates mRNA degradation by 
facilitating de-adenylation of RNA, which is critical for mRNA protection. There are two 
pathways by which AREs facilitate mRNA degradation, non-processive and processive 
mechanisms. Some mRNAs are degraded in a non-processive way by first being de-
adenylated, then, followed by degradation of mRNA cores, and others undergo mRNA 
degradation in a processive way by being degraded simultaneously by exo- and endo-
nucleases (149).   
 Micro RNAs (miRNAs) are trans-acting elements and non-coding RNAs which 
regulate expression of protein-coding genes by destabilizing transcripts or repressing 
translation (150, 151). A number of reports demonstrated that the major inhibitory effect 
of miRNAs is to lower levels of target transcripts and their ability to inhibit translation is 
milder (152, 153). In humans, over 1,000 miRNAs have been identified comprising about 
5% of the human genome (154). Pre-miRNA are processed to 21–25 nucleotide via its 
maturation processes and enter RNA interference pathway. The first 7 nucleotides, 
except the very first one, are the seed regions which specifically recognize a 
corresponding nucleotide sequence in 3’UTR and antagonize the transcripts (153, 155). 
A recent study demonstrated that miRNAs target both coding regions and 3’UTR, but its 
inhibitory effect is greater when 3’UTR is targeted, suggesting that 3’UTR is the main 
target of miRNAs for gene regulation (155). Moreover, the number of miRNA binding 
sites is directly proportional to the strength of inhibitory effect (153). In summary, miRNA 
is an important regulator of gene expression targeting 3’UTR of mRNA to destabilize 
transcripts and inhibit translation. 
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Polyadenylation  
Alternative Polyadenylation  
 3’UTR of eukaryotic cells is polyadenylated to enhance its stability against mRNA 
degradation. The cleavage and addition of a PolyA tail to mRNAs are tightly regulated 
by the polyadenylation and cleavage machinery (145). 3’UTR is cleaved by an 
endonuclease about 25 nucleotides downstream of a polyA signal (PAS), typically 
AAUAAA, preferentially after a CA dinucleotide (156, 157). Following the cleavage of 
RNA, a few hundreds of adenosine monophosphates are added to the end of 3’UTR via 
polyadenylation. The polyA sequence is recognized by polyA binding proteins to prevent 
mRNA from degradation. This polyadenylation is important not just for mRNA stability 
but also for mRNA transport from nucleolus to cytoplasm.  
 About 85 proteins are involved in the cleavage and polyadenylation machinery for 
3’UTR processing in mammalians (158). The most critical subunits in the machinery are 
cleavage and polyadenylation specificity factor (CPSF), symplekin, and cleavage factors 
I and II (CFIm and CFIIm). CPSF has five subunits, including CPSF-30, CPSF-73, CPSF-
100, CPSF-160, and hFIP1. CPSF-160 has an RNA binding motif recognizing the PAS, 
such as AAUAAA and AUUAAA, and physically interacts with Cleavage Stimulation 
Factor (CstF) and polyA polymerase (PAP) (159). CPSF-73 is the endonuclease which 
cleavages 3’UTR (160, 161). Although CPSF-100 is considered a homology of CPSF-
73, the lack of a zinc-binding domain in CPSF-100 suggesting its inactivity as an 
endonuclease (162). CPSF-30 contains a zinc-finger motif which helps the 
polyadenylation machinery bind to pre-mRNA and enhances the efficacy of cleavage and 
polyadenylation (163). hFIP1 interacts CPSF-30 and directs PAP to the PAS (164). 
Simplekin acts as a scaffolding protein bringing binding partners of the cleavage and 
polyadenylation (165). 
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 CFIm and CFIIm are the subunits that are primarily responsible for the process of 
cleavage (166). CFIm is distinguished from CFIIm because CFIm physically recognizes 
and binds to upstream sequence elements (USE), which is a few nucleotides upstream 
of PAS, enhancing the specificity of polyadenylation on 3’UTR. Nudix hydrolase 
21(NUDT21, which is also known as cleavage factor 25, CFIm25) is a subunit in the 
CFIm and is one of the most important sub-protein of the cleavage and polyadenylation 
machinery due to its ability to recognize UGUA signals in USE regions and interact with 
PAP and polyadenylation binding protein (PABP), providing additional specificity of 
polyadenylation in the case of having multiple PAS (167). CFIIm interacts with CFIm and 
CPSF to enhance the cleavage reaction (168). PAP is the catalytic subunit which 
synthesizes polyadenylated tails and adds to 3’UTR and PABP binds to polyA tails to 
stabilize the mRNA and help control the length of the polyA tails (169). 
 About 50 - 70% of human genes contain more than one PAS (170). Therefore, 
polyadenylation can occur at a different PAS even for an identical gene, generating 
mRNAs with the same coding sequence but different lengths of 3’UTRs (170, 171). 
Hence, this process is called alternative polyadenylation (APA). In general, distal 
polyadenylation sites (dPAS), which are farther from the last exon, are preferred for 
PolyA, leading to long 3’UTRs. However, in highly proliferating cells, proximal 
polyadenylation sites (pPAS) are preferred for PolyA, leading to 3’UTR shortening (172). 
The transcripts with shortened 3’UTR are more stable and associated with enhanced 
protein expression because the shortened mRNAs may no longer contain miRNA binding 
sites or ARE which are destabilizing elements of mRNA (173).  APA leading to shortening 
and lengthening of mRNAs is differentially regulated during development and 
pathogenesis of certain diseases. The roles of APA in normal physiology and pathology 
will be discussed in the next section. 
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Alternative Polyadenylation in Physiology 
 APA plays important roles in physiology, especially neural development, immunity, 
and cancer (174, 175). Mutations in PAS are associated with hematological disorders 
and cancer. FOXP3 is an important transcriptional regulator for the maintenance of 
regulatory T cells. A single point mutation in a PAS from AATAAA to AATGAA causes a 
significantly reduced expression of FOXP3 leading to dysregulated T cell development 
and immunodeficiency in the patients (176, 177). This type of SNP is found in cancer as 
well. A SNP in a PAS within p53 from AATAAA to AATACA is associated with 
dysregulated 3’UTR processing in the transcripts and increased risk for a several cancers, 
such as cutaneous basal cell carcinoma, prostate cancer, glioma and colorectal 
adenoma (178). This type of mutation in PAS and disrupted 3’UTR processing are found 
in other diseases, including neonatal diabetes (179), α-thalassaemia (180), β-
thalassaemia (181), and systemic lupus erythematosus (SLE) (182). In these cases, the 
loss-of-function mutation in PAS are associated with reductions in transcript and protein 
levels of the affected genes due to the impaired 3’UTR processing. These results indicate 
that APA is important for mRNA stability and translation. A gain-of-function mutation and 
an insertion of a new proximal PAS in 3’UTR of interferon regulatory factor 5 (IRF5) is 
associated with increased use of a proximal PAS generating a shorter and more stable 
IRF5 transcripts. This mutation, due to the increased stability of IRF5 transcripts, leads 
to increased protein production for IRF5 and ultimately SLE, an autoimmune disease, in 
the patients (183). In summary, the mutations disrupting PAS are associated with 
decreased protein expression, and the SNP inserting an early PAS induces 3’UTR 
shortening and is associated with enhanced mRNA stability and protein expression. 
These results collectively suggest that APA is an important regulatory process for mRNA 
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stability and protein expression and its significant impact is not just at cellular but also at 
organism levels. 
During development, protein expression for some genes are regulated by APA. In 
a recent report for APA and neurological development, it has been demonstrated that 
mRNAs with long and short 3’UTR are associated with decreased and increased protein 
expression respectively in mouse neurons (184). These results suggest that APA can 
affect protein expression as a post-transcriptional regulation. Another study in neurons 
revealed that there is a global lengthening of mRNA in differentiated granule cells, 
suggesting that APA may play a pivotal role in neuronal differentiation. In the study, 
Memo1 mRNA, a regulator of proliferation in the neurons, is a target of APA and 
displayed a significant shortening in the transcript associated with reduced expression of 
the protein, suggesting that global mRNA shortening in differentiated neurons leads to 
decreased cell proliferation via suppression of protein expression (185).  
mRNAs of highly proliferative or cancerous cells have shortened 3’UTR 
associated with fewer miRNA target sites (186, 187). The 3’UTR shortening by APA 
potentially leads to increased protein expression, especially for oncogenes, such as 
cyclin D1 (CCND1) (145, 188). During the development of colorectal cancer, a distinctive 
pattern of APA was observed. When colorectal adenoma was progressed to carcinoma, 
global 3’UTR shortening of mRNA was found. APA target genes, dermokine (DMKN), 
pyridoxal kinase (PDXK), and peptidylpropyl isomerase E (PPIE), showed that 3’UTR 
shortening in the transcripts is the most evident at the carcinoma stage (189). 
Considering the fact that the transition from normal to colorectal adenoma does not 
significantly induce global 3’UTR shortening, 3’UTR may affect progression of tumor, not 
initiation. This hypothesis is consistent with the result from a recent study which 
demonstrated that global 3’UTR shortening in glioblastoma enhances tumor growth (190).  
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Recent studies in cancer suggest that a protein in the polyadenylation machinery, 
NUDT21, determines PolyA site usage (190, 191). Knock-down of NUDT21 leads to 
usage of proximal PolyA sites and, therefore, global 3’UTR shortening in mRNAs (190). 
Moreover, NUDT21 reduction promotes cell proliferation and tumor growth in HeLa and 
glioblastoma cells. These results suggest a novel mechanism by which NUDT21 
reduction promotes robust protein expression and ultimately tumor growth via global 
mRNA shortening/stabilization. Similar to cancer, fibrotic progression is also 
characterized by uncontrolled proliferation and production of pathological proteins, which 
are pro-fibrotic mediators in fibroblasts, suggesting that NUDT21 reduction and thus 
overexpression of pathological proteins may be implicated in the pathogenesis of 
pulmonary fibrosis. 
Despite the importance of APA and NUDT21 reduction in gene expression, 
whether NUDT21 downregulation contributes to the pathogenesis of pulmonary fibrosis 
was unknown when this project was first initiated. Therefore, the goal of this thesis project 
was to characterize the role of NUDT21 in the pathogenesis of IPF and reveal the 
mechanisms governing NUDT21-mediated APA. 
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Dissertation Overview 
IPF is a fatal lung disease, characterized by proliferation of fibroblasts and 
accumulation of ECM proteins. Outcomes for IPF patients are poor, with the 5-year 
survival rate being only 18% (44). Moreover, the mean survival of IPF patients is only 
2~3 years (38). The current therapies for IPF are limited in that they do not improve the 
mortality rate (75, 192–194). Therefore, the development of better therapeutic 
approaches for IPF is urgently needed. To achieve this clinical goal, a better 
understanding of the mechanisms of pulmonary fibrosis is necessary to promote novel 
IPF drug development. 
Fibroblasts are the most common producers of ECM proteins, such as collagen 
and fibronectin in fibrosis. These cells are frequently found in the fibroblastic foci in the 
lungs of IPF patients, surrounded by ECM (195). This clinical observation suggests that 
fibroblasts are critical cells in the pathogenesis of IPF producing the majority of matrix 
proteins (120, 196, 197). Although the over-production of ECM by fibroblasts is, in part, 
responsible for the uncontrollable progression of pulmonary fibrosis, the exact 
mechanisms governing the excessive production of pro-fibrotic proteins are poorly 
understood. 
Polyadenylation is a mRNA process which adds polyA tails to 3’UTRs of mRNA. 
This process enhances mRNA stability and promotes a transport of mRNAs from nucleus 
to cytoplasm for mRNA translation. About 50 - 80% of human genes contain more than 
one PAS which leads to generation of isoforms mRNAs with the same coding sequence 
but different lengths of 3’UTR (170). Due to the possible polyadenylation on different 
PAS, this process is called alternative polyadenylation. Since APA regulates the length 
of the 3’UTR on mRNAs, this post-transcriptional regulation affects gene expression by 
modulating the interaction between 3’UTR and mRNA-degrading elements.  In general, 
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3’UTR shortening through APA makes mRNAs more stable and resistant to degradation 
(198, 199). This stabilization of mRNAs results in enhanced protein expression (195). A 
recent study revealed that NUDT21 (which is also known as CFIm25, a subunit of the 
polyadenylation machinery) suppresses the usage of pPAS during APA and a reduction 
in NUDT21, found in cancer cells, leads to global mRNA shortening and enhanced 
protein expression for the APA target genes. The NUDT21 reduction promotes cell 
proliferation and tumor growth in glioblastoma cancer cells (190). This result suggests 
that NUDT21 reduction in cancer promotes tumor growth and cell proliferation via 3’UTR 
shortening and APA enhancing protein expression. IPF is a lung disease which is 
characterized as over-proliferation of fibroblasts and robust production of pathological 
proteins. These cellular characteristics are common in cancer and IPF, suggesting that 
APA may play important roles in IPF (200). Therefore, it was hypothesized that APA 
via NUDT21 reduction contributes to the pathogenesis of IPF. In order to test this 
hypothesis, the following 4 aims were investigated: 
 
Aim 1. Determine whether NUDT21 is depleted in the fibroblasts isolated from IPF 
patients and mice with bleomycin-induced fibrosis 
 Tissue sections from healthy and IPF lungs were used for immunohistochemistry 
(IHC) analysis to visualize expression of NUDT21. The IHC revealed that NUDT21 was 
evidently localized in nuclei of pulmonary cells in the normal lung, including epithelial 
cells, smooth muscle cells, and fibroblasts. However, in IPF lungs, NUDT21 was 
significantly reduced in lung fibroblasts, especially fibroblastic foci where fibroblasts 
actively proliferate and produce ECM. For quantitative analysis, primary lung fibroblasts 
from healthy or IPF patients were used to examine the expression of NUDT21 protein 
and transcripts. The Western Blot analysis demonstrated that NUDT21 was significantly 
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depleted in IPF lung fibroblasts. Additionally, the primary fibroblasts isolated from the 
mice with bleomycin-induced fibrosis had significantly reduced NUDT21 associated with 
an increase in ECM proteins (201). The key results of this aim are shown in Chapter 3. 
 
Aim 2. Characterize the roles of NUDT21 depletion in pulmonary fibrosis  
 In order to examine the impact of NUDT21 reduction in APA, siRNAs specific to 
mRNAs of NUDT21 were used to deplete NUDT21 in primary human lung fibroblasts. 
NUDT21 depletion caused global mRNA shortening, and the APA occurred in a number 
of pro-fibrotic genes, such as TGFbR1, WNT5a, and FZD2. The 3’UTR shortening in 
these genes was associated with increased expression of proteins, suggesting that 
NUDT21 reduction leads to enhanced protein expression via APA. To examine a causal 
relationship between NUDT21 reduction and lung fibrosis, NUDT21 was deleted in 
fibroblasts of the Col1a1-creER-NUDT21f/f mice followed by establishment of bleomycin-
induced fibrosis. Fibrosis was worse in the NUDT21 knockout mice as shown in multiple 
parameters of fibrosis. Moreover, NUDT21 deletion caused 3’UTR shortening of 
TGFbR1, WNT5a, and FZD2 associated with increased levels of the proteins. The details 
of these results are shown in Chapter 3. 
 
Aim 3. Examine the mechanism(s) of NUDT21 depletion in pulmonary fibrosis.  
 To identify the pro-fibrotic molecule which leads to NUDT21 depletion, primary 
human lung fibroblasts were cultured with cytokines/growth factors associated with IPF. 
TGFb1 decreased NUDT21 at mRNA and protein levels associated with an increase in 
ECM proteins. mRNA degradation assay revealed that TGFb1 enhanced mRNA 
degradation of NUDT21. miR203 which targets 3’UTR of NUDT21 was elevated following 
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TGFb1 via phosphorylated Smad3 and a transcriptional regulation. In addition, TGFb1 
reduced NUDT21 in primary lung fibroblasts isolated from mice via Smad3. Furthermore, 
TGFb1 overexpressing mice demonstrated that TGFb1 depleted NUDT21 in vivo 
associated with enhanced expression of ECM proteins. The results of this aim are 
included in Chapter 4. 
 
Aim 4. Investigate the role of TGFβ1 as a promoter of APA through NUDT21 
depletion.  
 To investigate the regulatory role of TGFb1 in APA, the fibroblasts which were 
cultured with TGFb1 and, therefore, had low NUDT21 were harvested for RNA-seq and 
APA analysis. TGFb1 treatment in the primary lung fibroblast promoted differential APA, 
both shortening and lengthening of mRNAs. This differential APA was also observed in 
IPF fibroblasts, suggesting that this APA pattern is a unique feature of the disease. 
FGF14, RICTOR, TMOD2, and UCP5 were the targets of APA both in NUDT21 knockout 
and TGFb1 fibroblasts and had increased levels of protein expression. The results of this 
aim are included in Chapter 4. 
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CHAPTER TWO 
EXPERIMENTAL PROCEDURES 
Note: This chapter is based upon:  
1) Tingting Weng, Junsuk Ko, Chioniso P. Masamha, Zheng Xia, Yu Xiang, Ning-
yuan Chen, Jose G. Molina, Scott Collum, Tinne C. Mertens, Fayong Luo, Kemly 
Philip, Jonathan Davies, Jingjing Huang, Cory Wilson, Rajarajan A. 
Thandavarayan, Brian A. Bruckner, Soma S.K. Jyothula, Kelly A. Volcik, Lei Li, 
Leng Han, Wei Li, Shervin Assassi, Harry Karmouty-Quintana, Eric J. Wagner, 
and Michael R. Blackburn. Cleavage factor 25 deregulation contributes to 
pulmonary fibrosis through alternative polyadenylation. 2019. The Journal of 
Clinical Investigation. https://www.jci.org/articles/view/122106. Copyright 
permission granted 26 March 2019 for 11801813 
2) Junsuk Ko, Tingting Mills, Jingjing Huang, Ning-yuan Chen, Tinne CJ Mertens, 
Scott D Collum, Garam Lee, Yu Xiang, Leng Han, Yang Zhou, Chun Geun Lee, 
Jack Elias, Soma SK Jyothula, Keshava Rajagopal, Harry Karmouty-Quintana, 
and Michael R. Blackburn. Transforming growth factor beta 1 alters the 3’UTR of 
mRNA to promote lung fibrosis. 2019. Journal of Biological Chemistry. 
http://www.jbc.org/content/early/2019/09/05/jbc.RA119.009148.short. The 
contents, data, and figures were modified and included following the guidelines of 
JBC. 
 
Human Subjects 
 Primary human lung fibroblasts were isolated directly from human lungs (explant 
IPF lungs or normal lungs from donors) in the laboratory following the institutional 
protocols. IPF lungs were de-identified and obtained from the Methodist Hospital 
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Cardiothoracic Transplant Center or the Lung Transplant Center at Memorial Hermann-
Texas Medical Center. The protocols for the use of human samples in this project were 
approved by the University of Texas Health Science Center at Houston (UT Health, 
Houston, TX, USA), the Methodist Hospital, and the Memorial Hermann Hospital 
institutional review boards. IPF lungs were collected during lung transplant surgery and 
were processed within 60 min. The normal human lung tissues were obtained from the 
International Institute for the Advancement of Medicine (IIAM). The information on patient 
samples or healthy controls are shown in Table 2.1. 
 Normal 
(n=10) 
IPF  
(n=15) 
p-value 
Gender, n (%) 10 15 N/A 
   Males 7 8 N/A 
   Females 3 3 N/A 
Age (Mean ± SD) 36.7 (±17.0) 63.5 (±11.0) 0.0004 
BMI (Mean ± SD) 26.9 (±4.8) 27.6 (±4.3) 0.6815 
PA Mean N/A 19.2 (±4.9) N/A 
FVC, % (Mean ± SD) N/A 50.7 (±14.6) N/A 
DLCO, % (Mean ± SD) N/A 45.2 (±18.4) N/A 
FEV1, % (Mean ± SD) N/A 58.1 (±15.0) N/A 
TLC, %(Mean ± SD) N/A 62.5 (±17.2) N/A 
Table 2.1. Clinical Information on Patient Samples 
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Generation and Genotyping of Mouse Lines 
 C57BL/6 mice were purchased from Envigo and housed following the guidelines 
of the Animal Welfare Committee at UTHealth. All experiment designs were reviewed 
and approved by the institutional review committee. The detail of the protocol for 
bleomycin administration is written in the section below. 
CC10-tTS-rtTA-TGF-β1 transgenic mice with C57BL/6 background were bred and 
housed in the animal facility at Brown University. As described previously, 6-8-week-old 
mice and control littermates were randomized to either regular water or doxycycline water 
(0.5mg/mL)  (202). The transgenic and control mice were sacrificed and harvested for 
fibroblast isolation and histology as described below. 
All mouse models used in this thesis were in C57/BL6 background. Col1a1-creER-
NUDT21fl/fl mice were generated by crossing NUDT21fl/fl mice with Col1a1-cre/ERT2 
mice (stock no. 016241, The Jackson Laboratory).  Similarly, Foxd1-cre-NUDT21fl/+ mice 
were generated by crossing NUDT21fl/+ mice with Foxd1tm1(GFP/Cre)Amc (or 
FoxD1GC) mice (stock no. 012463, The Jackson Laboratory). For controls, sex- and 
age-matched littermates with Cre were used. In order to confirm the deletion of target 
genes and expression of Cre, genotyping was performed in addition to other technical 
assays, such as Western Blot, RT-qPCR, and immunohistochemistry. NUDT21 was 
deleted by activating cre in Col1a1-creER-NUDT21fl/fl mice via i.p. injection tamoxifen at 
75 mg/kg once every 24 hours for a total of 5 consecutive days (Sigma Aldrich). The 
successful deletion of NUDT21 was confirmed by the western blot analysis and 
immunohistochemistry (IHC) staining as shown in Figure 3.5 A and B. 
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Transforming Growth Factor b1 Mouse Model 
 This transgenic mouse was first generated by the research group of Dr. Jack Elias 
(202). In this mouse, tTS, which represses transcription of transgenic TGFb1, is 
constitutively expressed and thereby expression of TGFb1 is tightly controlled. For a 
conditional expression in the lung, rtTA expression is driven by CC10 promoter, which is 
specific to club cells. Upon administration of doxycycline, the repression effect of tTS is 
reduced and rtTA binds to the tet Operator to promote expression of TGFb1 (Figure 1). 
The administer of doxycycline was maintained for 2 weeks to induce pulmonary fibrosis 
followed by sacrifice. 
 
Figure 2.1. Regulation of TGFb1 Expression by Doxycycline (adopted and modified 
from the original figure (203)) 
 
Bleomycin Mouse Model 
For a chronic fibrosis model, 0.035 U/g of bleomycin was administered into male 
mice intraperitoneally (i.p.) twice a week for 4 weeks, for a total of 8 injections (Teva 
Pharmaceutical) (Figure 2). For these experiments, male mice were chosen intentionally 
TGFβ1
TGFβ1 
Expression
TGFβ1
No TGFβ1 
Expression
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as IPF is more prevalent in males than females (204). Additionally, male mice in the 
C57B/6 background has a more robust response to bleomycin-induced injury than 
female mice (205). Therefore, for the initial experiments where the i.p bleomycin 
treatment was used to induce fibrosis, male mice were used as an animal model to 
recapitulate the male-dominant features of fibrosis in male patients. As written below, an 
oropharyngeal aspiration of bleomycin, which is a different type of fibrosis models, 
utilized both female and male mice which provide additional information on sex 
differences in fibrosis. For a longitudinal analysis, lungs and bronchoalveolar lavage 
(BAL) fluid were harvested on day 7, 28, and 33 after the initial bleomycin injection. 
 
Figure 2.2. Chronic Intraperitoneal Fibrosis Model 
 
For oropharyngeal aspiration (o.p.a) of bleomycin, female mice were given 
isoflurane and subsequently administrated 2.5 μ/kg bleomycin (o.p.a.) (206). Mouse 
lungs were harvested 21 days after the injection of bleomycin as shown in Figure 3. 
 
Figure 2.3. Oropharyngeal Aspiration Fibrosis Model 
 
For delayed Cre activation, mice were given bleomycin either i.p. or o.p.a. as 
described above (0.035 U/g twice a week for 4 weeks or 2.5 U/kg once). Following the 
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bleomycin injection, the mice were administered i.p. tamoxifen to activate cre once a day 
for 5 days as shown in Figure 4 (75 mg/kg tamoxifen). Lung samples and BAL fluid were 
harvested on day 33 and day 21 for i.p. and o.p.a respectively. 
 
 
 
Figure 2.4. Delayed Cre Model 
 
Lung Function Assay 
FlexiVent FX System with FX1 module was used to analyze parameters of lung 
function in vivo (SCIREQ Inc.). Throughout the measurement, basal ventilation was 
maintained at a tidal volume of 10 ml/kg, frequency of 150 breaths per minute, and a 
positive end expiratory pressure (PEEP) of 3 cmH2O. For this measurement, the mice 
which were on day 33 (i.p.) or day 25 (o.p.a.) of bleomycin treatment were administered 
5% Avertin i.p. (0.012 ml/g BW). Following the anesthesia, tracheostomy was performed 
and a cannula was inserted for actual measurements (18-gauge metal cannula and 
resistance of 0.2–0.3 cmH2O∙s/ml) 
After insertion of the cannula, the mice were under the basal ventilation for at least 
1 minute to stabilize the lung. Then, the quality of the experimental apparatus was tested 
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by inflating the lung to 30 cmH2O over 6 seconds and returning to normal ventilation for 
1 minute. The following parameters were measured using FlexiVent: respiratory system 
resistance (Rrs), dynamic compliance (Crs), elastance (Ers), Newtonian airway 
resistance (Rn), tissue damping (G), and tissue elastance (H) in addition to generating a 
pressure-volume (PV) curve using a ramp-style pressure-driven (PVr-P) maneuver to a 
maximum of 30 cmH20 to calculate static compliance (Cst) (203). 
 
Inflammation and Cellular Differential Assay  
Mouse lungs were lavaged 3 times with PBS to harvest BAL fluid. A portion of the 
BAL fluid which contains lung cells was used for BAL cell count assay. Another portion 
of the BAL fluid was centrifuged onto microscope slides so that the lung cells were 
attached to the glass. The slides were used for cell differential assay using Diff-Quik 
(Dade Behring, B4132-1A). After the BAL fluid was collected, the lungs were harvested 
for subsequent Western Blot or RT-qPCR analysis by freezing the samples in liquid 
nitrogen. For histochemistry analysis, following BAL fluid, the lungs were inflated at a 
constant pressure, fixed in 10% formalin and embedded in paraffin. 
 
Masson's Trichrome Staining and Ashcroft Assay 
 Human lung sections were deparaffinized and rehydrated through alcohol 
gradient from 100% to 30%. Then, the slides were hydrated in distilled water. The tissue 
sections were incubated with Bouin’s solution at 56 C for 15 minutes, followed by cooling 
at room temperature for 15 minutes. The yellow dye was washed by dipping the slides 
in distilled water three times briefly. Weigert’s mix was added and the slides were 
incubated for 5 minutes. After rinsed in running tap water, the slides were incubated with 
Acid Fuschin for 2 minutes. After rinsed in distilled water, the mixture of PTA/PMA was 
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added for incubation for 5 minutes. Then, the slides were further incubated with Aniline 
Blue for 15 minutes. 1% of acetic acid was used to rinse off the blue dye in the slide. 
After rinsed in distilled water, the slides were dehydrated through alcohol gradient from 
30% to 100%, then histoclear. After cytoseal, the slides were used for assessment. 
 After Masson’s Trichrome Staining, the slides were randomly and blindly assigned 
to two different individuals to score the severity of fibrosis. This assay was performed for 
at least 40 randomly chosen areas for each lung and sample (207, 208). 
 
Immunohistochemistry and Fluorescent Staining 
 Immunohistochemistry was performed on 5 µm sections of formalin-fixed paraffin-
embedded lungs. First, the section was rehydrated through a gradient of histoclear-
alcohol from 100% to 30%. Then, antigen retrieval was performed using Tris-based 
Antigen Unmasking Solution (Vector Laboratories) followed by quenching endogenous 
signals of peroxidase and alkaline phosphatase using Bloxall (Vector Laboratories). 0.1% 
of Triton X was used to permeabilize membranes of the section and 2.5% horse serum 
was used to prevent unspecific signals. Then, the tissue section was incubated with 
primary antibodies overnight. After incubation, the section was incubated with 
ImmPRESS-ABC reagent, which contains peroxidase for 30 minutes (Vector 
Laboratories). Then, the sample was incubated with DAB to develop (Vector 
Laboratories). 
 For dual staining with fluorescence, the developed section was incubated with 
Bloxall to quench the peroxidase activity. After quenching, the sample was further 
blocked with 2.5% normal horse serum, followed by incubation with anti-αSMA 
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conjugated with fluoro (Sigma-aldrich). After the incubation with anti-αSMA, the slide was 
mounted with anti-fading DAPI (Abcam).  
For dual staining with Vector Red, the developed section which contained HRP 
was incubated with Bloxall to terminate the peroxidase reaction. The tissue section was 
re-incubated with 2.5% normal horse serum, followed by incubation with anti-αSMA 
(Sigma-aldrich). After the incubation, Vector Red was used to recognize the primary 
antibody and tag the alkaline phosphatase (Vector Laboratories). The section was 
developed with the reagents for red color (Vector Laboratories), followed by mounting 
with anti-fading DAPI (Abcam). 
For dual immunofluorescence staining for NUDT21 and α-SMA, lung sections 
were prepared as previously described for deparaffinization and dehydration. The lung 
sections were then incubated with anti-NUDT21 antibodies overnight followed by 
ImmPress and Vector Red. The sections were incubated with anti-αSMA conjugated with 
fluoro (Sigma-aldrich). After the incubation with anti-αSMA, the slide was mounted with 
anti-fading DAPI (Abcam).  
 
Isolation of Primary Lung Fibroblasts and Cell Culture 
 Primary human lung fibroblasts were isolated as described below. First, the lowest 
lobes of normal or IPF lungs were harvested. The lobes were washed with sterile PBS 
and the tissues were cut into ~1 mm3 fragments by McIlwain Tissue Chopper. The 
fragments were cultured without media for two hours in a CO# incubator to attach the 
cells on the dish. Then, the cells were further cultured in complete culture media (Eagle's 
Minimum Essential Medium, EMEM, with 10% of FBS) for two weeks. This method allows 
only fibroblasts to migrate out of the tissues and survive in the media. The cells were 
used until passage 6. Primary mouse lung fibroblasts were isolated through the same 
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procedure with several modifications; 1) mouse lungs were perfused with PBS prior to 
the chopping 2) Dulbecco's Modified Eagle Medium, DMEM, with 10% of FBS was used 
as complete media and 3) the mouse cells were used until passage 3. CCD8Lu, a 
primary human lung fibroblast, was purchased from the American Type Culture 
Collection (ATCC). 
 For siRNA transfection, cells were incubated with antibiotic-free media. miRNA 
mimic or siRNA were transfected into the cells using Lipofectamine-based RNAiMAX on 
day 0 and 1 (miRNA mimic or siRNA from Sigma-aldrich and RNAiMAX from Thermo 
Fisher Scientific). Then, the cells were harvested for Western Blot or RT-qPCR on day 
4. 
 
In vitro Inhibition of Smad3 Phosphorylation 
 An inhibitor of Smad3, SIS3, was purchased from Torcris. This inhibitor was 
developed as the first specific inhibitor of Smad3 phosphorylation, thereby inhibiting 
expression of matrix proteins in fibroblasts (209). Primary lung fibroblasts were 
pretreated with 5 µM of SIS3 for one hour and then treated with TGFb1 in the absence 
or presence of the inhibitor. 
 
Overexpression of NUDT21 via Electroporation 
 For NUDT21 overexpression, the coding region (CDS) of human NUDT21 was 
inserted into pcDNA3.1 vectors (Thermo Fisher Scientific) via Gibson Cloning. 6 µg of 
control or NUDT21 plasmids were transfected into 5X106 healthy or IPF fibroblasts 
through electroporation (Biorad Gene Pulser, 500uF, 120V, 2mm cuvette, exponential). 
Following the electroporation, the cells were cultured for up to 3 days. 
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3’UTR Reporter Assays 
 For the dual luciferase where the binding sites of miR203 were examined, 
psiCHECK-2 vector was purchased from Promega. 3’UTR of human NUDT21 was added 
into the CDS of Renilla (hRluc) in the psiCHECK-2 to generate a 3’UTR wildtype reporter. 
To generate a mutant which is resistant to miR203-mediated degradation, three sites of 
miR203 were deleted by primer-directed mutagenesis via Gibson Assembly (New 
England Biolabs, Ipswich, MA, USA). The deletion of the miR203 binding sites was 
confirm by Sanger Sequencing (Genewiz, Plainfield, NJ, USA). Primary human lung 
fibroblasts were electroporated at 500uF, 120V, 2mm, and exponential settings with the 
control, WT, and mutant plasmids (Biorad Gene Pulser System). The transfected cells 
were cultured without anti-biotics for 2 days and then were treated with TGFb1 to induce 
miR203 expression. The measurement of dual-luciferase was performed following the 
manufacture’s protocol (GenDEPOT).  
For the dual luciferase where miR203, 23a, 27b were tested, the plasmids which 
contains human NUDT21 3’UTR were transfected into HEK293T and NIH3T3 in the 
presence of miR203, 23a, and 27b mimics or control (Sigma-aldrich). The measurement 
of dual-luciferase was performed following the manufacture’s protocol (GenDEPOT). 
For GFP 3’UTR reporter, pCMV3-GFPSpark plasmid was utilized (Sino Biological, 
Beijing, China). Similar to the cloning of dual-luciferase, 3’UTR of human NUDT21 was 
added into the CDS of GFPSpark, and the 3’UTR mutant was generated. Following 
electroporation with the plasmids, primary human lung fibroblasts were cultured on a 
glass coverslip. The electroporated cells were treated with TGFb1 for 4 days. On day 4, 
the cells were fixed with formaldehyde and 70% acetone. Then, the stress fibers of the 
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cells (F-actin) were stained with Alexa Fluor™ Phalloidin for 30 min at room temperature 
(Thermo Fisher Scientific). After the incubation, the coverslip was mounted with DAPI for 
assessment. 
 
 
mRNA Degradation Assay 
 Primary lung fibroblasts were pre-treated with SIS3 for 30 min to reduce 
phosphorylation on Smad3. Then, the cells were further treated with TGFb1 for 9 hours 
in the presence or absence of SIS3. After 9 hours of culture, the cells were incubated 
with actinomycin D at 10ug/mL for up to 36 hours. The RNA samples were harvested for 
RT-qPCR analysis at 0, 12, 24, and 36 hours. The RNAs were used for cDNA synthesis 
followed by RT-qPCR to quantify the gene expression of NUDT21, b-actin, c-FOS, IL-6, 
and 18S. The relative levels of the genes were compared to 18S since 18S was the most 
stable transcript among the tested genes. 
 
Stimulation of Fibroblasts by Cytokines 
 Primary human lung fibroblasts were cultured with the following pro-fibrotic 
cytokines: transforming growth factor beta 1 (TGFb1, purchased from GenDEPOT), 
insulin-like growth factor 1 (IGF1, purchased from GenDEPOT), connective tissue growth 
factor (CTGF, purchased from GenDEPOT), platelet-derived growth factor BB (PDGF 
BB, purchased from GenDEPOT), and interleukin 4 (IL-4, purchased from PeproTech), 
6 (IL-6, purchased from PeproTech), and 13 (IL-13, purchased from PeproTech) (210–
212). After 7 days of treatment, the cells were harvested for RNA and protein analyses. 
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Western Blot Analysis 
 RIPA buffers with protease inhibitors were used to lyse cells and the cell lysates 
were centrifuged at 12,000 RCF for 5 minutes (Boston Bioproducts for RIPA and Thermo 
Scientific for the protease inhibitors). The supernatant was used for BCA protein assay. 
15ug of boiled protein was added into a well of a precast 4-20% gel (Biorad) and was 
stably run at 100V. After SDS-PAGE, the samples were transferred at 80V for 1 hour and 
45 minutes. Then, the membrane was blocked with 5% lab-grade milk for 30 minutes, 
followed by incubation with an antibody overnight. After the incubation overnight, the 
membranes were washed with TBST solution for 10 minutes 3 times followed by 
development with ECL (GenDEPOT). The following antibodies were used for 
experiments in this thesis (Table 2.2). 
Target Origin Dilution Company 
NUDT21 Rabbit WB (1:1000) IHC/IF (1:200)  Proteintech 
CFIm59 Rabbit WB (1:1000) Proteintech 
CFIm68 Rabbit WB (1:1000) Proteintech 
b-actin Mouse WB (1:10000) Sigma-Aldrich 
GAPDH Mouse WB (1:10000) Life Technology 
Vinculin Mouse WB (1:10000) Cell Signaling Technology 
Collagen 1 Rabbit WB (1:1000) Abcam 
Fibronectin Rabbit WB (1:5000) Sigma-Aldrich 
a-smooth-muscle-cell-actin Mouse WB (1:5000) IHC/IF (1:1000) Sigma-Aldrich 
GFP Mouse WB (1:1000) GenDEPOT 
Smad3 Rabbit WB (1:1000) Cell Signaling Technology 
P-Smad3 (S423/425) Rabbit WB (1:1000) Cell Signaling Technology 
UCP5 Rabbit WB (1:1000) NOVUS 
RICTOR Rabbit WB (1:1000) NOVUS 
FGF14 Rabbit WB (1:1000) Abcam 
TMOD2 Rabbit WB (1:1000) Proteintech 
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TGFBR1 Rabbit WB (1:1000) Sigma-Aldrich 
WNT5A Rabbit WB (1:1000) Thermo Fisher Scientific 
FZD2 Rabbit WB (1:1000) Thermo Fisher Scientific 
Cre Rabbit WB (1:1000) IHC/IF (1:200) Cell Signaling Technology 
Anti-rabbit (HRP) N/A WB (1:8000) Cell Signaling Technology 
Anti-mouse (HRP) N/A WB (1:8000) Cell Signaling Technology 
Table 2.2. Information on Antibodies 
 
Analysis of Fibroblast RNA 
 Cultured cells were lysed by TRIzol (Thermo Fisher Scientific). 200uL of 
chloroform was added to every 1mL of TRIzol to make two phases. After 10 seconds of 
vortexing, the mixture was centrifuged at 12,000 RCF and 4 C for 15 min for separation 
of phase. The top layer was transferred to a clean tube, and 200 proof alcohol was added 
to make 70% of alcohol solution (about 2.2 times of the volume of the top layer). After 
inverting three times, the solution was transferred to a column of RNeasy mini kit 
(Qiagen). RNAs were isolated and were purified following the manufacturer’s protocol. 
The purity of RNA was measured by Tecan Infinite Plate Reader. 1ug of RNA was used 
for cDNA synthesis using random hexamers and oligo dT primers (Quantabio). For cDNA 
of miRNAs, miRNA cDNA Synthesis Kit from Qiagen was used. For realtime-qPCR, 
SYBR green from Biorad was used to detect differential gene expressions in cDNA. All 
primers were from Sigma except the following items; RNU-6, miR203 and pre-miR203 
were from Qiagen (pre-designed primers). The sequences of the primers are shown in 
Table 2.3. 
Gene Forward primer Reverse Primer 
Homo_NUDT21 TGAAGTTGAAGGACTAAAACGCT ACCAGTTACCAATGCAATCGTC 
Homo_NUDT21_distal GGCCAGTTCAGGTGTATTTTG TTTCCCTCAACAGAACAGCA 
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Homo_COL1A1 GTGCGATGACGTGATCTGTGA CGGTGGTTTCTTGGTCGGT 
Homo_COL1A1_distal GTGAGGGAGACAGACACCTG GTGTTCTGGGGATTCAGGAG 
Homo_FN1 CCGTGGGCAACTCTGT TGCGGCAGTTGTCACAG 
Homo_FN1_distal TTGCTAGTTTACCGTTCAGAAGT TTCAATGAAGGAAAGGTGGA 
Homo_FGF14 TGCCCCTCTTCAGGAGAACT ATCCAGCAGCTTAGACACCC 
Homo_FGF14_distal GTGGGATCAATGTACTGGCCT TGGGGAAAATGATGACTGGGT 
Homo_Rictor CCGCTCTCTGAAGAACCTCC AGGTTCTCGGGTCAGATCCA 
Homo_Rictor_distal CCCCAAATGGTTTTGCTCACC AGGAGGCTTTTAATGCCCTTGA 
Homo_TMOD2 ATTGACAACCAGAGGCAGCA TGGCCCTTGCTTGGTAAACT 
Homo_TMOD2_distal TATTCAGGACCCCAGTTGGC GCATTAGGTCTGGCTGGCTA 
Homo_UCP5 TTGTCAGGAATGATGGGCGA TTCGAACCACATCAACCGGG 
Homo_UCP5_distal TGGGCTAGAGCAGAAGGCAT ACTTTAATGAGAACCGAGGTCTG 
Homo_FZD2 GTGCCATCCTATCTCAGCTACA CTGCATGTCTACCAAGTACGTG 
Homo_FZD2_distal CTTTGCTGGTGTGAGAACTCC ATGGAAGATGGCGAAAACTGAG 
Homo_TGFBR1 ACGGCGTTACAGTGTTTCTG GCACATACAAACGGCCTATCTC 
Homo_TGFBR1_distal TTTGTGCAGGATTCTTTAGGCTT GGCTTCTCAGTATCATTCGACTT 
Homo_VMA21 GATAAGGCGGCGCTGAACGCACTGC TGAGCCTTCATTCCAGGCCACATACACA 
Homo_VMA21_distal CATCTGCACAGCACCTTACAGTTTGC GAAATGCAGCACATCCAAATCCTCCC 
Homo_WNT5A ATTCTTGGTGGTCGCTAGGTA CGCCTTCTCCGATGTACTGC 
Homo_WNT5A_dstal GGTGAAAGAGAGATGCCGTG GTGTAAAGTTTGTGTGAACAGGG 
Homo_IL-6 CCAGCTATGAACTCCTTCTC GCTTGTTCCTCACATCTCTC 
Homo_cFOS TAGTTAGTAGCATGTTGAGCCAGG ACCACCTCAACAATGCATGA 
Homo_beta ACTIN CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 
Mus_NUDT21 GCGCATGAGGGAGGAATTTGA TCCCCACCAGGTAATTTGAAGAA 
Mus_COL1A1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG 
Mus_COL1A1_distal GGCAATGCTGAAATGTCCCA ACAGTCCAAGAACCCCATGT 
Mus_COL1A2 AAGGGTGCTACTGGACTCCC TTGTTACCGGATTCTCCTTTGG 
Mus_COL2A1 GGGAATGTCCTCTGCGATGAC GAAGGGGATCTCGGGGTTG 
Mus_FZD2 CTTCACGGTCACCACCTATTTAG CGCAATGTAGGCCACTGACA 
Mus_FZD2_distal TAGTGTGAGAATCCCAGTTTCCA CTGGTCTTCAGATCGCTTCTTT 
Mus_WNT5A CAACTGGCAGGACTTTCTCAA CATCTCCGATGCCGGAACT 
Mus_WNT5A_distal TGGTCACAGGATTGCTCACAT GAGAGGGTGAGCCTTTTTGATT 
Mus_TGFBR1 TCTGCATTGCACTTATGCTGA AAAGGGCGATCTAGTGATGGA 
Mus_TGFBR1_distal TACGTCAGAAACACCATGGGA ACAAAGGCCCCAAAAGTACC 
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Mus_FN1 GCTCAGCAAATCGTGCAGC CTAGGTAGGTCCGTTCCCACT 
Mus_beta ACTIN GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Mus_Homo_18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Table 2.3. Information on Primers used for RT-qPCR 
 
RNA Sequencing and PDUI Analysis 
 RNA sequencing was performed for the two sets of samples: 1) primary human 
normal and IPF fibroblasts and 2) CCD8-Lu that were treated with TGFb1 and their 
control cells. RNAs were isolated as described above and were sent for RNA-seq by 
HiSeq 2000 (Novogene, China). Pair-end RNA-seq was performed to yield at least 80 
million reads per sample. RNA-Seq gene expressions were quantified by RSEM in 
combination with a de novo transcriptome assembler. Briefly, the significance of the 
difference of mean PDUIs between the expression levels of short and long 3’UTRs in 
two samples in each condition were first computed using Fisher's exact test, and further 
adjusted using Benjamini-Hochberg (BH) procedure to control false discovery rate (FDR) 
at 5% level. Genes with the absolute difference of mean PDUIs no less than 0.15 and 
the absolute log2-ratio (fold-change) of mean PDUIs no less than 1 were identified to 
have significant shifted 3’ UTR events. 
 
miRNA Analysis 
 The miRNAs which lost their binding sites on 3’UTR due to APA were predicted 
using TargetScan (213). For this analysis, mRNAs which had 3’UTR shortening were 
filtered out, followed by identification of the shortened sequences. The miRNAs which 
interact with the shortened sequences were predicted. For cutoff values, 0.15 and 0.05 
were chosen for PDUI and FDR respectively for the 808 shortened genes. 
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Analysis of Alternative Polyadenylation by RT-qPCR 
 As previously described (190, 201), two sets of primers were generated to detect 
PAS usage; one set, binding to an exon of a transcript to detect all transcripts and the 
other targeting to a distal 3’UTR, which is an upstream of distal PAS, to detect transcripts 
with long 3’UTR (Figure 5). Percentage of PAS usage was calculated as 
ΔCT=CTdistal − CTtotal. Data were presented as log-fold changes normalized to controls 
by calculating ΔΔCT=ΔCTaverage target  − ΔCTaverage of control. 
 
Figure 2.5. RT-qPCR-based Polyadenylation Site Usage Analysis 
 
Statistical Analysis  
 All of the statistical analyses were done with the Graphpad Prism 6. For all 
statistical analyses listed below, the data values were tested for normalization prior to 
the t-test or ANOVA. For two groups, student’s t-test (parametric) was performed with 
two-tailed settings. For multiple groups, one-way ANOVA (parametric) was used with 
Tukey’s multiple comparison test.  p values that are equal or less than 0.05 were 
considered statistically significant. The detail of the statistics regarding p values is written 
in figure legends. 
 
 
 
Exon
AAUAAA AAUAAA AAUAAA
Primer #1 Primer #2
3’UTR
RNA
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CHAPTER THREE 
NUDT21 DEPLETION IN LUNG FIBROBLASTS CONTRIBUTES  
TO THE DEVELOPMENT OF PULMONARY FIBROSIS 
INTRODUCTION 
Note: This chapter is based upon: Tingting Weng, Junsuk Ko, Chioniso P. Masamha, 
Zheng Xia, Yu Xiang, Ning-yuan Chen, Jose G. Molina, Scott Collum, Tinne C. Mertens, 
Fayong Luo, Kemly Philip, Jonathan Davies, Jingjing Huang, Cory Wilson, Rajarajan A. 
Thandavarayan, Brian A. Bruckner, Soma S.K. Jyothula, Kelly A. Volcik, Lei Li, Leng Han, 
Wei Li, Shervin Assassi, Harry Karmouty-Quintana, Eric J. Wagner, and Michael R. 
Blackburn. 2015. Cleavage factor 25 deregulation contributes to pulmonary fibrosis 
through alternative polyadenylation. The Journal of Clinical Investigation. 
https://www.jci.org/articles/view/122106. Copyright permission granted 26 March 2019 
(confirmation # 11801813). 
 
APA in Fibroblasts and IPF 
 Idiopathic pulmonary fibrosis (IPF) is a fatal chronic lung disease which affects 
about 5 million people worldwide (214). This disease is the most severe type of interstitial 
lung diseases with 25% of a 5-year survival rate (38). Despite the high prevalence and 
poor prognosis in the patients, little is known about the mechanisms by which IPF is 
developed and progressed in the patients. Therefore, there is an urgent medical need to 
better understand the pathogenesis of IPF which may lead to scientific breakthroughs 
and innovative therapies for the disease. 
 Recent studies suggest that repeated injuries in alveolar epithelial cells is a critical 
initial step in the pathogenesis of pulmonary fibrosis (102). The chronic epithelial injuries 
lead to elevation of pro-fibrotic cytokines and recruitment of inflammatory immune cells 
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which further promotes the generation of pro-fibrotic mediators, such as TGFβ, 
connective tissue growth factor (CTGF), sonic hedgehog signaling molecule (Shh), and 
prostaglandin E2 (PGE2) (215). The increase in pro-fibrotic growth factors and cytokines 
activates progenitors of fibroblasts and differentiates the cells into myofibroblasts which 
actively produce extracellular matrix (ECM) proteins in addition to other pro-fibrotic 
cytokines acting as a positive feedback (216, 217). Additionally, IPF ECM proteins itself 
constitutes a pro-fibrotic microenvironment which amplifies the progression of fibrosis via 
ECM-receptor mediated signaling pathways (216).  Considering that IPF patients are 
diagnosed with the disease in their late stage of the disease where fibrosis is already 
established due to the lack of early diagnosis, it is critical to halt the progression of the 
disease by antagonizing the activation of fibroblasts and overexpression of pro-fibrotic 
mediators and ECM from the cells.  Alternative polyadenylation (APA) is a post-
transcriptional modification that regulates the length of 3’UTRs (218). This process is 
implicated in the progression of cancer cells as APA can lead to overexpression of APA 
target genes by shortening 3’UTR and, therefore, stabilizing the transcripts (218). 3’UTR 
shortening via APA promotes overexpression of the genes contributing to cell 
proliferation and tumor growth (190). IPF and cancer share a series of signaling 
pathways which promote the generation of pathological mediators and cell proliferation 
(200). Although APA is an important cellular mechanism for tumor growth and 
progression, the involvement of this pathway in fibroblasts and its contribution to IPF 
were completely unknow. Therefore, in this chapter, we investigated the association and 
roles of APA in the pathogenesis of IPF. 
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Experimental Rationale 
 Our lab and collaborators previously demonstrated that NUDT21, which is also 
known as CFIm25, is a repressor of proximal polyadenylation. In glioblastoma, NUDT21 
is significantly reduced, leading to global 3’UTR shortening via APA (190, 219). This 
NUDT21 reduction was associated with increased protein expression for APA target 
genes, such CyclinD1. NUDT21 knockdown causes increased cell proliferation in Hela 
cells and promotes tumor growth in glioblastoma. These results collectively suggest that 
3’UTR shortening and APA by NUDT21 reduction contributes to tumor progression by 
increasing the protein expression of APA target genes. We hypothesized that APA by 
NUDT21 contributes to the pathogenesis of pulmonary fibrosis, which is characterized 
by activation of fibroblasts and overexpression of pro-fibrotic mediators from the cells. In 
order to examine this hypothesis, a number of explant samples from IPF patients or 
donors with no evidence of ILD were utilized to measure the levels of NUDT21. 
Furthermore, conditional knockout mice lacking NUDT21 in fibroblasts were exposed to 
bleomycin to examine the detrimental role of NUDT21 reduction in the progression of 
fibrosis. 
  
RESULTS 
NUDT21 is reduced in the IPF fibroblasts and the fibroblasts isolated from 
bleomycin-treated mice. 
We recently demonstrated that NUDT21 is a key regulator of APA and 3’UTR 
shortening in HeLa cells (190). In order to demonstrate the association of NUDT21 
depletion in IPF, we examined the expression of NUDT21 in IPF or healthy lungs. 
NUDT21 was significantly depleted in the IPF lungs as compared to the healthy donor 
lungs (Figure 3.1 A). To reveal the correlation between the depletion of CFIm 
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components and the severity of fibrosis, IPF lungs with various levels of FN1 were 
selected for western blot analysis. CFIm components (NUDT21, CFIm59, and CFIm68) 
were negatively correlated with FN1 expressions (Figure 3.1 B), suggesting that the 
expression of CFIm complex is reduced in the lungs of the patients with pulmonary 
fibrosis. Immunohistochemistry (IHC) for NUDT21 showed that NUDT21 was expressed 
in the nuclei of various cell types in the healthy lungs. However, in the IPF lungs, NUDT21 
was significantly depleted in the fibroblastic foci which were positive for alpha smooth 
muscle cell actin (αSMA) (Figure 3.1 C). Furthermore, for quantitative analysis, 
fibroblasts were isolated from IPF and healthy lungs and were utilized for western blot 
analysis. The result demonstrated that NUDT21, CFIm59, and CFIm68 were depleted in 
the IPF fibroblasts (Figure 3.1 D).  
 The regulatory elements of APA are evolutionarily conserved across various 
eukaryotic species (170). To understand whether a key regulator of APA, NUDT21, is 
also implicated in an animal model of lung fibrosis, we induced pulmonary fibrosis using 
bleomycin in mice and used the diseased lungs for western blot analysis. The protein 
components of CFIm, NUDT21, CFIm59 and CFIm68, were depleted in the lungs from 
the bleomycin mice that were exposed to bleomycin for 33 days (Figure 3.1 E). 
Immunofluorescence (IF) and IHC revealed that NUDT21 is reduced in the αSMA 
positive cells in the fibrotic lungs (Figure 3.1 F). Furthermore, primary lung fibroblasts 
isolated from PBS or bleomycin-treated mice showed that all three components were 
depleted in the fibrotic lungs (Figure 3.1 G). Collectively, these data suggest that 
NUDT21, a key component of CFIm25, is depleted in the lungs of IPF patients and the 
mice with bleomycin-induced fibrosis and the reduction was evident in the αSMA positive 
fibroblasts. 
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Figure 3.1. NUDT21 is depleted in the Lungs from IPF Patients or the Mice with 
Bleomycin-induced Fibrosis. Explanted IPF or transplant-grade normal lungs were 
used for western blot analysis. Each lane represents individual patient samples (Panel 
A and B). Immunohistochemistry (IHC) was performed on paraffin-embedded lung 
sections from normal or IPF (Panel C). Primary lung fibroblasts originated from IPF or 
healthy control were used for western blot analysis to semi-quantify CFIm25, CFIm59, 
and CFIm68 (Panel D). C57BL/6 mice were exposed to bleomycin intraperitoneally(i.p.) 
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for 33 days twice a week. The fibrotic lungs were used for western blot analysis (Panel 
E) or immunofluorescent/IHC analysis (Panel F). Primary lung fibroblasts were isolated 
from the mice exposed to bleomycin or PBS on Day 33 and were used for western blot 
analysis (Panel G). Scale bars: 100 μm. Used with permission from Ning-Yuan Chen and 
Tingting Weng Mills who performed experiments and assembled data, respectively. 
Junsuk Ko contributed to the data shown in this figure by repeating the experiments in 
Panel C, D, E, F, and G. 
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NUDT21 depletion induces overexpression of fibrotic markers in normal lung 
fibroblasts 
NUDT21 is a repressive regulator of proximal APA, and the depletion of NUDT21 
causes global 3’UTR shortening in various types of cancer cells (190). Based on the 
cancer data, we hypothesized that the reduction of NUDT21 promotes 3’UTR shortening 
in human lung fibroblasts leading to overexpression of fibrotic markers. In order to test 
this hypothesis, NUDT21 was depleted by siRNA. The reduction in NUDT21 increased 
the expression of fibrotic markers, such as Collagen 1 (Col1) and FN1 (Figure 3.2 A). 
Interestingly, NUDT21 knockdown did not alter proliferation of the fibroblasts (Figure 3.2 
B) which is different from the data of glioblastoma (201). We further tested our hypothesis 
by measuring the 3’UTR shortening of the target genes via RT-qPCR. For the 3’UTR 
assay, two pairs of primers were used with one set targeting the coding region of the 
transcript to measure total transcripts and the other set targeting distal region of the 
3’UTR to measure long 3’UTRs (Figure 3.2 C). The 3’UTR assay revealed that mRNA 
levels of COL1A1 were increased and the transcript underwent 3’UTR shortening 
following the depletion of NUDT21 (Figure 3.2 C). However, the transcript levels and 
PAS usage of FN1 were not affected by the reduction of NUDT21, suggesting that FN1 
protein expression was increased via an indirect pathway. These data collectively 
suggest that NUDT21 depletion is sufficient to promote overexpression of fibrotic 
markers in normal lung fibroblasts via shortening of 3’UTR. 
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Figure 3.2. NUDT21 Depletion by siRNA increases Markers of Fibrosis in Normal 
Human Lung Fibroblasts. Primary human lung fibroblasts were transfected with 
siRNAs targeting CFIm25. The cells were harvested for western blot analysis (Panel A) 
or used for WST-1 cell proliferation assay (Panel B) or RT-qPCR-based PAS analysis 
(Panel C). Used with permission from Ning-Yuan Chen and Tingting Weng Mills who 
performed experiments and assembled data, respectively. Junsuk Ko contributed to the 
data shown in this figure by repeating the experiments in Panel A, B, and C. 
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TGFb1 and Wnt signaling pathways are APA targets of NUDT21 
To comprehensively identify the targets of NUDT21 in human lung fibroblasts, 
RNA-seq was performed at 300 million reads in the human lung fibroblasts which were 
knocked down for NUDT21 or control. The RNA-seq data were further utilized for 
Dynamic Analysis of Alternative Polyadenylation from RNA-Seq (DaPars) which 
identifies 3’UTR signatures for each transcript (190, 201). DaPars revealed 808 
transcripts, which underwent significant 3’UTR shortening via APA (Figure 3.3 A and 
Table 3.1). This result is consistent with the previous report that NUDT21 reduction via 
siRNA promotes the use of pPAS in cancer cells (190). DAVID pathway analysis 
revealed that the APA genes were involved in various pro-fibrotic pathways, such as 
TGFb1, Wnt, and Hypoxia Inducible Factor 1 Alpha (HIF1A) (Figure 3.3 B). In order to 
validate the 3’UTR in transcriptome, vacuolar ATPase assembly factor (VMA21) was 
chosen due to the presence of multiple polyA signals and its sensitivity to APA as 
previously reported (190). The visualized read values of VMA21 3’UTR displayed 
significant shortening in response to NUDT21 depletion (Figure 3.3 C). Furthermore, 
RT-qPCR-based 3’UTR assay was performed to measure 3’UTR shortening of VMA21. 
Consistently, VMA21 had significant 3’UTR shortening after NUDT21 reduction (Figure 
3.3 D). 3’UTR shortening via APA causes increased protein expression due to the loss 
of miRNA binding sites and ARE in distal 3’UTRs (220). Therefore, we examined the 
protein expression of VMA21 via Western Blot and found that VMA21 was increased 
following NUDT21 depletion (Figure 3.3 E). The result of the global 3’UTR shortening 
led us to another hypothesis that the global APA releases miRNAs from the distal 3’UTR 
via shortening of transcripts and the released miRNAs target other mRNAs for gene 
regulation. To test this hypothesis, the miRNAs that lose their binding sites due to 3’UTR 
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shortening were identified. 209 miRNAs were found and the top 20 miRNAs were 
reported (Table 3.2). 10 of the 20 miRNAs were involved in fibrosis and cellular 
processes of fibroblasts, such as proliferation and differentiation. These data suggest 
that NUDT21 depletion promotes fibrosis via not only stabilization of profibrotic 
transcripts, but also deregulated gene regulation by released miRNAs. To further validate 
the biological relevancy of our finding, we compared our APA genes to IPF gene 
signatures (221) and the APA target genes of the glioblastoma cells (190) (Figure 3.3 
F). Among 808 APA genes, 159 genes were identified in the IPF gene signature, 
suggesting that many IPF genes may be indirectly regulated by APA (Figure 3.3 F). The 
comparison of APA genes between lung fibroblasts and glioblastoma revealed that there 
were 458 common APA genes which contain genes in cancer and Wnt pathways (Figure 
3.3 F). In summary, these data suggest that NUDT21 is a repressor of proximal APA and 
the dysregulation of NUDT21 leads to 3’UTR shortening and increased protein 
expression in human lung fibroblasts. 
The RNA-seq data and DaPars analysis revealed that a number of APA genes 
are involved in pro-fibrotic signaling pathways (Figure 3.3 G and H). To confirm the 
3’UTR shortening and the mRNA levels of these genes, Western Blot and RT-qPCR 
were performed. COL1A1, transforming growth factor beta receptor 1 (TGFBR1), Wnt 
family member 5A (WNT5A), and fizzled class receptor 2 (FZD2) had significant 3’UTR 
shortening (Figure 3.3 I and J) and their protein expression was increased (Figure 3.3 
K). These data demonstrate that 3’UTR shortening of these pro-fibrotic genes by 
NUDT21 depletion are sufficient to promote protein expression. In order to validate the 
clinical relevancy of this cellular process, we examined PAS usage in IPF fibroblasts. IPF 
fibroblasts utilized pPAS for polyadenylation of TGFBR1, WNT5A, and FZD2 as 
compared to normal fibroblasts (Figure 3.3 L). Moreover, the protein expression of the 
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three genes was higher in IPF fibroblasts (Figure 3.3 M) despite the fact that there was 
no difference in transcriptional levels of the three genes in normal and IPF fibroblasts 
(Figure 3.3 N). In addition, there was an evident negative correlation in protein 
expression between CFIm25 and the three APA target genes. These results suggest that 
the NUDT21 depletion activates profibrotic pathways and promotes expression of these 
factors in lung fibroblasts. 
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Figure 3.3. TGFb1 and Wnt signaling pathways are APA Targets of NUDT21. 
Primary human lung fibroblasts were transfected with siRNA targeting CFIm25 and were 
harvested for RNA purification followed by RNA-seq (Panel A). The RNA-seq data were 
utilized for pathway analyses (Panel B, G, and H), 3’UTR plot (Panel C and J), and 
comparison with the published IPF gene signature and APA data from HELA cells (Panel 
F, DEG = differentially expressed gene). RNAs from the CFIm25 knockdown cells were 
used for RT-qPCR-based PAS analysis (Panel D, I, and L) and the protein from the cells 
I J
K
L
M
N O
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was used for Western Blot analysis (Panel E and K). Protein lysate and RNAs from 
primary IPF or healthy fibroblasts were used for Western Blot analysis (Panel M and O) 
and RT-qPCR respectively (Panel N). Used with permission from Ning-Yuan Chen and 
Tingting Weng Mills who performed experiments and assembled data, respectively. 
Junsuk Ko contributed to the data shown in this figure by repeating the experiments in 
Panel D and E and performing the experiments for Panel M, N, and O. 
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Table 3.1. APA Genes in NUDT21 Knockdown Human Lung Fibroblasts 
*  all of the genes listed in the table are statistically significant (p < 0.05) 
Gene Symbol 
NUDT21KD 
vs Control 
PDUI 
 
Gene Symbol 
NUDT21KD 
vs Control 
PDUI 
 
Gene Symbol 
NUDT21KD 
vs Control 
PDUI 
LPP -0.805 
 
RPL28 -0.32 
 
USP7 -0.225 
ATP11C -0.775 
 
SGCD -0.32 
 
WWC2 -0.225 
ELMOD2 -0.75 
 
SORT1 -0.32 
 
ZNF295 -0.225 
SLC7A11 -0.71 
 
WDFY2 -0.32 
 
C8orf42 -0.22 
GXYLT1 -0.705 
 
ASIC1 -0.315 
 
CETN3 -0.22 
GPN3 -0.7 
 
C11orf75 -0.315 
 
DAB2 -0.22 
SLC12A2 -0.7 
 
C5orf24 -0.315 
 
EIF2S3 -0.22 
DCAF7 -0.69 
 
C9orf78 -0.315 
 
ESYT2 -0.22 
NCBP2 -0.675 
 
CD46 -0.315 
 
KIAA0494 -0.22 
TMOD2 -0.67 
 
CUL5 -0.315 
 
LOC100505876 -0.22 
BCAT1 -0.66 
 
FKTN -0.315 
 
NAPG -0.22 
ANP32E -0.635 
 
FZD6 -0.315 
 
NDFIP2 -0.22 
TMEM53 -0.625 
 
KAT6A -0.315 
 
PTEN -0.22 
NUDT12 -0.605 
 
MSH3 -0.315 
 
TMEM56-
RWDD3 -0.22 
BNIP3 -0.585 
 
RCE1 -0.315 
 
XPO5 -0.22 
IGF2BP1 -0.585 
 
SNPH -0.315 
 
ASXL1 -0.215 
ITCH -0.575 
 
TMEM241 -0.315 
 
DICER1 -0.215 
C17orf76-AS1 -0.57 
 
ZWINT -0.315 
 
GJC1 -0.215 
NUDT13 -0.57 
 
AKAP11 -0.31 
 
GK -0.215 
VMA21 -0.565 
 
ARHGAP18 -0.31 
 
LONRF1 -0.215 
KLHDC5 -0.56 
 
CD109 -0.31 
 
LPCAT4 -0.215 
GRPEL2 -0.555 
 
COQ10A -0.31 
 
MKI67IP -0.215 
IL6 -0.55 
 
CPEB2 -0.31 
 
MTSS1 -0.215 
SNX4 -0.55 
 
GPATCH3 -0.31 
 
OAZ1 -0.215 
TRAPPC2 -0.55 
 
GPRC5B -0.31 
 
SLC31A1 -0.215 
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ADAM12 -0.545 
 
HP1BP3 -0.31 
 
TMEM48 -0.215 
LIMCH1 -0.545 
 
INO80 -0.31 
 
TRIP11 -0.215 
TBC1D12 -0.545 
 
JMJD4 -0.31 
 
UBE2J1 -0.215 
ADAMTS6 -0.535 
 
KIAA1143 -0.31 
 
UBE4B -0.215 
JAZF1 -0.535 
 
MAP2 -0.31 
 
ZRANB1 -0.215 
SETD6 -0.535 
 
SCAF4 -0.31 
 
C16orf87 -0.21 
CYLD -0.53 
 
SIKE1 -0.31 
 
CBWD2 -0.21 
AGTPBP1 -0.525 
 
TTC8 -0.31 
 
CDH2 -0.21 
CHST11 -0.525 
 
ZNF608 -0.31 
 
CEP104 -0.21 
NFATC2IP -0.525 
 
BAG5 -0.305 
 
CHMP4B -0.21 
CHST7 -0.52 
 
CNOT4 -0.305 
 
DNAJC25 -0.21 
OSBPL8 -0.52 
 
CRTC2 -0.305 
 
DNM2 -0.21 
SMAD5 -0.52 
 
DHFR -0.305 
 
GATAD2A -0.21 
EDEM1 -0.51 
 
FMN1 -0.305 
 
GNG2 -0.21 
PAPD4 -0.51 
 
KIAA0182 -0.305 
 
GPT2 -0.21 
RFC5 -0.51 
 
PHF15 -0.305 
 
HADH -0.21 
PTAR1 -0.505 
 
PROSER1 -0.305 
 
HNRNPA0 -0.21 
WRN -0.505 
 
TBCC -0.305 
 
MDM4 -0.21 
SYT11 -0.5 
 
USP42 -0.305 
 
MIER1 -0.21 
VPS36 -0.5 
 
BTBD9 -0.3 
 
SFXN1 -0.21 
XPO4 -0.5 
 
C1orf55 -0.3 
 
UBIAD1 -0.21 
DENND3 -0.495 
 
CSTF3 -0.3 
 
UCK2 -0.21 
TMEM59 -0.495 
 
GOLM1 -0.3 
 
YBEY -0.21 
ACSS3 -0.49 
 
LDLRAD3 -0.3 
 
AES -0.205 
KLF12 -0.49 
 
PAK2 -0.3 
 
ATXN2 -0.205 
SYPL1 -0.49 
 
RUNX1 -0.3 
 
C15orf40 -0.205 
TBRG1 -0.485 
 
SEC24A -0.3 
 
CDC42BPA -0.205 
FAM91A1 -0.48 
 
TFEB -0.3 
 
CEP57L1 -0.205 
IDH3A -0.475 
 
TMEM87B -0.3 
 
CSNK1G3 -0.205 
PLA2G4A -0.475 
 
WDR77 -0.3 
 
DOK1 -0.205 
LARGE -0.47 
 
WDR92 -0.3 
 
HSDL2 -0.205 
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TEAD4 -0.47 
 
ZBTB41 -0.3 
 
KIAA0586 -0.205 
TMEM186 -0.47 
 
ZNF688 -0.3 
 
NOL8 -0.205 
AASDHPPT -0.465 
 
ANGPTL2 -0.295 
 
PRKAR1A -0.205 
C7orf41 -0.465 
 
BCKDHB -0.295 
 
RPL34 -0.205 
ETNK1 -0.465 
 
C6orf228 -0.295 
 
SMAD3 -0.205 
SPAG16 -0.465 
 
DPH3 -0.295 
 
TMEM123 -0.205 
DNM1L -0.46 
 
DYNC1LI1 -0.295 
 
ASNSD1 -0.2 
EIF2C4 -0.46 
 
EIF4G3 -0.295 
 
ATF2 -0.2 
WDR89 -0.46 
 
GPR155 -0.295 
 
CCBE1 -0.2 
ARSK -0.455 
 
LETM1 -0.295 
 
COL5A2 -0.2 
EGLN1 -0.455 
 
MYO5A -0.295 
 
GRB10 -0.2 
MIS12 -0.455 
 
OXR1 -0.295 
 
PARD3 -0.2 
C1GALT1C1 -0.45 
 
PCMT1 -0.295 
 
PP7080 -0.2 
C1orf159 -0.45 
 
RPIA -0.295 
 
SH3BP2 -0.2 
DCP2 -0.45 
 
SBF2 -0.295 
 
SIK3 -0.2 
CEP70 -0.445 
 
STX12 -0.295 
 
SNX5 -0.2 
DLG3 -0.445 
 
TIA1 -0.295 
 
SYF2 -0.2 
FGF14 -0.445 
 
ZBTB44 -0.295 
 
TLE3 -0.2 
FLNB -0.445 
 
ZBTB45 -0.295 
 
TMEM230 -0.2 
LOC439994 -0.445 
 
CNOT3 -0.29 
 
TSPAN6 -0.2 
TNRC6B -0.445 
 
GEMIN2 -0.29 
 
VAMP4 -0.2 
CCL28 -0.44 
 
GTF2H2B -0.29 
 
VCPIP1 -0.2 
PELI2 -0.44 
 
LOC440944 -0.29 
 
YIPF6 -0.2 
SMC5 -0.44 
 
MRPS18A -0.29 
 
ABHD13 -0.195 
WDR25 -0.44 
 
NEURL4 -0.29 
 
ACER3 -0.195 
FBRSL1 -0.435 
 
RCAN2 -0.29 
 
AP1G1 -0.195 
G2E3 -0.435 
 
RTN2 -0.29 
 
BNIP3L -0.195 
PLXNA1 -0.435 
 
TAF12 -0.29 
 
CCDC90B -0.195 
SPOPL -0.43 
 
ZNF507 -0.29 
 
CREM -0.195 
STON1 -0.43 
 
ABCA6 -0.285 
 
CTNNBIP1 -0.195 
C18orf25 -0.425 
 
ATL3 -0.285 
 
HDGFRP3 -0.195 
 77 
DCAF17 -0.425 
 
ATP6V1G2 -0.285 
 
IMPACT -0.195 
DYRK2 -0.425 
 
BAALC -0.285 
 
ISCA1 -0.195 
ISCU -0.425 
 
C1D -0.285 
 
KCTD10 -0.195 
LRRC49 -0.425 
 
CPNE3 -0.285 
 
MAP3K13 -0.195 
NUP107 -0.425 
 
DSEL -0.285 
 
MECP2 -0.195 
ABL2 -0.42 
 
INSIG1 -0.285 
 
TPT1-AS1 -0.195 
C3orf23 -0.42 
 
MSI2 -0.285 
 
WDR7 -0.195 
DEPDC5 -0.42 
 
PDE4DIP -0.285 
 
AKT3 -0.19 
IFNAR1 -0.42 
 
PTP4A2 -0.285 
 
C12orf65 -0.19 
MAGI1 -0.42 
 
PTRH2 -0.285 
 
CAST -0.19 
SLC35B4 -0.42 
 
SARS2 -0.285 
 
CEBPG -0.19 
TNKS -0.42 
 
YME1L1 -0.285 
 
HLTF -0.19 
NEDD4 -0.415 
 
ZBTB1 -0.285 
 
KLHL5 -0.19 
OSBPL3 -0.415 
 
APPBP2 -0.28 
 
MAPKAP1 -0.19 
RAB3B -0.415 
 
C20orf20 -0.28 
 
MFSD8 -0.19 
SLC23A2 -0.415 
 
CBFB -0.28 
 
MLLT3 -0.19 
CDC42SE2 -0.41 
 
CD164 -0.28 
 
RBPMS -0.19 
CERS6 -0.41 
 
DNAJC3 -0.28 
 
SCD -0.19 
IMMP2L -0.41 
 
FAM208A -0.28 
 
SERP1 -0.19 
RGN -0.41 
 
MAPRE2 -0.28 
 
SH3GLB1 -0.19 
MPHOSPH9 -0.405 
 
PEX19 -0.28 
 
SLC25A37 -0.19 
MSRA -0.405 
 
PHC3 -0.28 
 
STAM2 -0.19 
NRF1 -0.405 
 
RASSF4 -0.28 
 
STRN -0.19 
SPCS3 -0.405 
 
SRR -0.28 
 
TRIM27 -0.19 
USP47 -0.405 
 
UST -0.28 
 
ZNF576 -0.19 
ZNF138 -0.405 
 
ANKS3 -0.275 
 
ADH1B -0.185 
C14orf79 -0.4 
 
CASP6 -0.275 
 
CLUAP1 -0.185 
HNRNPUL2 -0.4 
 
DCUN1D1 -0.275 
 
DPY19L4 -0.185 
KRT8 -0.4 
 
GFPT1 -0.275 
 
GATAD2B -0.185 
MUTED -0.4 
 
HMGN3 -0.275 
 
IRF2BP2 -0.185 
RASAL2 -0.4 
 
INO80C -0.275 
 
KDM1B -0.185 
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SLC9A7 -0.4 
 
MRPL35 -0.275 
 
KHSRP -0.185 
UBR3 -0.4 
 
SGSM3 -0.275 
 
LOC100128252 -0.185 
ZEB1-AS1 -0.4 
 
SLC30A7 -0.275 
 
RALA -0.185 
ZNF862 -0.4 
 
TGIF2 -0.275 
 
REEP5 -0.185 
CPNE7 -0.395 
 
TMEM41A -0.275 
 
SRSF10 -0.185 
FAM173B -0.395 
 
ZNF697 -0.275 
 
TMBIM6 -0.185 
LAMC1 -0.395 
 
AKIRIN2 -0.27 
 
TMEM136 -0.185 
PDHB -0.395 
 
CHD3 -0.27 
 
TRAF3IP1 -0.185 
PIR-FIGF -0.395 
 
GABPB2 -0.27 
 
VGLL3 -0.185 
RTKN -0.395 
 
HSD17B7 -0.27 
 
ZNF652 -0.185 
TMEM50B -0.395 
 
KANSL1L -0.27 
 
ABHD5 -0.18 
EIF2C2 -0.39 
 
KIAA0564 -0.27 
 
CDS2 -0.18 
JHDM1D -0.39 
 
L3MBTL3 -0.27 
 
CIAO1 -0.18 
MBLAC2 -0.39 
 
MORC3 -0.27 
 
EWSR1 -0.18 
TGFBR1 -0.39 
 
PDE12 -0.27 
 
HSPBP1 -0.18 
TMCC1 -0.39 
 
RAB11FIP1 -0.27 
 
MAP4K4 -0.18 
UBR1 -0.39 
 
RWDD2A -0.27 
 
ME1 -0.18 
C20orf24 -0.385 
 
SIAH1 -0.27 
 
MRPL42 -0.18 
MTMR11 -0.385 
 
SOCS6 -0.27 
 
NBN -0.18 
PBX1 -0.385 
 
SPTLC2 -0.27 
 
NDRG3 -0.18 
ADAMTSL1 -0.38 
 
ATP10A -0.265 
 
PRKD3 -0.18 
CCDC91 -0.38 
 
BTRC -0.265 
 
RBM39 -0.18 
CHD6 -0.38 
 
CREBRF -0.265 
 
STX7 -0.18 
HIPK1 -0.38 
 
CYB5R2 -0.265 
 
STXBP5 -0.18 
ITSN1 -0.38 
 
FAM114A2 -0.265 
 
SUPT3H -0.18 
MED6 -0.38 
 
IPO7 -0.265 
 
ZNF592 -0.18 
PTBP3 -0.38 
 
MEX3B -0.265 
 
ATG13 -0.175 
QSER1 -0.38 
 
RAB4A -0.265 
 
MPZL1 -0.175 
CEP68 -0.375 
 
TAF1D -0.265 
 
NAV2 -0.175 
EIF2C3 -0.375 
 
CAV2 -0.26 
 
NCOA3 -0.175 
FKBP14 -0.375 
 
CPEB1 -0.26 
 
SP1 -0.175 
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HMGCR -0.375 
 
CTHRC1 -0.26 
 
STXBP6 -0.175 
IGHMBP2 -0.375 
 
ENPP1 -0.26 
 
UBL3 -0.175 
JAK2 -0.375 
 
HS2ST1 -0.26 
 
UBQLN1 -0.175 
MAP2K7 -0.375 
 
MIF4GD -0.26 
 
UBR2 -0.175 
NPAS2 -0.375 
 
PAK1 -0.26 
 
WDR44 -0.175 
PUS7 -0.375 
 
RCHY1 -0.26 
 
WDR5 -0.175 
SHC3 -0.375 
 
RLIM -0.26 
 
ZFX -0.175 
ZNF480 -0.375 
 
RNASEH2A -0.26 
 
ABCA8 -0.17 
ARID5A -0.37 
 
TIMM8A -0.26 
 
ARL4A -0.17 
C21orf91 -0.37 
 
TMEM30A -0.26 
 
CDH6 -0.17 
C22orf39 -0.37 
 
TMTC3 -0.26 
 
CUL4B -0.17 
CHCHD7 -0.37 
 
ZNF211 -0.26 
 
FAM126A -0.17 
FAM168B -0.37 
 
ZNF673 -0.26 
 
GOT1 -0.17 
GTF2H2D -0.37 
 
ATL2 -0.255 
 
GPR180 -0.17 
LOC100506714 -0.37 
 
BACE1 -0.255 
 
KIAA0100 -0.17 
RNF2 -0.37 
 
BICD2 -0.255 
 
MAN1C1 -0.17 
VWA5A -0.37 
 
CAB39L -0.255 
 
PXMP4 -0.17 
WNT5A -0.37 
 
CEP112 -0.255 
 
RABGEF1 -0.17 
ZNF207 -0.37 
 
HIST1H2BC -0.255 
 
RBM12 -0.17 
ABI2 -0.365 
 
LOC100507463 -0.255 
 
REEP3 -0.17 
FGF1 -0.365 
 
MGEA5 -0.255 
 
SCARB2 -0.17 
MGAT2 -0.365 
 
MPPE1 -0.255 
 
SPATA2 -0.17 
MRS2 -0.365 
 
NFASC -0.255 
 
TMEM33 -0.17 
SPINT2 -0.365 
 
PBX3 -0.255 
 
TTC39C -0.17 
AHDC1 -0.36 
 
RGL1 -0.255 
 
U2SURP -0.17 
ARHGAP32 -0.36 
 
SLAIN2 -0.255 
 
ATP6V1G1 -0.165 
C20orf112 -0.36 
 
SLC35A2 -0.255 
 
CADM1 -0.165 
ITGA1 -0.36 
 
TIPRL -0.255 
 
CAMK2N1 -0.165 
LRRC8C -0.36 
 
TMF1 -0.255 
 
ENSA -0.165 
NEO1 -0.36 
 
TTC28-AS1 -0.255 
 
IMPAD1 -0.165 
PMS1 -0.36 
 
VPS29 -0.255 
 
LNPEP -0.165 
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SETD8 -0.36 
 
ZC3H14 -0.255 
 
NIPA2 -0.165 
ABCC5 -0.355 
 
ZFHX3 -0.255 
 
PIGK -0.165 
DNAJC5 -0.355 
 
ZNF846 -0.255 
 
PLA2G12A -0.165 
FAM179B -0.355 
 
ALMS1 -0.25 
 
SDC2 -0.165 
HACE1 -0.355 
 
DCAF5 -0.25 
 
SKIL -0.165 
NIPSNAP3A -0.355 
 
DCTN6 -0.25 
 
SLC2A8 -0.165 
NSD1 -0.355 
 
KANSL2 -0.25 
 
SPRYD7 -0.165 
PDK1 -0.355 
 
MEIS2 -0.25 
 
STAU2 -0.165 
SEPT6 -0.355 
 
MUT -0.25 
 
TCF3 -0.165 
SLC25A22 -0.355 
 
PRKCA -0.25 
 
BAHD1 -0.16 
STX6 -0.355 
 
RC3H2 -0.25 
 
C19orf12 -0.16 
SUPT4H1 -0.355 
 
SNAI1 -0.25 
 
CCDC47 -0.16 
TRABD -0.355 
 
SPRED1 -0.25 
 
COPS2 -0.16 
VOPP1 -0.355 
 
TANC1 -0.25 
 
EEF1E1 -0.16 
ZNF498 -0.355 
 
TBX2 -0.25 
 
GOLGB1 -0.16 
ZRSR2 -0.355 
 
TRERF1 -0.25 
 
METTL2A -0.16 
ADAMTS5 -0.35 
 
TRMT11 -0.25 
 
MRI1 -0.16 
CYB561D1 -0.35 
 
UBASH3B -0.25 
 
MTERFD2 -0.16 
GNB4 -0.35 
 
ZCCHC11 -0.25 
 
NAP1L1 -0.16 
KLHL24 -0.35 
 
ZFYVE1 -0.25 
 
PCMTD1 -0.16 
POLR1D -0.35 
 
ASB1 -0.245 
 
PDS5A -0.16 
PPIL2 -0.35 
 
C4orf46 -0.245 
 
PGM2 -0.16 
SNX30 -0.35 
 
CHD9 -0.245 
 
PPM1B -0.16 
UFM1 -0.35 
 
CYP2U1 -0.245 
 
PTPLAD2 -0.16 
ZNF267 -0.35 
 
FAM122B -0.245 
 
SEL1L -0.16 
ACADM -0.345 
 
HUS1 -0.245 
 
STK10 -0.16 
ACADSB -0.345 
 
MCPH1 -0.245 
 
SYAP1 -0.16 
AGPAT5 -0.345 
 
MED13L -0.245 
 
USP32 -0.16 
ATG4A -0.345 
 
MRE11A -0.245 
 
WDFY3 -0.16 
C7orf42 -0.345 
 
PCGF6 -0.245 
 
WDR36 -0.16 
C8orf83 -0.345 
 
RORA -0.245 
 
YIPF4 -0.16 
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DHCR7 -0.345 
 
RPRD1A -0.245 
 
ATG2B -0.155 
FAM50B -0.345 
 
RPS6KB1 -0.245 
 
CYBRD1 -0.155 
LMCD1 -0.345 
 
SSBP3 -0.245 
 
DCBLD1 -0.155 
PODXL -0.345 
 
SYTL2 -0.245 
 
ELP2 -0.155 
PRPF38A -0.345 
 
TCFL5 -0.245 
 
FAM103A1 -0.155 
RNF44 -0.345 
 
ADSS -0.24 
 
FAM82B -0.155 
SGTB -0.345 
 
C6orf89 -0.24 
 
LOC401093 -0.155 
TBL1XR1 -0.345 
 
C7orf23 -0.24 
 
PDCL3 -0.155 
TBP -0.345 
 
CCRL1 -0.24 
 
PRDX6 -0.155 
ACAP2 -0.34 
 
EP400 -0.24 
 
PTPLA -0.155 
AP1AR -0.34 
 
HAUS6 -0.24 
 
RTN3 -0.155 
ARNTL2 -0.34 
 
METTL8 -0.24 
 
SCN9A -0.155 
CCDC77 -0.34 
 
PHACTR2 -0.24 
 
UBE2Q2 -0.155 
CLASP1 -0.34 
 
TMEM106B -0.24 
 
ZCCHC10 -0.155 
CPSF2 -0.34 
 
TPP2 -0.24 
 
ZNF148 -0.155 
GOLGA1 -0.34 
 
ZHX3 -0.24 
 
APH1B -0.15 
GSK3B -0.34 
 
ZNF74 -0.24 
 
ARMC8 -0.15 
IGF1R -0.34 
 
C12orf29 -0.235 
 
C11orf73 -0.15 
KITLG -0.34 
 
C5orf22 -0.235 
 
CCDC72 -0.15 
LPGAT1 -0.34 
 
CDC73 -0.235 
 
DOCK5 -0.15 
MED28 -0.34 
 
DNAJB6 -0.235 
 
GUCY1B3 -0.15 
MEF2C -0.34 
 
FOXF1 -0.235 
 
MARCH6 -0.15 
OSGIN1 -0.34 
 
IREB2 -0.235 
 
PIGN -0.15 
PFAS -0.34 
 
ISG20L2 -0.235 
 
PTPN18 -0.15 
RABEP1 -0.34 
 
LRRFIP2 -0.235 
 
TBC1D19 -0.15 
SMAD6 -0.34 
 
PMEPA1 -0.235 
 
SUV420H1 0.15 
VDR -0.34 
 
PRPF18 -0.235 
 
SENP3-EIF4A1 0.17 
XRN1 -0.34 
 
PTGER2 -0.235 
 
LOX 0.175 
ZMYM4 -0.34 
 
RNF141 -0.235 
 
ITGB1BP1 0.18 
ADAMTS8 -0.335 
 
WIPF1 -0.235 
 
THRA 0.18 
ATXN1 -0.335 
 
ZNF516 -0.235 
 
LOC284385 0.195 
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NPR3 -0.335 
 
ACP1 -0.23 
 
TNFAIP6 0.225 
PHKA1 -0.335 
 
AGPS -0.23 
 
C16orf5 0.23 
SAR1A -0.335 
 
AIMP1 -0.23 
 
ANGEL1 0.235 
SDHD -0.335 
 
APPL1 -0.23 
 
DOHH 0.24 
SMARCA1 -0.335 
 
ARL8B -0.23 
 
USP33 0.25 
SMN1 -0.335 
 
BAZ2A -0.23 
 
FLCN 0.255 
WWTR1 -0.335 
 
BCORL1 -0.23 
 
TRPM4 0.255 
ZADH2 -0.335 
 
CRYBB2P1 -0.23 
 
PSG1 0.265 
CMTM7 -0.33 
 
DCUN1D4 -0.23 
 
CAMK2D 0.275 
GNB1 -0.33 
 
DDHD2 -0.23 
 
MBD1 0.275 
IP6K2 -0.33 
 
DNAJC18 -0.23 
 
LACTB 0.28 
KCTD1 -0.33 
 
EIF2AK2 -0.23 
 
PTPN4 0.28 
NIN -0.33 
 
ERC1 -0.23 
 
NMT2 0.29 
PPP2R5A -0.33 
 
GOLT1B -0.23 
 
SLC11A2 0.29 
SNRNP48 -0.33 
 
HCFC2 -0.23 
 
N4BP1 0.295 
TMEM55A -0.33 
 
NUS1 -0.23 
 
SEPT1 0.295 
TNFRSF6B -0.33 
 
PAXIP1 -0.23 
 
LOC100652739 0.305 
ATP2C1 -0.325 
 
PWWP2A -0.23 
 
WDYHV1 0.305 
CRLF3 -0.325 
 
SBDSP1 -0.23 
 
CREB3L2 0.31 
DEGS1 -0.325 
 
SEH1L -0.23 
 
GTPBP3 0.31 
EFNA4 -0.325 
 
SNX13 -0.23 
 
LOC652276 0.31 
GTF2H2C -0.325 
 
TNPO1 -0.23 
 
RAD51D 0.31 
KANK1 -0.325 
 
VHL -0.23 
 
C1orf27 0.32 
LIN52 -0.325 
 
ZNF780A -0.23 
 
PLEKHF1 0.32 
MAN2A1 -0.325 
 
BBIP1 -0.225 
 
ARHGEF19 0.335 
MAP3K2 -0.325 
 
BMP2K -0.225 
 
NAPB 0.345 
MED23 -0.325 
 
CARD8 -0.225 
 
TYW1B 0.35 
MTA1 -0.325 
 
CD44 -0.225 
 
METTL18 0.355 
PAFAH1B1 -0.325 
 
CGGBP1 -0.225 
 
WDR4 0.36 
RALGAPB -0.325 
 
COX15 -0.225 
 
NFATC1 0.365 
SERPINB8 -0.325 
 
CREB1 -0.225 
 
PINX1 0.365 
 83 
SYNJ2BP -0.325 
 
GSTM2 -0.225 
 
PPP2R5B 0.365 
ZCCHC9 -0.325 
 
HIRA -0.225 
 
ECT2 0.37 
ZNF785 -0.325 
 
IER3IP1 -0.225 
 
ABCC3 0.38 
CCDC68 -0.32 
 
KIF1B -0.225 
 
ZNF184 0.4 
CCNY -0.32 
 
NSUN4 -0.225 
 
EIF2B3 0.425 
DUSP6 -0.32 
 
NUFIP1 -0.225 
 
TRIM52 0.43 
EVI5 -0.32 
 
PBRM1 -0.225 
 
CLEC16A 0.45 
FZD2 -0.32 
 
PSMD12 -0.225 
 
TXNDC16 0.46 
LZTFL1 -0.32 
 
RAB27A -0.225 
 
BCCIP 0.475 
MAPRE1 -0.32 
 
RNF170 -0.225 
 
PMS2P5 0.485 
MXD4 -0.32 
 
RWDD4 -0.225 
 
MAPK1 0.605 
ODZ4 -0.32 
 
TUSC2 -0.225 
 
BCAP29 0.715 
PKNOX1 -0.32 
 
ULBP2 -0.225 
 
    
 
Table 3.2. The Top 20 miRNAs that lose their Binding Sites Due to the APA Events 
in NUDT21 Knockdown Human Lung Fibroblasts 
miRNA # of Sites Lost 
miR-124-3p.1 131 
miR-30-5p 120 
miR-181-5p 103 
miR-340-5p 95 
miR-124-3p.2/506-3p 93 
miR-15-5p/16-5p/195-5p/424-5p/497-5p 92 
miR-101-3p.2 90 
miR-23-3p 89 
miR-200bc-3p/429 88 
miR-9-5p 88 
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miR-144-3p 87 
miR-182-5p 86 
miR-19-3p 86 
miR-27-3p 83 
miR-101-3p.1 80 
miR-17-5p/20-5p/93-5p/106-5p/519-3p 80 
miR-128-3p 79 
miR-130-3p/301-3p/454-3p 79 
miR-29-3p 77 
miR-141-3p/200a-3p 76 
 
*MiRNAs in bold are known to play a role in fibroblast differentiation/proliferation or tissue 
fibrosis. 
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NUDT21 overexpression reduces expression of pro-fibrotic proteins in lung 
fibroblasts 
To validate the therapeutic effect of NUDT21, we generated a NUDT21 
overexpression (OE) plasmid by inserting the human NUDT21 cDNA into a pcDNA3.1 
vector. As a control, pcDNA3.1 null plasmid was used for experiments. Primary lung 
fibroblasts successfully overexpressed NUDT21 following electroporation with the 
NUDT21 plasmids (Figure 3.4 A). The fibroblasts that overexpressed NUDT21 displayed 
3’UTR shortening on the NUDT21 target genes, such as COL1A1, TGFBR1, WNT5A, 
and FZD2 (Figure 3.4 B). In addition to the mRNA modification, their protein expression 
on the genes was reduced two days for WNT5A and three days for COL1A1 and FZD2 
after electroporation in IPF fibroblasts (Figure 3.4 A). This result suggests that the fibrotic 
phenotype in IPF fibroblasts can be reversed by the NUDT21 overexpression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
 
Figure 3.4. Overexpression of NUDT21 decreases Protein Expression of APA 
Target Genes and Markers of Fibrosis. Primary human lung fibroblasts were 
electroporated with pcDNA3.1 expressing human CFIm25. The cells were harvested on 
Day 2 and 3 for Western Blot analysis and RT-qPCR-based PAS analysis (Panel A and 
B). Junsuk Ko contributed to the data shown in this figure by performing the experiments 
for Panel A and B. 
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NUDT21 reduction in fibroblasts worsens the bleomycin-induced pulmonary 
fibrosis 
To investigate the causal relationship between NUDT21 reduction and fibrosis in 
an in vivo model, we generated conditional knockout mice by crossing Col1a1-creER 
mice with NUDT21f/f mice. Although Col1a1-creER is not the best creER system due to 
the expression of col1a1 in other cell types, such as osteoblasts (222), this cre was 
chosen for the following reason; Col1a2-creER mice which are more widely accepted for 
fibroblast studies did not produce any progeny with the Col1a2-creER-NUDT21f/f 
genotype when they were crossed with NUDT21f/f, presumably due to the presence of 
those two transgenes on the same chromosome (data not shown). Nonetheless, this 
mouse system successfully allowed to conditionally delete NUDT21 in Col1a1-
expressing cells including fibroblasts upon administration of tamoxifen. Although Col1a1 
is expressed in other cell types, such as osteoblasts and odontoblasts, this Col1a1 
system has been widely used and accepted in the field to study functions of a gene in 
lung fibroblasts (223). 4-5-week-old mice were administered tamoxifen daily for five days 
to induce translocation of creER. The tamoxifen successfully reduced NUDT21 in Cre-
positive cells (Figure 3.5 A). For quantitative analysis, primary lung fibroblasts were 
isolated from control or the Col1a1-creER-NUDT21f/f mice one week after the tamoxifen 
treatment. Cre was expressed and the fibroblasts isolated from the creER-NUDT21f/f 
mice displayed significant reduction in NUDT21 (Figure 3.5 B). Consistent with the 
hypothesis, the NUDT21 depleted cells had significant 3’UTR shortening on COL1A1, 
TGFBR1, FZD2, and WNT5a mRNAs and, moreover, their protein expression was 
reduced (Figure 3.5 C). This result indicates that these pro-fibrotic genes are regulated 
by NUDT21 for their APA not only in human but also in mouse lung fibroblasts.  
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Based on this data, we further hypothesized that NUDT21 reduction in fibroblasts 
exacerbates experimental fibrosis in mice. To test this hypothesis, the NUDT21 knockout 
mice were treated with tamoxifen followed by bleomycin injection to induce lung fibrosis. 
As compared to the control mice, the Col1a1-creER-NUDT21f/f mice had increased Col1 
and FN1 protein expression, suggesting that fibrosis was worse in the NUDT21 knockout 
mice (Figure 3.5 D). Consistent with the data from the isolated lung fibroblasts, the 
NUDT21 knockout mice had elevated levels of protein for TGFBR1, FZD2, and WNT5A. 
Moreover, Col1a1 mRNA underwent more evident 3’UTR shortening in the NUDT21 
knockout mice upon bleomycin injury (Figure 3.5 E). Additional markers and assays of 
fibrosis were conducted to assess the severity of fibrosis in the NUDT21 conditional 
knockout mice. RT-qPCR revealed that FN1 and Col2a1 mRNAs were elevated in the 
Col1a1-creER-NUDT21f/f mice which were treated with bleomycin (Figure 3.5 F). 
Additionally, the Col1a1-creER-NUDT21f/f mice had increased levels of Col1 in their 
bronchial alveolar lavage fluid (BAL) as compared to the BAL from control (Figure 3.5 
G). Moreover, the accumulation of αSMA-positive cells, a marker of myofibroblasts, were 
more evident in the Col1a1-creER-NUDT21f/f mice as shown in the Masson’s Trichrome 
and immunostaining data (Figure 3.5 H). A quantitative blinded assay of fibrosis, 
Ashcroft scoring, indicated that the Col1a1-creER-NUDT21f/f mice had more severe 
fibrosis following the chronic bleomycin injury (Figure 3.5 I). These data collectively 
suggest that depletion of NUDT21 in fibroblasts exacerbates pulmonary fibrosis by 
promoting overexpression of profibrotic factors through APA. 
 Conditional knockout of NUDT21 in fibroblasts affected the pro-inflammatory 
profile in the mice. There was an increase in total number of inflammatory cells, such as 
infiltrated macrophages and lymphocytes, in the BAL fluid of NUDT21 knockout mice 
which were sacrificed 28 days after the first bleomycin treatment (Figure 3.5 J). 
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Interestingly, the NUDT21 deleted mice displayed an increase in lymphocytes at 7 days 
after the first bleomycin administration, suggesting that NUDT21 depletion may cause 
inflammation in the early stages of injury response (Figure 3.5 K).  
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Figure 3.5. Deletion of NUDT21 in Lung Fibroblasts exacerbates Pulmonary 
Fibrosis induced by Bleomycin. NUDT21 is conditionally deleted by repeated 
administration of tamoxifen (75 mg/kg) daily for 5 days. Immunofluorescent staining was 
performed to confirm the deletion of NUDT21 and the presence of cre (Panel A). In 
addition, the lungs from NUDT21 knockout or control mice were harvested for Western 
Blot analysis or RT-qPCR-based PAS analysis (Panel B and C). Following the cre 
activation by tamoxifen, the mice were exposed to PBS or bleomycin (0.035u/g) via i.p 
twice a week for 4 weeks. Then, the lungs from the bleomycin-treated mice were 
harvested for Western Blot analysis (Panel D), RT-qPCR-based PAS analysis (Panel E), 
quantification of gene expression by RT-qPCR (Panel F), Sircol assay (Panel G), IHC 
staining (Panel H), Ashcroft assay (Panel I), and BAL cell count (Panel J). In addition to 
the analysis of bleomycin-induced at a late phase, lung analysis at an earlier time point 
was performed where the bleomycin-treated mice were sacrificed 7 days after the initial 
treatment (Panel K). Used with permission from Ning-Yuan Chen and Tingting Weng 
Mills who performed experiments and assembled data, respectively. Junsuk Ko 
contributed to the data shown in this figure by repeating the experiments for Panel C and 
E. 
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Conditional Knockout of NUDT21 in the late phase of fibrosis exacerbates 
bleomycin-induced fibrosis without altering inflammation. 
The chronic i.p. bleomycin model causes an early inflammatory response followed 
by fibrotic response. The previous data demonstrate that NUDT21 depletion may cause 
inflammation even in the absence of bleomycin. To minimize the effect of NUDT21 in 
inflammation during the early phase of bleomycin injury and, therefore, better understand 
their role in the fibrotic phase, cre activation was delayed until Day 15 after the first 
injection of i.p. bleo which allowed fibroblasts to delete NUDT21 in the fibrotic phase 
(Figure 3.6 A). The delayed tamoxifen successfully depleted NUDT21 protein and 
mRNAs in the lungs of knockout mice. The BAL fluid analysis revealed that there is no 
difference in inflammatory profile between Col1a1-creER-NUDT21f/f and control mice 
(Figure 3.6 B). Despite the insignificant difference in inflammatory feature, the fibrosis 
induced by bleomycin treatment was more severe in the Col1a1-creER-NUDT21f/f mice 
as shown by elevated protein and mRNAs levels of fibrotic markers, such as Col1 and 
FN1 (Figure 3.6 C and D), increased soluble collagen (Figure 3.6 E), enhanced collagen 
and myofibroblast accumulation (Figure 3.6 F), and augmented Ashcroft score (Figure 
3.6 G). Moreover, parameters on FlexiVent, which reflects lung functions, indicated that 
Col1a1-creER-NUDT21f/f mice had severe tissue damping (G), tissue elastase (H), and 
resistance (R), and decreased compliance (C), and inspiratory capacity (IC) without 
altering the Newtonian resistance (Rn) (Figure 3.6 H). These data demonstrate that 
NUDT21 reduction in the late phase of fibrosis worsens the lung fibrosis by bleomycin 
injection without altering inflammatory profile.  
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Figure 3.6. NUDT21 Deletion by Late Activation of Cre worsens Pulmonary Fibrosis 
induced by Bleomycin without significantly affecting Inflammation. Bleomycin was 
administered i.p. in Col1a1-creER-CFIm25f/f or control mice twice a week for 4 weeks. 
On day 15 after the first bleomycin, tamoxifen was administered i.p. to induce cre 
activation and to delete CFIm25 (Panel A). BAL fluid was harvested and used for BAL 
cell count assay (Panel B). The lungs from the CFIm25 knockout or control mice were 
used for Western Blot analysis (Panel C), quantitative RT-qPCR analysis (Panel D), 
soluble collagen assay (sircol assay) (Panel E), immuno and Masson’s Trichrome 
H
F G
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staining (Panel F) and Ashcrost assay (Panel G). Flexivent analysis was performed to 
measure the lung functions in the mice (Panel H). Scale bar: 200 um. Used with 
permission from Ning-Yuan Chen and Tingting Weng Mills who performed experiments 
and assembled data, respectively. Junsuk Ko contributed to the data shown in this figure 
by performing the experiments for Panel H. 
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NUDT21 depletion exacerbates pulmonary fibrosis induced by a single dose of 
oropharyngeal injection of bleomycin 
The chronic i.p. bleomycin injection model is widely used to investigate the 
features of progressive and irreversible fibrosis (210, 224, 225). However, the single 
dose of oropharyngeal administration model (OPA) induces progressive but reversible 
fibrosis in vivo (100, 225). The OPA fibrosis model was utilized to investigate the role of 
NUDT21 depletion in pulmonary fibrosis (Figure 3.6 A). Consistent with the chronic i.p. 
model, removal of NUDT21 in fibroblasts by tamoxifen induced pulmonary inflammation 
in the absence of bleomycin (Figure 3.6 B), suggesting that NUDT21 deletion may 
promote inflammation. The OPA model showed that conditional deletion of NUDT21 
fibroblasts increased the markers of fibrosis, such as Col1 and FN1 protein and mRNA 
(Figure 3.6 C and D). Furthermore, Sircol assay demonstrated that there was an 
increase in soluble collagen in the BAL fluids from the Col1a1-creER-NUDT21f/f mice 
upon OPA of bleomycin (Figure 3.6 E). Additionally, the NUDT21 knockout mice had 
increased tissue elastase and resistance, and decreased compliance and inspiratory 
capacity (Figure 3.6 F). Moreover, there was more collagen deposition and a-SMA 
positive cells in the NUDT21 knockout mice as shown in the Masson’s Trichrome and 
immunostaining (Figure 3.6 G). The Ashcroft score showed that the fibrosis in the 
NUDT21 knockout mice was more severe than in control (Figure 3.6 H). These data 
collectively suggest that NUDT21 depletion in fibroblasts worsens fibrosis established by 
single dose OPA of bleomycin.  
 Similar to the delayed cre in the i.p. model, we performed the late cre activation 
in the OPA model to understand the role of NUDT21 in the fibrotic phase. Cre was 
activated 15 days after the OPA of bleomycin (Figure 3.6 H). The delayed cre activation 
resulted in insignificant inflammatory profiles in the control and NUDT21 knockout mice, 
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which is consistent with the key result in the i.p. model (Figure 3.6 J). Nonetheless, the 
OPA of bleomycin induced more severe fibrosis in the NUDT21 knockout mice as 
compared to the control (Figure 3.6 K, L, M, N, O, and P). These data suggest that 
conditional depletion of NUDT21 in fibroblasts during the late fibrotic phase sufficiently 
worsens OPA bleomycin-induced lung fibrosis without significantly altering inflammation.  
 To further investigate the role of NUDT21 depletion in pulmonary fibrosis, we 
utilized a different cre system, Foxd1-cre, which expresses cre in precursor cells of 
pulmonary fibroblasts as Foxd1 is a marker of pericytes which give rise to a large 
proportion of Col1a1 positive fibroblasts in pulmonary fibrosis in mice (226). We noticed 
that homozygous deletion of NUDT21 using Foxd1-cre was lethal in mice. Instead, 
heterozygous Foxd1-cre-NUDT21f/f mice were utilized for bleomycin experiments. In the 
mice, NUDT21 was successfully reduced as shown by the transcript and protein levels 
of NUDT21 (Figure 3.6 Q), and the reduction in NUDT21 was associated with 3’UTR 
shortening in FZD2 and Vma21 (Figure 3.6 R). Following i.p. or OPA bleomycin injection 
and establishment fibrosis, the conditional knockout mice displayed severe fibrosis as 
compared to the control mice in both models (Figure 3.6 S, T, U, and V for the i.p. model 
and Figure 3.6 W, X, Y, and Z for the OPA model). These results suggest that reduction 
of NUDT21 in precursors of fibroblasts exacerbates pulmonary fibrosis. 
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Figure 3.7. NUDT21 Depletion amplifies Pulmonary Fibrosis induced by a single 
Dose of Oropharyngeal Injection of Bleomycin. Col1a1-creER-CFIm25f/f or control 
mice were administered bleomycin oropharyngeally once (3.5 U/kg) after activation of 
cre by tamoxifen (Panel A). On day 21, the mice were sacrificed for BAL cell count (Panel 
B), Western Blot (Panel C), quantitative gene expression by RT-qPCR (Panel D), Sircol 
assay (Panel E), Flexivent (Panel F), IHC (Panel G), and Ashcrost assay (Panel H). In 
order to delay the activation of cre, Col1a1-creER-CFIm25f/f or control mice were first 
administered bleomycin oropharyngeally once (3.5 U/kg) followed by activation of cre 15 
days after the bleomycin injection (Panel I). On day 21, the mice were sacrificed for BAL 
cell count (Panel J), Western Blot (Panel K), quantitative gene expression by RT-qPCR 
(Panel L), Sircol assay (Panel M), Flexivent (Panel N), IHC (Panel O), and Ashcrost 
assay (Panel P). Heterozygous Foxd1-cre-CFIm25f/f or control mice were generated to 
confirm the efficiency of partial deletion. These heterozygous mice were sacrificed 
without any fibrotic injury from bleomycin to quantify the NUDT21 reduction and were 
utilized for RT-qPCR, Western Blot (Panel Q), and PAS analysis by RT-qPCR (Panel R).  
Heterozygous Foxd1-cre-CFIm25f/f or control mice were administered bleomycin 
intraperitoneally as previously described. The lungs were harvested for Western Blot 
(Panel S), RT-qPCR (Panel T), Sircol assay, BAL cell count, Ashcroft (Panel U), IHC 
staining (Panel V). Heterozygous Foxd1-cre-CFIm25f/f or control mice were administered 
bleomycin oropharyngeally once (3.5 U/kg) as previously described. The lungs were 
utilized for Western Blot (Panel W), RT-qPCR (Panel X), Sircol assay, BAL cell count, 
Ashcroft (Panel Y), IHC staining (Panel Z). Scale bars = 200 um. Used with permission 
from Ning-Yuan Chen and Tingting Weng Mills who performed experiments and 
assembled data, respectively. Junsuk Ko contributed to the data shown in this figure by 
performing the experiments for Panel F and N. 
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DISCUSSION 
IPF is a fatal lung disease with a relatively high prevalence and low 5-year survival 
rate being up to 64.7 cases per 100,000 persons and 25% respectively (4, 38). 
Fibroblasts and myofibroblasts, which are activated fibroblasts, are producers of 
extracellular matrix proteins, contributing to the development of pulmonary fibrosis. 
However, the mechanisms by which the cells overexpress profibrotic and matrix proteins 
are not fully understood. Therefore, the knowledge in the novel biological processes 
which regulate expression of pathological genes can be beneficial if the pathways are 
discovered and therapeutically targeted to halt the progression of pulmonary fibrosis. In 
this current project, we investigated the role of APA in pulmonary fibrosis and reported 
for the first time in the field of fibrosis that the reduction of the key CFIm components is 
associated with the disease (NUDT21, CFIm59, and CFIm68). We further demonstrated 
that the reduction of NUDT21 is evident in myofibroblasts from the lungs of IPF patients 
and mice with bleomycin-induced lung fibrosis, suggesting that these pathological cells 
may overexpress pro-fibrotic factors via global 3’UTR shortening and APA of mRNAs. 
Furthermore, depletion of NUDT21 was sufficient to induce 3’UTR shortening of genes 
involved in the pro-fibrotic pathways, such as Col1a1, TGFBR1, in addition to promoting 
their protein expression. More importantly, using the conditional NUDT21 knockout 
models, we showed that NUDT21 reduction in fibroblasts exacerbates the experimental 
fibrosis induced by bleomycin administration, suggesting that the NUDT21 reduction in 
the IPF patients contributes to the development of pulmonary fibrosis. In summary, we 
discovered APA and NUDT21 reduction as a novel mechanism amplifying the 
progression of pulmonary fibrosis. 
The innovation in sequencing technologies has allowed to explore untraditional 
mRNA modifications, such as alternative RNA splicing and alternative polyadenylation, 
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and their roles in human diseases (227, 228). Despite the advances in RNA-seq and 
biological importance of the mRNA modifications, the implication of APA in pulmonary 
fibrosis has not been investigated. More than 70% of human genes contain more than 
one polyadenylation site enabling to generate mRNAs with different 3’UTR lengths via 
APA (229). 3’UTR processing via APA has been implicated in many biological 
phenotypes, such as differentiation, proliferation, and tumor growth. Many of the genes 
involved in fibrosis generate mRNA isoforms with different 3’UTR lengths through APA. 
For example, TGFβ1 has two different 3’UTR isoforms generated from APA; the short 
isoform is the dominant type in various cell types and organs and is associated with more 
robust protein as demonstrated in the luciferase reporter assay (230). Moreover, platelet-
derived growth factor (PDGF), a pro-fibrotic growth factor activating fibroblasts, and 
GP130 regulating interleukin-6 trans-signaling undergo APA (231, 232). Despite the 
roles of APA on gene expression, transcriptome-wide APA analysis has not been 
investigated in the field of IPF. Our project described that NUDT21 and the other two 
components of CFIm25 complex, CFIm59 and CFIm68, are depleted in myofibroblasts 
isolated from IPF lungs of the experimental fibrosis models. Deregulation of CFIm 
components, including NUDT21, CFIm59 and CFIm68, leads to 3’UTR shortening on 
APA target genes (190). This phenomenon was first described in HeLa cells and later 
observed in cancer and stem cells as well (190, 233, 234). Similar to these findings, our 
RNA-seq analysis identified 808 transcripts with shortened 3’UTR and 29 transcripts with 
lengthened 3’UTR following NUDT21 reduction in human lung fibroblasts. This result 
indicates that NUDT21 is a repressor of proximal polyadenylation and promotes to 
generate transcripts with long 3’UTRs. The pathway analysis revealed that many genes 
in the pro-fibrotic pathways underwent 3’UTR shortening, such as TGFβ, Wnt, and HIF1A, 
suggesting that 3’UTR shortening on these genes may contribute to pulmonary fibrosis 
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via protein overexpression. The reduction of NUDT21 in IPF fibroblasts suggests that 
APA events may be associated with IPF. To validate this hypothesis further, additional 
APA analyses should be performed to characterize the APA profile in the IPF fibroblasts 
and the potential role of APA in differentiation and proliferation of pathological fibroblasts. 
In addition to regulating genes via APA, NUDT21 reduction may contribute to 
pulmonary fibrosis in other pathways. We discovered that NUDT21 depletion driven by 
Col1a1-creER or Foxd1-cre led to mild inflammation in the lungs in the absence of any 
external lung injury. We speculate that NUDT21 depletion may trigger pro-inflammatory 
pathways, such as JAK/STAT3 signaling pathway. STAT3 is an important regulator of 
inflammatory response and can be activated by multiple upstream pathways, such as IL-
6/IL-6R and WNT5A/FZD2 (210, 235). IL-6, JAK2, WNT5A, and FZD2 were found in the 
APA list and had significant 3’UTR shortening in the NUDT21 depleted fibroblasts, 
suggesting that STAT3 pathway may be responsible for the enhanced inflammatory 
response in the NUDT21 knockout mice. Another possibility for the inflammatory 
phenotype is the involvement of other Col1a1 expressing cells in the Col1a1-creER-
NUDT21f/f mice; Col1a1 is expressed in other cell types, such as osteoblasts and 
odontoblasts (236). Therefore, it is possible that depletion of NUDT21 in Col1a1 positive 
cells increases basal levels of inflammation in other organs which might contribute to 
pulmonary inflammation via circulation. Nonetheless, it is evident that NUDT21 reduction 
in fibroblasts exacerbates lung fibrosis because the Foxd1-cre system revealed that 
NUDT21 depletion in the precursors of lung fibroblasts results in worse fibrosis induced 
by bleomycin. Moreover, the data from the delayed cre activation model supports this 
hypothesis as the mice given bleomycin first and then tamoxifen still promoted pulmonary 
fibrosis without affecting the inflammatory profile in both repeated i.p. and OPA 
bleomycin models. This result clearly indicates that NUDT21 depletion in fibroblasts is 
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sufficient to promote pulmonary fibrosis without altering inflammation in vivo. Another 
phenotype we analyzed was the dysregulation of miRNAs due to the loss of their binding 
sites on 3’UTRs. Based on the data from RNA-seq, we predicted that NUDT21 reduction 
may alter the miRNA pool via global shortening of 3’UTR. Many of the miRNAs that lost 
their binding sites were involved in fibrosis or proliferation and differentiation of fibroblasts, 
implicating that the released miRNAs by NUDT21 depletion may regulate these 
pathways via miRNA-RNA interaction. Collectively, these finding indicate that NUDT21 
reduction contributes to the development of pulmonary fibrosis presumably via multiple 
biological pathways, including 3’UTR shortening, protein overexpression, miRNA 
dysregulation, and inflammation. 
APA plays important roles in cellular processes, such proliferation, differentiation, 
tumor growth, immunogenicity, and neuronal development (237, 238). For example, 
during T and B cell activation, the cells undergo differential APA events, shortening and 
lengthening, depending on the cellular stimuli and the type of affected regulators in the 
polyadenylation machinery (187, 218). Similarly, 3’UTR shortening is evident in many of 
cancer cell types, such as colorectal carcinoma, breast, lung, and transformed cancer 
cells (189, 239, 240). On the contrary, 3’UTR lengthening on transcripts is reported for 
mouse and Drosophila embryogenesis and neuronal development (241, 242). There is 
growing evidence that APA is tightly associated with cell proliferation and differentiation; 
3’UTR shortening is positively correlated with increased proliferation but negatively with 
differentiation in certain cell types (187). For example, NUDT21 depletion results in 
3’UTR shortening and increased cell proliferation in HeLa cells (190). However, 
interestingly, NUDT21 knockdown in stem cells affects cell fate without altering cell 
proliferation, suggesting that the effect of 3’UTR on cell proliferation is cell-type 
dependent (234). Consistent with this statement, we reported that NUDT21 reduction 
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decreased cell proliferation in human lung fibroblasts although the reduction was 
sufficient to induce global 3’UTR shortening (Figure 3.2). The inconsistent role of 
NUDT21 reduction in cell proliferation in different cell types may be explained by the 
intrinsic difference between cancer cells and non-cancer cells. NUDT21 reduction leads 
to overexpression of oncogenes and increased cellular proliferation in HeLa and 
glioblastoma cells where checkpoint systems and tumor-suppressors are functionally 
impaired (190). However, the activation of these oncogenic pathways following NUDT21 
knockdown in human lung fibroblasts promoted expression of p21 and p53 (data not 
shown), suggesting that tumor-suppressor genes induced cellular senescence and cell 
cycle arrest as a defensive mechanism toward tumorigenesis (243). However, this theory 
needs to be experimentally validated further. In addition to the reduced cell proliferation, 
we found that NUDT21 reduction by siRNA does not cause 3’UTR shortening on the 
mRNAs of Cyclin D1 in human lung fibroblasts, which was identified as the responsible 
factor for increased cell proliferation via APA in cancer cells. This result suggests that 
human lung fibroblasts might not over-proliferate by NUDT21 reduction because the 
genes involved in cell proliferation do not undergo APA for 3’UTR shortening in this cell 
type. There might be other factors that potentially affect the differential effect of NUDT21 
depletion, such as the presence of AU-rich element, RNA-binding proteins, miRNAs, and 
involvement of other APA regulatory factors. In summary, these findings indicate that 
global 3’UTR shortening affects cell proliferation or differentiation in various cell types, 
but its exact effect is cell and tissue dependent. 
While the primary interest of this study was to characterize the functions of 
NUDT21 in APA and pulmonary fibrosis, there are other critical factors that regulate APA 
events. Cleavage stimulating factor 64 (CstF64) and PolyA binding protein nuclear 1 
(PABPN1) were identified as the most significantly associated genes with 3’UTR 
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shortening in various cancer cells (186, 244). In addition, upregulation of CSTF64 
promotes 3’UTR shortening in macrophages exposed to lipopolysaccharide (LPS)-
stimulated macrophages and differentiating B cells (245, 246). Furthermore, antagonistic 
partners of CSTF64, such as polypyrimidine tract binding protein (PTB), Drosophila sex 
lethal proteins, and RNA-binding protein HuR, can affect APA (247–249). 3’UTR 
lengthening can occur by APA regulators. For example, reduction of FIP1 or PCF11 can 
lead to global 3’UTR lengthening in C2C12 mouse cells (250). As these key factors 
regulate APA events in cancers and cellular processes, it is important to investigate the 
molecular functions of them in other diseases where APA might play important roles for 
disease progression including pulmonary fibrosis. Moreover, in addition to fibroblasts and 
myofibroblasts, other cell types are the subjects of through investigation to reveal 
whether the cells contribute to pulmonary fibrosis via APA. 
mRNAs with shortened 3’UTRs are generally more stable than the shorter forms 
due to the lack of miRNA binding sites and RNA-binding proteins (RBP) that are 
responsible for mRNA degradation. However, there are some exceptions; a few RBPs 
on 3’UTRs enhance mRNA translation (251, 252). Therefore, a careful bioinformatic 
analysis should be performed to identify the presence of stabilizing or destabilizing 
miRNAs and RBPs in the deleted 3’UTR sequence (252, 253). This analysis can explain 
why only a small subset of APA genes are associated with enhanced protein expression 
in stem cells following NUDT21 reduction (234). In addition to the role of APA as a 
stabilizing factor of mRNAs, APA may regulate gene expression by releasing miRNAs 
from the shortened 3’UTRs and allowing the free miRNAs to target other genes (253). 
Additional follow-up studies need to be performed to further elucidate the interacting 
networks of mRNA-miRNA and mRNA-RNA binding protein following APA events in 
pathological conditions. 
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Foxd1 positive pericytes are one of the progenitor cells of Col1a1 positive 
fibroblasts as they differentiate into fibroblasts following bleomycin injury. About 50% of 
the collagen producing cells originate from the Foxd1 positive pericytes (226). Despite 
the importance of pericytes as the origin of fibroblasts, little is known about how these 
cells contribute to pulmonary fibrosis. Our study reported that heterozygous deletion of 
NUDT21 in Foxd1 positive cells is sufficient to reduce NUDT21 and promote 3’UTR 
shortening of NUDT21 target genes. Moreover, depletion of NUDT21 in the pericytes 
exacerbates pulmonary fibrosis by bleomycin administration, and this phenotype is 
associated with increased accumulation of myofibroblasts, collagen and fibronectin 
deposition, and lung remodeling which are the critical features of fibrosis. These results 
suggest that 3’UTR shortening by NUDT21 depletion in pericytes promotes lung fibrosis 
by activating and differentiating the cells into fibroblasts and myofibroblasts. Little is 
known about the molecular mechanisms driving the NUDT21 reduction in fibroblasts. 
Advanced knowledge in APA events and the regulation of NUDT21 is important as this 
information can lead to potential therapeutic treatments to halt the disease progression. 
In summary, our study characterized the role and function of a key APA complex, 
NUDT21, in the pathogenesis of pulmonary fibrosis using in vivo and in vitro models. We 
discovered that NUDT21 along with other APA components, CFIm59 and CFIm68, is 
depleted in the fibroblasts from IPF patients or mice with lung fibrosis. The reduction in 
NUDT21 was sufficient to promote global 3’UTR shortening, especially for the genes 
involved in pro-fibrotic pathways, such as TGFBR1, WNT5A, and FZD2, and results in 
worse fibrosis in the experimental fibrosis models. These findings have significantly 
advanced our understanding on the role of APA on gene expression in pulmonary fibrosis. 
This project lays the foundation for identifying critical factors in this pathway which can 
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be therapeutically targeted to halt the progression of pulmonary fibrosis and other 
diseases where APA plays a pivotal role. 
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CHAPTER FOUR 
TGFb1 DEPLETES NUDT21 TO PROMOTE APA IN LUNG FIBROBLASTS TO 
EXACERBATE LUNG FIBROSIS 
INTRODUCTION 
Note: This chapter is based upon: Junsuk Ko, Tingting Mills, Jingjing Huang, Ning-yuan 
Chen, Tinne CJ Mertens, Scott D Collum, Garam Lee, Yu Xiang, Leng Han, Yang Zhou, 
Chun Geun Lee, Jack Elias, Soma SK Jyothula, Keshava Rajagopal, Harry Karmouty-
Quintana, and Michael R. Blackburn. Transforming growth factor beta 1 alters the 3’UTR 
of mRNA to promote lung fibrosis. 2019. Journal of Biological Chemistry. 
http://www.jbc.org/content/early/2019/09/05/jbc.RA119.009148.short. The contents, 
data, and figures were modified and included following the guidelines of JBC. 
 
TGFb1 and NUDT21 regulation 
 In the previous chapter, we demonstrated that NUDT21 reduction causes global 
3’UTR shortening in pulmonary fibroblasts. Moreover, NUDT21 depletion promotes 
overexpression of ECM proteins and pro-fibrotic APA target genes, such as TGFBR1, 
WNT5A, and FZD2. Our conditional knockout model demonstrated that NUDT21 
reduction worsens the pulmonary fibrosis induced by bleomycin administration, 
suggesting that NUDT21 depletion in IPF patients is not just an associated factor, but 
contributes to the pathogenesis of lung fibrosis. However, the factors that lead to the 
NUDT21 reduction in fibroblasts were unknown.  
 We hypothesized that transforming growth factor beta 1 (TGFb1) may cause the 
NUDT21 reduction in fibroblasts based on its potent effect as an activator of fibroblasts. 
TGFb1 is a pro-fibrotic growth factor which is elevated in IPF patients (113). Upon 
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repeated injuries in alveolar epithelial cells, there is an increase in TGFb1 originating 
from injured epithelial cells, immune cells, and resident fibroblasts (113, 254). TGFb1 
binds to TGFb receptors leading to phosphorylation of Smad proteins which activates 
these proteins to act as a transcription factor (255). TGFb1 is important for proliferation 
and activation of fibroblasts. As demonstrated in a number of studies, TGFb1 
differentiates fibroblasts to myofibroblasts which have more active phenotypes for 
fibrogenesis (256). Furthermore, TGFb1 stimulates proliferation of fibroblasts 
contributing to accumulation of fibroblasts (257, 258). TGFb1 without any other external 
injuries or fibrotic factors can cause spontaneous fibrosis in TGFb1 transgenic mice (202) 
and antagonizing TGFb1 using monoclonal antibodies is sufficient to halt the progression 
of fibrosis induced by bleomycin in vivo, suggesting that TGFb1 is an important 
contributor of pulmonary fibrosis (259). As these results suggest, TGFb1 is important for 
pulmonary fibrosis and activation of fibroblasts. Since TGFb1 is one of the most potent 
activators of fibroblasts as the evidence demonstrated, we hypothesized that TGFb1 
causes NUDT21 reduction in lung fibroblasts. 
  
Experimental Rationale 
  APA is an important post-transcriptional regulation which affects protein 
expression of various genes by modulating the length of 3’UTRs and stabilizing 
transcripts. NUDT21 is a key regulator of APA as NUDT21 reduction causes global 
3’UTR shortening leading to enhanced protein expression (218). As demonstrated in the 
Chapter 3, a reduction in NUDT21 is found in IPF patients (201). This reduction in 
NUDT21 is associated with 3’UTR shortening in transcriptome including profibrotic 
transcripts and increased protein expression, including ECM proteins and pro-fibrotic 
 115 
mediators. Conditional knockout mice lacking NUDT21 in fibroblasts demonstrated that 
a depletion in NUDT21 exacerbates fibrosis induced by bleomycin, suggesting that the 
NUDT21 reduction in IPF patients is an amplifier of the disease. However, the factors 
leading to a reduction in NUDT21 in fibroblasts were completely unknow. In order to 
reveal the molecular mechanisms governing the NUDT21 reduction, we screened pro-
fibrotic molecules that are associated with IPF and are known to activate pulmonary 
fibroblasts (211). The screening found that TGFβ1 decreased NUDT21 protein and 
transcripts in primary human lung fibroblasts (Figure 4.1 A). This observation led to a 
central hypothesis that TGFβ1 alters the 3’UTR of mRNA via NUDT21 reduction 
contributing to pulmonary fibrosis. First, to test this hypothesis, the TGFβ1 pathway was 
investigated in depth. We inhibited Smad3, a downstream of TGFβ1 pathway, using a 
Smad3 specific inhibitor to examine the involvement of Smad3 in the TGFβ1-mediated 
NUDT21 reduction. Due to the reduction in NUDT21 transcripts following TGFβ1, we 
investigated the impact of TGFβ1 on miRNA-mediated mRNA degradation of NUDT21. 
Furthermore, we examine the linkage between miRNA regulation and Smad3 upon 
TGFβ1 treatment. This pathway was also validated in vivo and ex vivo models, including 
TGFβ1 transgenic mice and isolation of primary fibroblasts from mice. The results of this 
chapter elucidate the molecular mechanisms for NUDT21 reduction and broaden our 
understanding for APA and gene expression.  
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RESULTS 
TGFβ1 downregulates NUDT21 in primary human lung fibroblasts 
To identify a pro-fibrotic cytokine that downregulates NUDT21 in human lung 
fibroblasts, primary fibroblasts (CCD8Lu) were cultured with 7 cytokines that are 
associated with pulmonary fibrosis: transforming growth factor beta 1 (TGFβ1), insulin-
like growth factor 1 (IGF1), connective tissue growth factor (CTGF), platelet-derived 
growth factor BB (PDGF BB), and interleukin 4 (IL-4), 6 (IL-6) and 13 (IL-13) for 7 days 
which allowed enough time for a response to the cytokines (210–212). TGFβ1 
downregulated NUDT21 to the greatest extent in fibroblasts (Figure 4.1 A). Next, to 
longitudinally determine the capacity of TGFβ1 to deplete NUDT21, fibroblasts were 
cultured with TGFβ1 and harvested each day for western blot analysis (Figure 4.1 B). 
NUDT21 was downregulated by TGFβ1 on day 3. CCD8Lu which was used for the 
previous experiments was a commercially available primary cell. Other primary lung 
fibroblasts isolated from 3 normal lungs were used to validate NUDT21 reduction by 
TGFβ1. It was found that NUDT21 was consistently downregulated following TGFβ1 
treatment, suggesting that NUDT21 reduction by TGFβ1 may be a general cellular 
feature in human lung fibroblasts (Figure 4.1 C). We previously reported that fibroblasts 
from IPF patients displayed reduced levels of NUDT21 (201). To determine whether 
TGFβ1 can further deplete NUDT21 in IPF fibroblasts, we treated the IPF fibroblasts with 
TGFβ1 and found that TGFβ1 additionally reduced NUDT21 in the fibroblasts that had 
high basal NUDT21 levels (Figure 4.1 D). In addition to protein reduction, NUDT21 
mRNAs were also reduced following 24 hrs of treatment with TGFβ1 in CCD8Lu cells 
and in the 3 primary human fibroblasts, suggesting that NUDT21 protein reduction 
correlates with mRNA reduction (Figure 4.1 E). 
 
 117 
 
Figure 4.1. Transforming Growth Factor beta 1 (TGFβ1) decreases NUDT21 in 
Primary Human Lung Fibroblasts. Primary normal human lung fibroblasts (CCD8Lu) 
were cultured with human recombinant transforming growth factor beta 1 (TGFb1), 
insulin-like growth factor 1 (IGF1), connective tissue growth factor (CTGF), platelet-
derived growth factor BB (PDGF BB), interleukin (IL) 4, 6, and 13 for 5 days. The protein 
lysates were harvested for western blot analysis to probe NUDT21 and b-actin protein 
levels. b-actin was used as a loading control (Panel A). The lung fibroblasts were cultured 
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with TGFb1 for up to 6 days. Alpha smooth muscle cell actin (αSMA) was used as a 
positive control for TGFb1 treatment (Panel B). Primary human lung fibroblasts from 
three independent human donors were cultured with TGFb1 for 4 days (Panel C). 
Primary lung fibroblasts from normal or IPF lungs were cultured with TGFb1 for 4 days 
followed by Western Blot analysis (Panel D). The primary human lung fibroblasts were 
challenged with TGFb1 for 2 days and then were harvested for real-time qPCR analysis. 
18S was used as a normalization control for the assay (Panel E). ****p < 0.0001 
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miR203 targets the 3’UTR of NUDT21 
NUDT21 mRNA reduction by TGFβ1 led to the hypothesis that TGFβ1 facilitates 
NUDT21 mRNA degradation in human lung fibroblasts (Figure 4.1 E). To test this 
hypothesis, mRNA degradation assays were performed. Human lung fibroblasts were 
cultured with TGFβ1 for 9 hrs because TGFβ1 requires 24 hrs of treatment to reduce 
NUDT21 mRNA measured by real time PCR; this 9 hr time period was intentionally 
chosen to follow mRNA degradation. After treatment, the cells were incubated with 
actinomycin D, which is a transcription inhibitor, allowing only mRNA degradation to 
affect the remaining transcript levels, and the samples were harvested to measure 
NUDT21 mRNA transcript levels in TGFβ1 or control groups. The cells with TGFβ1 
treatment showed a rapid NUDT21 mRNA degradation as compared to the vehicle 
control (Figure 4.2 A). This result suggests that NUDT21 reduction by TGFβ1 is due to 
enhanced NUDT21 mRNA degradation.  
TGFβ1 upregulates various miRNAs, which can potentially affect the stability and 
degradation of target mRNAs (260–263). Therefore, it was hypothesized that TGFβ1 
downregulates NUDT21 by upregulating miRNAs that target NUDT21 transcripts. 
TargetScanHuman showed that miR-23a, miR-27b and miR203 are predicted to target 
human NUDT21 3’UTR with at least two binding sites (Figure 4.2 B). To examine 
whether NUDT21 3’UTR is indeed a target of these miRNAs, dual luciferase 3’UTR 
reporter assay was performed in vitro. In the vector, the firefly luciferase gene was 
conjugated with either human NUDT21 3’UTR, allowing the gene expression of firefly to 
be regulated by the 3’UTR. The renilla luciferase gene was used to normalize the number 
of transfected vectors in the cells. HEK293T and NIH3T3 cells were transfected with miR-
23a, miR-27b and miR203 and also with the dual luciferase vectors to monitor the effect 
of miRNAs on firefly expression. It was found that miR203 consistently decreased the 
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firefly expression in both cell types, indicating that exogenous miR203 targets the 3’UTR 
of NUDT21 to regulate gene expression (Figure 4.2 C). To assess whether these 
miRNAs can affect the endogenous protein expression of NUDT21, human lung 
fibroblasts were transfected with the miRNA mimics. Indeed, NUDT21 protein was 
significantly reduced by miR203 and miR27b mimics (Figure 4.2 D and E). Collectively, 
miR203 most consistently targeted the 3’UTR of NUDT21 and most robustly reduced 
protein levels in all experiments. Therefore, miR203 was chosen for further study. To 
examine whether miR203 elevation is associated with IPF, fibroblasts isolated from 4 
different IPF lungs and 4 healthy lungs were used for RT-PCR analysis. In the IPF 
fibroblasts, miR203 was markedly upregulated in association with an elevated αSMA 
expression (Figure 4.2 F). 
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Figure 4.2. miR203 targets 3’UTR of NUDT21. Primary lung fibroblasts were treated 
with actinomycin D for mRNA degradation assay (Panel A). miRNAs that can target 
3’UTR of human NUDT21 were predicted by TargetScanHuman 7.1. The relative binding 
positions of the miRNAs were shown (Panel B). HEK293T and NIH3T3 cells were 
transfected with dual luciferase plasmids containing NUDT21 3’UTR behind of the firefly 
coding sequence (CDS) in the presence of miRNA 203, 23a, 27b or control. Dual 
luciferase assay was performed to measure luciferase intensities (Panel C). Primary 
normal human lung fibroblasts were transfected with miRNA control, 203, 27b or 23a and 
were cultured 2 days. The cells were harvested to probe NUDT21 protein levels (Panel 
D). Densitometry analysis was performed to quantify NUDT21 in the transfected human 
primary samples (Panel E). Primary human lung fibroblasts isolated from healthy normal 
or IPF patient lungs were lysed for RNA extraction. miR203 levels in the samples were 
measured. RNU6 was used as a normalization control (Panel F). *p < 0.05, **p < 0.01, 
and ****p <0.0001 
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TGFβ1 targets NUDT21 mRNA through miR203 
To investigate whether TGFβ1 can promote miR203 expression, human lung 
fibroblasts were cultured with TGFβ1 for up to 2 days in vitro. These experiments 
demonstrated that starting at 2 ~ 4 hrs after TGF-b treatment, increased miR203 levels 
were apparent (Figure 4.3 A), and multiple primary human lung fibroblasts showed 
TGFβ1-associated miR203 expression (Figure 4.3 B). Studies have demonstrated that 
miRNA upregulation by TGFβ1 is mediated through Smad pathways in vitro for various 
miRNAs (261–263), and Smad3 acts as a master regulator for fibrogenesis and fibroblast 
activation through phosphorylation on serine 423/425 (264). Therefore, it was 
hypothesized that TGFβ1 upregulates miR203 through phosphorylation of Smad3 on Ser 
423/425. To test this hypothesis, a commercially available inhibitor of Smad3, SIS3, was 
used. This inhibitor inhibits phosphorylation of Smad3 specifically on Ser 423/425 
residues (209). SIS3 successfully inhibited phosphorylation on Ser 423/425 on Smad3 
in human lung fibroblasts (Figure 4.3 C). Inhibition of Smad3 phosphorylation in the 
human lung fibroblasts was sufficient to reduce TGFβ1-mediated miR203 
overexpression, demonstrating that miR203 induction is Smad3 phosphorylation 
dependent (Figure 4.3 D). These results were consistent with SIS3 inhibiting TGFβ1-
mediated NUDT21 reduction in primary healthy fibroblasts (Figure 4.3 E and F). 
Moreover, the inhibition of Smad3 alone by SIS3 increased NUDT21 mRNA and 
decreased miR203 in IPF fibroblasts which had intrinsically low NUDT21 (Figure 4.3 G 
and H). These results collectively suggest that TGFβ1 elevates miR203 via Smad3 
phosphorylation. 
Since Smad3 acts as a transcription factor following phosphorylation, it was 
hypothesized that activated Smad3 transcriptionally targets a miR203 promoter to 
upregulate its expression. Based on the public ChIP-seq data from the Cistrome Project 
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and Smad3 DNA binding motif, two independent promoter regions of miR203 were 
chosen: 12k and 1.6k upstream from the miR203 transcription start site. Two sets of ChIP 
primers were designed to target these regions. In this experiment, Serpine1 was used 
as a positive control because this gene is a direct target of Smad3 (265). It was found 
that these two promoter regions were bound by phosphorylated Smad3 following 3 hrs 
of TGFβ1 treatment in human lung fibroblasts, but SIS3 decreased the Smad3 binding, 
suggesting that phosphorylated Smad3 acts as a transcription factor for miR203 
expression (Figure 4.3 I). To further investigate whether an endogenous elevation of 
miR203 following TGFβ1 treatment can regulate gene expression, GFP NUDT21 3’UTR 
reporters were generated. The GFP 3’UTR WT contained the WT 3’UTR of human 
NUDT21 following the coding sequence of GFP. However, the GFP 3’UTR mutant had 
a human NUDT21 3’UTR mutant where all three key binding sites of miR203 were 
mutated to random sequences, preventing the gene expression regulation by miR203 
(Figure 4.3 J). These plasmids were transfected in human lung fibroblasts followed by 
TGFβ1 treatment. It was found that the cells transfected with the GFP 3’UTR mutant 
were resistant to a TGFβ1-mediated GFP reduction, although the GFP 3’UTR WT cell 
showed a reduction in GFP expression as shown in Western Blot analysis and the 
densitometry (Figure 4.3 K and L). Florescent images consistently revealed that the GFP 
3’UTR WT displayed a reduction in GFP following TGFβ1 treatment, but the mutation on 
the miR203 binding sites prevented TGFβ1 induced GFP reduction (Figure 4.3 M). 
Furthermore, quantitative analysis of the images showed that TGFβ1 did not reduce the 
GFP intensity and the number of GFP positive cells in the GFP 3’UTR mutant transfected 
fibroblasts (Figure 4.3 N). These data collectively suggest that endogenous miR203 
upregulation following TGFβ1 treatment is sufficient to affect NUDT21 gene expression. 
To validate these data in a different experimental setting, dual luciferase assay was 
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performed. Three dual luciferase vectors were utilized: vectors with a stable SV40 3’UTR 
for control, human NUDT21 WT 3’UTR, and NUDT21 mutant 3’UTR with mutations in 
miR203 binding sites (Figure 4.3 O). These vectors were transfected into human lung 
fibroblasts followed by TGFβ1 treatment, similar to the previous GFP 3’UTR reporter 
experiment. Consistent with the previous data, TGFβ1 significantly reduced the firefly 
signal in the NUDT21 WT 3’UTR group but not in the mutant 3’UTR group, indicating that 
the reduction in gene expression is mediated through miR203 (Figure 4.3 P). To 
examine whether inhibition of miR203 prevents NUDT21 reduction, antagomiR, a 
synthetic miRNA inhibitor, was used (Figure 4.3 Q). Human primary lung fibroblasts 
transfected with antagomiR203 showed an increased endogenous level of NUDT21 and 
were more resistant to TGFβ1-mediated NUDT21 reduction (Figure 4.3 R and S). In 
addition, fibronectin was reduced by the antagomiR203 transfection (Figure 4.3 Q and 
R), suggesting that NUDT21 restoration through antagomiR203 prevents the activation 
of some profibrotic pathways by APA (201). Overall, these experiments demonstrate that 
TGFβ1 targets NUDT21 mRNA through miR203. 
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Figure 4.3. TGFβ1 targets NUDT21 mRNA through miR203. Primary human lung 
fibroblasts were challenged with TGFb1 up to 2 days (Panel A) or for 24 hours (Panel 
B). RNAs from these samples were extracted and used for miRNA measurement by RT-
qPCR (Panel A and B). Primary lung fibroblasts were pre-treated with SIS, a smad3 
inhibitor, for 30 minutes followed by TGFb1 treatment for 30 minutes and Western Blot 
analysis (Panel C). Primary lung fibroblasts were treated with TGFb1 in the presence or 
absence of SIS3 for 24 hours (Panel D and F) or 4 days (Panel E). mRNA levels of 
human NUDT21 were measured by RT-qPCR (Panel F). Primary IPF lung fibroblasts 
were treated with SIS3 only for 24 hours and were used for RT-qPCR (Panel G and H).  
Chromatin immunoprecipitation (ChIP) was performed for p-Smad3 in the primary human 
lung fibroblasts following 2 hrs of TGFb1 treatment. IgG and Serpine 1 were used as an 
antibody and a TGFb1 signaling control respectively (Panel I). A schematic view of 3’UTR 
GFP reporter (Panel J). Western blot data for GFP in the GFP 3’UTR transfected cells 
and densitometry analysis for 3 independent experiments (Panel K and L). Fluorescent 
images for human lung fibroblasts treated with TGFb1 for 4 days following transfection 
with GFP 3’UTR reporters. F-actin displays stress-fibers in the cells (Panel M). 
Quantitative data for relative GFP intensities and the number of GFP positive cells in 10 
randomly taken pictures of each group (Panel N). A schematic view of 3’UTR dual-
luciferase reporter (Panel O). The primary human lung fibroblasts were transfected with 
the dual-luciferase plasmids and were cultured with TGFb1 (Panel P). Primary human 
lung fibroblasts were pre-treated with antagomiR203, a miR203 inhibitor, followed by 
TGFb1 treatment and densitometry analysis for 4 independent experiments (Panel Q, R, 
and S). *p < 0.05, ***p < 0.001, and ****p < 0.0001 
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TGFβ1 decreases NUDT21 in mouse lung fibroblasts 
Primary lung fibroblasts were isolated from C57Bl/6 mice to examine whether 
TGFβ1 downregulates NUDT21 in vitro. Western blot analysis revealed that NUDT21 
protein was reduced following 3 days of TGFβ1 treatment in mouse lung fibroblasts 
(Figure 4.4 A). Moreover, consistent with human data, NUDT21 mRNA was decreased, 
suggesting that the NUDT21 protein reduction may be due to its mRNA reduction (Figure 
4.4 B). We previously reported that fibroblasts isolated from mice with bleomycin-induced 
fibrosis had reduced NUDT21 (201). We examined whether TGFb1 can further deplete 
NUDT21 in these fibroblasts and found that NUDT21 was depleted only in the fibroblasts 
that had relatively high NUDT21 levels (Figure 4.4 C). To investigate the role of Smad3 
phosphorylation on NUDT21 downregulation, mouse lung fibroblasts were pretreated 
with SIS3 for 1 hr, followed by TGFβ1 in the presence or absence of SIS3 for 3 days. 
Smad3 inhibition prevented TGFβ1-mediated NUDT21 reduction, indicating that TGFβ1 
downregulates NUDT21 through Smad3 phosphorylation in mouse lung fibroblasts 
(Figure 4.4 D and E). To investigate the role of miR203 in TGFβ1-mediated NUDT21 
reduction, primary mouse lung fibroblasts isolated from C57Bl/6 were treated with TGFβ1 
for 2 days and were harvested to determine miR203 levels. TGFβ1 treatment induced 
miR203 expression, suggesting that miR203 is associated with NUDT21 reduction in 
mouse lung fibroblasts (Figure 4.4 F). To further demonstrate that NUDT21 is the target 
of miR203 in mouse, miR203 mimic was transfected into mouse lung fibroblasts. 
NUDT21 was significantly downregulated by the miR203 mimic and associated with the 
increase in matrix proteins, such as collagen 1 and fibronectin (Figure 4.4 G and H). 
Similar to the antagomiR203 experiment in human primary lung fibroblasts, mouse cells 
were transfected with antagomiR203 followed by TGFβ1 treatment. TGFβ1-mediated 
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NUDT21 depletion was attenuated by antagomiR203 treatment, indicating that miR203 
is important for NUDT21 reduction in mouse lung fibroblasts (Figure 4.4 I and J). To 
verify whether TGFβ1 could deplete NUDT21 in vivo, conditional TGFβ1 transgenic mice 
were utilized. As previously reported (202), this mouse model has a rtTA-tTS controlled 
CC10 driven TGFβ1 system on a C57Bl/6 background where TGFβ1 expression is 
controlled by doxycycline water administration being secreted from club cells into 
alveolar space to induce lung fibrosis. Immunohistochemistry (IHC) for NUDT21 in the 
lung showed reduced nuclear NUDT21 in fibrotic areas from TGFβ1 transgenic mice 
compared to controls (Figure 4.5 A and B). Next, fibroblasts from TGFβ1 transgenic 
mice were isolated and harvested for quantitative analysis. The fibroblasts isolated from 
TGFβ1 transgenic mice showed a reduction in NUDT21 protein expression correlated 
with an increased expression of collagen and fibronectin (Figure 4.5 C). Densitometry 
analysis revealed that the reduction was statistically significant (Figure 4.5 D). 
Interestingly, NUDT21 mRNA was not reduced significantly in TGFβ1 fibroblasts, 
although collagen 1a1, fibronectin mRNAs, and miR203 were significantly increased 
(Figure 4.5 E and F). These findings demonstrate that TGFβ1 decreases NUDT21 in 
mouse lung fibroblasts. 
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Figure 4.4. TGFβ1 decreases NUDT21 via miR203 in Mouse Lung Fibroblasts. 
Primary mouse lung fibroblasts isolated from C57BL/6 mice were challenged with TGFβ1 
alone (Panel A and B) or in the presence of SIS3 (Panel C and D) for 3 days (n=3). RNAs 
were isolated and used for mRNA and miR203 measurement in the primary mouse lung 
fibroblasts (Panel E and F). Primary lung fibroblasts isolated from C57BL/6 mice were 
transfected with miR203 mimics and harvested for WB analysis (Panel G). Densitometry 
analysis displays the result of 3 independent experiments (Panel H). The cells were pre-
treated with antagomiR203, and then challenged with TGFβ1 for 3 days (Panel I). 
Densitometry analysis displays the result of 4 independent experiments (Panel J). *p < 
0.05 and **p < 0.01. 
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Figure 4.5. TGFβ1 transgenic mice display the NUDT21 reduction in the Lung 
Fibroblasts. NUDT21 protein was visualized by immunohistochemistry (IHC) in the 
lungs of TGFβ1 transgenic mice. αSMA and DAPI were used to show a fibrotic area and 
nuclei respectively (Panel A and B). Primary mouse lung fibroblasts were isolated from 
TGFβ1 transgenic mice for western blot, densitometry and RT-qPCR analysis (Panel C, 
D, E, and F, n=8). *p < 0.05, **p < 0.01, ***p < 0.001, and ***p < 0.0001 
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TGFβ1 differentially regulates APA in human lung fibroblasts contributing to 
increased protein expression 
NUDT21 is a key regulator of APA in human lung fibroblasts (201). To 
demonstrate that TGFβ1-mediated NUDT21 reduction also causes APA in primary 
human lung fibroblasts, cells were challenged with TGFβ1 and RNA seq was conducted. 
RNA seq data was subjected to PDUI analysis to investigate the APA pattern in the cells 
(190). The APA analysis revealed that TGFβ1 treatment differentially regulated APA in 
human lung fibroblasts showing 311 shortened and 297 lengthened transcripts (Figure 
4.6 A). KEGG pathway analysis revealed that the APA target genes in the dataset were 
enriched for pathways associated with fibrosis, such as PI3K-Akt, chemokine signaling, 
ECM-receptor interaction, and focal adhesion (Figure 4.6 B). Among the APA target 
genes, FGF14, RICTOR, TMOD2, and UCP5 were chosen for further validation because 
these genes were the common APA targets reported in our previous study (Figure 4.6 
C) (201), and these genes are important for fibrogenesis and the biology of fibroblasts 
(266–272). To further investigate APA usage in the transcripts, two sets of primers were 
designed for the RT-qPCR-based APA analysis: one set targeting CDS and the other 
targeting the distal 3’UTR of transcripts (201). The APA analysis demonstrated that 
FGF14, RICTOR, TMOD2, and UCP5 showed 3’UTR shortening both in the NUDT21 
knockdown fibroblasts and the fibroblasts challenged with TGFβ1 (Figure 4.6 D and E). 
To further demonstrate that the 3’UTR shortening is associated with increased protein 
expression, the protein levels of the 4 genes were measured by Western blot analysis in 
human lung fibroblasts treated with TGFβ1. Western blot revealed that their protein 
expression was increased following TGFβ1 treatment (Figure 4.6 F). These data 
collectively suggest that TGFβ1-mediated NUDT21 reduction promotes differential APA 
and the shortened 3’UTR by APA is associated with increased protein in human lung 
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fibroblasts. This differential APA pattern by TGFβ1 was a unique pattern that has not 
been reported previously. To further demonstrate the pathological relevancy of this result, 
fibroblasts were isolated from explanted lungs from patients with IPF and utilized for APA 
analysis. As previously reported, IPF fibroblasts had significantly reduced NUDT21 and 
elevated αSMA as shown by the Western Blot, Densitometry, and RT-PCR (Figure 4.6 
G, H, I, and J) (201). APA analysis by RNA seq on these fibroblasts revealed that IPF 
fibroblasts have differentially regulated APA patterns similar to the TGFβ1 dataset 
(Figure 4.6 K). These findings demonstrate that TGFβ1 differentially regulates APA in 
human lung fibroblasts contributing to increased protein expression. 
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Figure 4.6. TGFβ1 differentially regulates APA in Human Lung Fibroblasts 
contributing to the increased Protein Expression. Primary human lung fibroblasts 
were challenged with TGFβ1 for 4 days and t ghen harvested for RNA Seq. The PDUI 
algorithm was used to plot shortening and lengthening of 3’UTR for transcripts (Panel A). 
The APA genes were used for KEGG pathway analysis (Panel B). The top APA genes 
that are commonly found in the NUDT21 KD and TGFβ1 RNA seq were chosen to show 
PDUI values (Panel C). RT-qPCR-based APA analysis was performed using two sets of 
primers to measure the PAS Usage on mRNAs in the NUDT21 KD and lung fibroblasts 
that were challenged with TGFβ1 (Panel D and E). Western blot was performed to probe 
the overexpressed APA genes in the human lung fibroblasts (Panel F). Primary lung 
fibroblasts were isolated from normal or IPF lungs and used for Western Blot analysis 
(Panel G). Densitometry and RT-qPCR analysis were performed (Panel H, I, and J). The 
PDUI algorithms and APA analysis were performed for the IPF and normal FB (Panel K). 
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Table 4.1. Common APA Genes between the NUDT21 KD and the TGFβ1 dataset. 
*  all of the genes listed in the table are statistically significant (p < 0.05) 
Gene Name 
TGF  
APA PDUI 
CFIm25 APA 
PDUI 
 
Gene Name 
TGF  
APA PDUI 
CFIm25 APA 
PDUI 
CCDC77 -0.40491 -0.34 
 
FGF14 -0.15716 -0.445 
RBPMS -0.25331 -0.19 
 
VAMP4 -0.03612 -0.2 
WDR89 -0.250675 -0.46 
 
PDE4DIP -0.003395 -0.285 
VMA21 -0.249985 -0.565 
 
POLR1D -0.00129 -0.35 
AHDC1 -0.24954 -0.36 
 
CLUAP1 0.05069 -0.185 
C1orf159 -0.22597 -0.45 
 
FAM122B 0.07179 -0.245 
SNAI1 -0.22153 -0.25 
 
TMEM41A 0.153085 -0.275 
C1orf27 -0.211065 0.32 
 
ZNF211 0.1548 -0.26 
TMOD2 -0.207785 -0.67 
 
MAP3K13 0.15696 -0.195 
HUS1 -0.20756 -0.245 
 
RFC5 0.157425 -0.51 
TMEM186 -0.20339 -0.47 
 
KDM1B 0.16121 -0.185 
TTC39C -0.19861 -0.17 
 
ARHGEF19 0.164825 0.335 
WDR92 -0.1965 -0.3 
 
FAM91A1 0.164915 -0.48 
BCCIP -0.19292 0.475 
 
CRLF3 0.170245 -0.325 
C3orf23 -0.18958 -0.42 
 
GABPB2 0.172415 -0.27 
ABCC5 -0.18628 -0.355 
 
PTPN4 0.1741 0.28 
SLC30A7 -0.17948 -0.275 
 
DLG3 0.17895 -0.445 
LIMCH1 -0.17834 -0.545 
 
CASP6 0.187845 -0.275 
COQ10A -0.17555 -0.31 
 
SARS2 0.194615 -0.285 
LOC652276 -0.171965 0.31 
 
MSI2 0.20367 -0.285 
MAN2A1 -0.16961 -0.325 
 
COL5A2 0.20381 -0.2 
ECT2 -0.16897 0.37 
 
TPP2 0.204715 -0.24 
WDR4 -0.16556 0.36 
 
KCTD1 0.24309 -0.33 
ZNF780A -0.16145 -0.23 
 
ITGB1BP1 0.24929 0.18 
MKI67IP -0.15825 -0.215 
 
MPHOSPH9 0.29779 -0.405 
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Table 4.2. APA Genes for the TGFβ1 dataset. 
*  all of the genes listed in the table are statistically significant (p < 0.05) 
Gene Name 
TGF APA 
PDUI 
 
Gene Name 
TGF APA 
PDUI 
 
Gene Name 
TGF APA 
PDUI 
MIS18BP1 -0.473775 
 
COQ10A -0.17555 
 
CCDC130 0.173535 
ZNF845 -0.46039 
 
IFI6 -0.17547 
 
DENND1B 0.173665 
PCDH7 -0.41427 
 
KLHL13 -0.175055 
 
PTPN4 0.1741 
RPL32P3 -0.40734 
 
IKBKG -0.17488 
 
C9orf156 0.175135 
IQCK -0.405265 
 
CA5B -0.174785 
 
FOXL1 0.176735 
CCDC77 -0.40491 
 
ABCB10 -0.174135 
 
BTG2 0.17759 
ZNF222 -0.39528 
 
NUBPL -0.17392 
 
TADA1 0.1782 
CDCA3 -0.382565 
 
APBA2 -0.173465 
 
MOCS1 0.17861 
PSRC1 -0.38174 
 
SNX16 -0.173035 
 
DLG3 0.17895 
MIS18A -0.37055 
 
ATG4C -0.1728 
 
RHBDL1 0.178985 
DCLRE1C -0.367605 
 
RPGRIP1L -0.17214 
 
RBBP5 0.17923 
DNAJC22 -0.36344 
 
LOC652276 -0.171965 
 
ALDH6A1 0.179365 
CCDC24 -0.362405 
 
GDF11 -0.17146 
 
TIMM44 0.179375 
DEPDC7 -0.36022 
 
WWP2 -0.17145 
 
RBBP5 0.179735 
ZNF844 -0.356815 
 
TMEM79 -0.17047 
 
ERCC1 0.180065 
FOXRED1 -0.35056 
 
PRMT3 -0.170415 
 
MASP1 0.18083 
EP400NL -0.34762 
 
SYN1 -0.170295 
 
ITGBL1 0.180885 
FANCC -0.34619 
 
SHOX2 -0.170165 
 
DUSP11 0.18191 
ELP4 -0.341395 
 
CNNM2 -0.170045 
 
CCDC115 0.181975 
NAPEPLD -0.334095 
 
MAN2A1 -0.16961 
 
TMEM51 0.181975 
CHKA -0.33404 
 
TMEM143 -0.169405 
 
ATF4 0.182505 
PPFIBP2 -0.332635 
 
FOXO4 -0.16902 
 
HOXA5 0.182775 
ZNF808 -0.3326 
 
ECT2 -0.16897 
 
PRADC1 0.18299 
SFR1 -0.3302 
 
LNX1 -0.16883 
 
FAM118A 0.18301 
DND1 -0.32902 
 
PPAPDC3 -0.168735 
 
ANG 0.18384 
LRRC45 -0.31847 
 
PIGU -0.16802 
 
SPATA7 0.18406 
B4GALNT4 -0.31348 
 
TTC5 -0.16748 
 
LOC100287216 0.184105 
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C12orf76 -0.311395 
 
NUDT7 -0.16741 
 
WEE1 0.18543 
COL6A1 -0.31061 
 
APTX -0.16737 
 
ZNF354C 0.185875 
ADORA2B -0.31057 
 
PRR7 -0.16737 
 
ZW10 0.186715 
ZFP112 -0.30928 
 
NINL -0.167225 
 
CAMTA1 0.186955 
KIAA1199 -0.308455 
 
TEFM -0.1668 
 
AGAP6 0.187 
CDK1 -0.30665 
 
ANAPC1 -0.16679 
 
KDM6B 0.18724 
LRRC15 -0.30473 
 
LOC400550 -0.166785 
 
HHEX 0.18767 
SAMD11 -0.300945 
 
CHAF1A -0.16665 
 
ZNF7 0.18779 
LAMB3 -0.30038 
 
ASB13 -0.16658 
 
CASP6 0.187845 
HIST3H2A -0.30017 
 
NSUN3 -0.16634 
 
VAMP1 0.1895 
CHST10 -0.29558 
 
CCDC51 -0.166205 
 
LYSMD2 0.18952 
ZNF347 -0.29534 
 
PRR7 -0.1658 
 
BBS10 0.18959 
EPS15L1 -0.29264 
 
RBBP9 -0.16565 
 
1-Sep 0.18975 
PLEKHH2 -0.290185 
 
WDR4 -0.16556 
 
IL7R 0.190735 
IFITM3 -0.289665 
 
FLJ20021 -0.164935 
 
PDK2 0.19083 
KIF2C -0.2877 
 
HOXA2 -0.16478 
 
CYP2R1 0.191175 
CCDC76 -0.28642 
 
IPMK -0.164765 
 
ARID3A 0.19124 
EIF4ENIF1 -0.28502 
 
POLR1D -0.164545 
 
PEPD 0.19144 
SETDB1 -0.283395 
 
ANKRD46 -0.164505 
 
BICD1 0.19202 
SETDB1 -0.28241 
 
SOGA1 -0.16359 
 
VAMP4 0.19247 
SP100 -0.27705 
 
SLC25A51 -0.163105 
 
RUNX2 0.19278 
PSEN2 -0.27381 
 
PTMA -0.16306 
 
ASB7 0.192795 
OTUD6B -0.272725 
 
TRUB2 -0.162995 
 
LYNX1 0.19292 
WDR90 -0.2714 
 
ZNF780A -0.16145 
 
LRRC40 0.193005 
SPTLC1 -0.269365 
 
NRP2 -0.160905 
 
P2RY6 0.19352 
ZNF765 -0.26763 
 
ERI2 -0.160865 
 
MYH9 0.19365 
ZNF570 -0.267025 
 
RNF112 -0.16082 
 
FAM59B 0.194545 
BRP44L -0.26517 
 
RICTOR -0.16051 
 
SARS2 0.194615 
ARAP3 -0.264925 
 
LINC00578 -0.16008 
 
PARP16 0.19464 
RNF138 -0.263055 
 
MTM1 -0.15985 
 
LOC100506233 0.195475 
NCF2 -0.26113 
 
NXPH4 -0.15983 
 
DNM1 0.19552 
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PRDM15 -0.26057 
 
ANKRD27 -0.15971 
 
ULK3 0.196395 
SLC43A1 -0.260525 
 
TSPAN2 -0.15937 
 
POLR3A 0.19695 
FTH1 -0.25945 
 
TFDP2 -0.15934 
 
MECOM 0.197155 
C9orf37 -0.258705 
 
KREMEN1 -0.15892 
 
MCM5 0.19732 
VEPH1 -0.255695 
 
BAZ1A -0.158865 
 
KDM4C 0.197455 
RBPMS -0.25331 
 
MAD2L1BP -0.158855 
 
SMCR7 0.197595 
TIGD7 -0.25324 
 
GNB5 -0.15885 
 
CWF19L2 0.197625 
MAP6D1 -0.25321 
 
VSIG10 -0.158585 
 
STEAP2 0.19825 
LIME1 -0.251755 
 
CACNB1 -0.158445 
 
MYLK 0.19838 
WDR89 -0.250675 
 
PLEKHH3 -0.158395 
 
TMEM204 0.199035 
VMA21 -0.249985 
 
LOC100132352 -0.15836 
 
KLHL26 0.19911 
AHDC1 -0.24954 
 
MKI67IP -0.15825 
 
EMILIN2 0.199465 
LPP-AS2 -0.246235 
 
SYT12 -0.15822 
 
C5orf4 0.200195 
MAOB -0.246 
 
PATZ1 -0.157585 
 
KLC4 0.20038 
TUBGCP5 -0.245095 
 
FGF14 -0.15716 
 
TMEM38B 0.200495 
PCGF5 -0.24234 
 
ATPAF2 -0.15712 
 
OBSL1 0.200935 
EPB41L5 -0.242 
 
SHOX2 -0.15695 
 
CRADD 0.201205 
APOBEC3F -0.240535 
 
ZNF696 -0.15627 
 
ABCB7 0.20139 
SUV39H2 -0.23985 
 
CENPF -0.15617 
 
BEND6 0.201425 
GRASP -0.239285 
 
POU6F1 -0.15588 
 
ECSIT 0.20148 
ESCO1 -0.23918 
 
PPP4R2 -0.155605 
 
C6orf226 0.201785 
ZNF420 -0.23794 
 
PEX16 -0.155605 
 
HSPA4L 0.20197 
DSTNP2 -0.23539 
 
SMC4 -0.155105 
 
CDKAL1 0.202225 
ZBTB49 -0.2351 
 
ANLN -0.154225 
 
CACNB1 0.202365 
LOC254896 -0.234335 
 
KIAA0391 -0.153425 
 
ZNF559 0.20307 
ZNF252 -0.233865 
 
YBX1 -0.15324 
 
MSI2 0.20367 
TMEM107 -0.22746 
 
NEK3 -0.153115 
 
COL5A2 0.20381 
ZBTB46 -0.22686 
 
C22orf25 -0.152525 
 
ZNF451 0.204695 
ZNF256 -0.22602 
 
ARID4A -0.152375 
 
TPP2 0.204715 
C1orf159 -0.22597 
 
ARMC6 -0.151895 
 
SLC27A3 0.2061 
PITPNM2 -0.22512 
 
OGFRL1 -0.15189 
 
TOMM34 0.206525 
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DHTKD1 -0.22413 
 
ARG2 -0.15175 
 
SPHK2 0.20708 
HES6 -0.22323 
 
NDUFB5 -0.151695 
 
JUP 0.207305 
SNAI1 -0.22153 
 
CLUAP1 -0.15129 
 
PEX7 0.20736 
HOTAIRM1 -0.21966 
 
ATG2A -0.151105 
 
PACRGL 0.207555 
NFKBIB -0.21924 
 
GPN2 -0.1509 
 
PIDD 0.20953 
C9orf172 -0.21884 
 
CC2D2A -0.15003 
 
HAUS8 0.20992 
ZNF154 -0.2187 
 
GOLGA4 0.15015 
 
NMRK1 0.2107 
GFOD2 -0.218015 
 
SLC27A5 0.150615 
 
RGS19 0.210865 
FUK -0.217705 
 
INMT 0.15081 
 
SAP130 0.21096 
DUSP10 -0.217645 
 
CTBP1 0.150875 
 
S100PBP 0.211265 
RPL13A -0.217095 
 
PRUNE 0.15128 
 
USP30 0.212215 
TAF1B -0.216475 
 
YTHDC2 0.151325 
 
NHEJ1 0.21248 
ZNF140 -0.21418 
 
RAB40B 0.152025 
 
CDK3 0.21303 
UNK -0.213355 
 
RAPGEF6 0.152195 
 
SNX21 0.213175 
DMD -0.21129 
 
DPP3 0.152215 
 
PARP3 0.21384 
C1orf27 -0.211065 
 
GULP1 0.15224 
 
TPM1 0.21421 
SLC25A14 -0.211055 
 
MMGT1 0.15234 
 
PPP1R16A 0.21564 
SLC22A15 -0.210135 
 
PPP2R3C 0.152505 
 
NCOA2 0.21667 
NKAP -0.209835 
 
AMT 0.152825 
 
ZNF415 0.21757 
NOL11 -0.209305 
 
HOOK3 0.153055 
 
LOC729678 0.21762 
ZSCAN12 -0.208135 
 
TMEM41A 0.153085 
 
SH3GLB2 0.217825 
TMOD2 -0.207785 
 
ISG15 0.153105 
 
DSN1 0.218555 
HUS1 -0.20756 
 
ARHGEF10L 0.153125 
 
RAD17 0.219585 
LSM11 -0.206465 
 
DGKQ 0.15326 
 
RAD17 0.219805 
ZNF25 -0.20629 
 
LOC100506668 0.153285 
 
PARP14 0.221185 
AURKA -0.20565 
 
LBH 0.15372 
 
TBKBP1 0.222685 
NUP188 -0.20518 
 
REXO4 0.154015 
 
PRICKLE3 0.22289 
TTC14 -0.204995 
 
PTGER1 0.15418 
 
SMCR7 0.222985 
ZNF767 -0.20425 
 
RNF166 0.15445 
 
IQGAP3 0.22377 
KIAA0146 -0.2042 
 
DEK 0.154635 
 
WASH2P 0.231875 
MSH2 -0.203695 
 
ROCK2 0.154675 
 
PDXDC2P 0.23254 
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TMEM186 -0.20339 
 
SAC3D1 0.154795 
 
FAM122B 0.23306 
KIAA0753 -0.20312 
 
ZNF211 0.1548 
 
YPEL2 0.233325 
ZNF790 -0.20261 
 
TOPORS 0.15522 
 
ADSSL1 0.2362 
HRSP12 -0.20226 
 
KIAA1737 0.15523 
 
SETMAR 0.23722 
NAF1 -0.201545 
 
RTEL1 0.15553 
 
LOC284581 0.237675 
LRRK1 -0.20133 
 
APLP1 0.155535 
 
PYGO1 0.23909 
MMACHC -0.2007 
 
NCK2 0.15572 
 
GPR153 0.240635 
TBXA2R -0.19969 
 
PIGC 0.155985 
 
SMPDL3A 0.24088 
CCDC74A -0.19962 
 
SLC25A40 0.156035 
 
KLHL7 0.24106 
DPH3P1 -0.199215 
 
DLEU1 0.15633 
 
ECE2 0.24109 
CPS1 -0.19913 
 
FBXO3 0.156535 
 
KCTD1 0.24309 
ZC3H12A -0.1988 
 
PPIP5K1 0.156825 
 
ZNF800 0.24409 
TTC39C -0.19861 
 
PQLC2 0.15695 
 
TXLNG2P 0.2462 
VPS37D -0.19825 
 
MAP3K13 0.15696 
 
SPARC 0.24685 
ZNF195 -0.197665 
 
CLASP2 0.15735 
 
P2RX5 0.24713 
MYO19 -0.196695 
 
RFC5 0.157425 
 
C14orf142 0.247625 
SLC9B2 -0.196605 
 
HSCB 0.157705 
 
TIMP3 0.247835 
WDR92 -0.1965 
 
DIS3L 0.15771 
 
DHX57 0.24869 
FBXO10 -0.196325 
 
FARS2 0.15782 
 
ITGB1BP1 0.24929 
TMEM200B -0.19612 
 
OXSM 0.15799 
 
STAG3L1 0.24972 
ALX3 -0.196075 
 
DIAPH3 0.15802 
 
ZNF8 0.252405 
SEMA5A -0.19575 
 
FASTKD3 0.15814 
 
SLC29A3 0.25411 
MBTD1 -0.19502 
 
C17orf56 0.15821 
 
C8orf55 0.256215 
FZD4 -0.19488 
 
PRPF39 0.158245 
 
CCT6P1 0.25667 
SELENBP1 -0.193915 
 
ATHL1 0.1583 
 
METTL1 0.256705 
LOC100505783 -0.19302 
 
PHF19 0.15883 
 
WDR53 0.256755 
C2orf89 -0.19297 
 
RAB4B 0.15886 
 
ZBTB2 0.259455 
BCCIP -0.19292 
 
CPA4 0.159025 
 
C17orf100 0.261585 
C1orf74 -0.19278 
 
FANCF 0.15912 
 
CASP8 0.261605 
RGPD5 -0.19263 
 
STAG3L2 0.15922 
 
RAB33A 0.262245 
ZNF510 -0.19236 
 
BANP 0.15925 
 
CAMK1D 0.263715 
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ICAM5 -0.192265 
 
PIGC 0.15932 
 
AMT 0.264565 
RGPD8 -0.190595 
 
NDOR1 0.159825 
 
CCDC75 0.26789 
GTF3C4 -0.190365 
 
RAD52 0.16086 
 
COL5A1 0.26851 
ZNF225 -0.18986 
 
ZNF394 0.161145 
 
PVR 0.27053 
C3orf23 -0.18958 
 
KDM1B 0.16121 
 
ZNF343 0.2737 
STAT5A -0.189565 
 
GDPD5 0.161355 
 
ANKRD36BP1 0.2741 
PI4KAP2 -0.1894 
 
GATAD1 0.16171 
 
C1QTNF6 0.278765 
PGAP3 -0.18877 
 
STX16 0.161785 
 
PALB2 0.284765 
MFSD6 -0.188735 
 
ADAMTSL5 0.16296 
 
BRI3BP 0.28581 
CHRNB1 -0.18839 
 
LGR4 0.16328 
 
IGF1 0.286995 
ANXA9 -0.18713 
 
ZNF558 0.163615 
 
C17orf65 0.28844 
TMEM206 -0.186915 
 
LOC646324 0.164135 
 
KRBA2 0.28854 
ZNF674 -0.18674 
 
AAED1 0.164445 
 
LENG9 0.28966 
ZNF674 -0.186445 
 
FOXO1 0.164565 
 
YEATS4 0.289705 
NUP153 -0.186385 
 
DIRC3 0.164635 
 
POC1B 0.290085 
ABCC5 -0.18628 
 
ARHGEF19 0.164825 
 
FN1 0.29494 
DEM1 -0.18622 
 
FAM91A1 0.164915 
 
STX1A 0.29512 
CDKN1C -0.18568 
 
E4F1 0.164965 
 
C1orf51 0.29772 
FANCG -0.18563 
 
SDCCAG3 0.165325 
 
MPHOSPH9 0.29779 
PTPRJ -0.18547 
 
SSSCA1 0.165455 
 
MSX1 0.29949 
KIAA1377 -0.185375 
 
ATE1 0.16562 
 
PER3 0.300455 
ACBD4 -0.18534 
 
ERN1 0.16621 
 
FLVCR1-AS1 0.30373 
HARS2 -0.185105 
 
GRIPAP1 0.166335 
 
TAF2 0.304755 
LRFN3 -0.18383 
 
ABCC10 0.16651 
 
TEKT4P2 0.30996 
RFXAP -0.18348 
 
TLCD1 0.16666 
 
PTBP2 0.31176 
TMEM201 -0.1828 
 
LOC100505806 0.16691 
 
CCDC61 0.313225 
CDC14B -0.18184 
 
CENPL 0.16723 
 
WDSUB1 0.318025 
HS3ST3B1 -0.181495 
 
THG1L 0.167245 
 
GMEB2 0.32032 
CCBL1 -0.180725 
 
LOC550112 0.1674 
 
HEATR5B 0.320685 
RECQL5 -0.180665 
 
ZNF564 0.167525 
 
C9orf116 0.32125 
GPR135 -0.180485 
 
IKBKE 0.1676 
 
COL3A1 0.3289 
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CDKN1C -0.18022 
 
SLC10A7 0.16785 
 
LOC646576 0.33023 
PCDHGA5 -0.17957 
 
C11orf95 0.168585 
 
GNB3 0.333805 
SMURF1 -0.179485 
 
OLFM2 0.16861 
 
NPHP4 0.340505 
SLC30A7 -0.17948 
 
DTX2 0.168745 
 
LIG4 0.34662 
RTN4 -0.179095 
 
RB1 0.169285 
 
C10orf114 0.346825 
ZMYM5 -0.179015 
 
GFOD1 0.170135 
 
INE1 0.35297 
ZNF529 -0.17891 
 
VAMP1 0.170135 
 
TCTN2 0.3576 
PRICKLE4 -0.178705 
 
CRLF3 0.170245 
 
TAGLN 0.359255 
ZNF16 -0.178655 
 
PIAS2 0.17044 
 
C9orf116 0.375085 
F8 -0.178395 
 
UTP20 0.17045 
 
BEND7 0.3791 
LIMCH1 -0.17834 
 
ZNF671 0.17084 
 
CC2D2A 0.38625 
TTF2 -0.17824 
 
CTGF 0.17109 
 
COL4A1 0.390375 
SLC19A1 -0.177515 
 
CTTNBP2 0.17114 
 
GANC 0.40477 
ZFP28 -0.17745 
 
PDE4DIP 0.1714 
 
AHNAK 0.41039 
ZNF772 -0.17694 
 
IFI35 0.17223 
 
ACTA2 0.413785 
C6orf132 -0.17684 
 
GABPB2 0.172415 
 
FAM171A2 0.41677 
TNFRSF11B -0.176705 
 
CMTM3 0.17247 
 
ELN 0.421915 
ZNF383 -0.176035 
 
WDR81 0.172745 
 
SERPINE2 0.42436 
RAB15 -0.17596 
 
RDH5 0.17277 
 
THBS2 0.43057 
FANCE -0.17578 
 
USP20 0.173035 
 
FTL 0.43496 
   
MAPKBP1 0.17335 
 
COL4A2 0.448335 
 
Table 4.3. APA Genes for the IPF dataset. 
*  all of the genes listed in the table are statistically significant (p < 0.05) 
Gene Name 
IPF 
APA 
PDUI 
 
Gene Name 
IPF 
APA 
PDUI 
 
Gene Name 
IPF APA 
PDUI 
ZBTB25 -0.441 
 
FKTN -0.166 
 
ZNF383 0.178 
KIF3A -0.405 
 
THAP5 -0.165 
 
AMT 0.178 
FLJ46906 -0.376 
 
SLC25A16 -0.165 
 
BAIAP2 0.179 
FAM70A -0.348 
 
SOD2 -0.164 
 
MTERFD2 0.179 
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PION -0.335 
 
ASAH1 -0.164 
 
COTL1 0.179 
IL31RA -0.334 
 
GABPB1 -0.164 
 
ZNF587B 0.179 
TAF5 -0.329 
 
TMEM194A -0.163 
 
PLEKHM1 0.181 
ADAM23 -0.328 
 
BST2 -0.163 
 
DUSP22 0.181 
MYOM2 -0.327 
 
NEK11 -0.163 
 
C9orf156 0.182 
CERKL -0.327 
 
GINS3 -0.162 
 
TMEM198 0.182 
NAA16 -0.318 
 
PLCD4 -0.161 
 
PLXNA2 0.183 
NAPB -0.312 
 
GINS4 -0.161 
 
FAM91A2 0.183 
WDR60 -0.312 
 
TMEM68 -0.161 
 
EDNRB 0.183 
GUSBP1 -0.308 
 
NDNF -0.160 
 
ZNF75D 0.184 
FUCA1 -0.303 
 
LTN1 -0.160 
 
EIF4ENIF1 0.184 
HNMT -0.303 
 
TXLNG2P -0.160 
 
CEP57L1 0.185 
ZNF614 -0.301 
 
TWIST2 -0.160 
 
TEFM 0.186 
PIAS1 -0.299 
 
ATG4C -0.160 
 
NUDT8 0.187 
LRRC23 -0.295 
 
MAX -0.159 
 
SPARC 0.187 
USP44 -0.291 
 
CLDN7 -0.159 
 
HSF2 0.187 
LRRC56 -0.290 
 
IBTK -0.159 
 
MSH2 0.188 
PTMA -0.289 
 
CNOT4 -0.159 
 
TTC39B 0.188 
LOC100630918 -0.284 
 
ARHGEF7 -0.158 
 
FGF18 0.189 
NFXL1 -0.279 
 
CTTNBP2 -0.158 
 
ALKBH8 0.190 
GUSBP11 -0.279 
 
DNER -0.158 
 
ZNF200 0.191 
NKX3-1 -0.279 
 
GFOD2 -0.158 
 
ZNF200 0.191 
NEIL3 -0.275 
 
TRIT1 -0.158 
 
TSPAN10 0.192 
PAPLN -0.258 
 
MASP1 -0.158 
 
DDO 0.192 
RWDD2A -0.257 
 
PARPBP -0.157 
 
RAP1GAP2 0.192 
SLC30A5 -0.256 
 
KAT2A -0.157 
 
SLC2A11 0.193 
CIB2 -0.254 
 
NRG1 -0.157 
 
HOXB8 0.193 
METTL21D -0.254 
 
TADA1 -0.157 
 
ZNF174 0.194 
PTGER1 -0.252 
 
LINC00526 -0.156 
 
SUV39H1 0.194 
LOC100505687 -0.252 
 
HEATR7A -0.156 
 
PRR14L 0.194 
SLC22A4 -0.251 
 
C15orf58 -0.156 
 
PANX2 0.194 
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ABCB10 -0.248 
 
C11orf54 -0.154 
 
SSR4P1 0.195 
KIAA0564 -0.247 
 
C10orf88 -0.154 
 
MAP3K4 0.195 
NLK -0.246 
 
NFATC3 -0.153 
 
ZNF350 0.196 
TAF1B -0.244 
 
ORC1 -0.153 
 
LTB4R2 0.196 
LOC100287314 -0.240 
 
CHCHD4 -0.153 
 
PGF 0.197 
KCNC4 -0.239 
 
C5orf15 -0.152 
 
LOC100132273 0.197 
SLC1A7 -0.233 
 
PPIL3 -0.152 
 
NS3BP 0.197 
PRMT10 -0.231 
 
MFAP1 -0.152 
 
ZNF784 0.197 
RAB11FIP3 -0.231 
 
DYX1C1-CCPG1 -0.151 
 
ZNF202 0.199 
FASTKD3 -0.231 
 
ZNF335 -0.151 
 
ULBP1 0.200 
PRR19 -0.231 
 
TYW3 -0.150 
 
DZIP1L 0.200 
CELSR2 -0.229 
 
SIGLEC15 0.150 
 
TRIM16L 0.201 
C5orf42 -0.229 
 
C6orf228 0.150 
 
ZNF239 0.201 
DBF4B -0.228 
 
PCGF6 0.151 
 
LOC100144603 0.202 
PICK1 -0.228 
 
TTTY15 0.151 
 
ZNF226 0.203 
NXT2 -0.226 
 
DOHH 0.151 
 
NBPF3 0.204 
RSPH3 -0.225 
 
FKBP1B 0.151 
 
TESK2 0.204 
LOC648987 -0.224 
 
NUDT7 0.151 
 
ADC 0.204 
LOC388152 -0.223 
 
LMF1 0.152 
 
ENOX1 0.204 
EXOSC7 -0.223 
 
LOC100131691 0.152 
 
RPL13AP20 0.205 
CTSH -0.221 
 
FAM58A 0.153 
 
IKBKG 0.206 
TRAIP -0.221 
 
E4F1 0.153 
 
HLA-B 0.206 
NUP35 -0.220 
 
MIIP 0.153 
 
STAT6 0.207 
SPATA5L1 -0.220 
 
STAU2 0.154 
 
PIK3R3 0.207 
NAF1 -0.219 
 
ORC6 0.154 
 
C9orf116 0.208 
MIS18BP1 -0.219 
 
FAM21B 0.154 
 
CBX2 0.210 
ZNF669 -0.219 
 
SALL2 0.154 
 
FAM86EP 0.210 
ZNF767 -0.218 
 
THAP7-AS1 0.155 
 
RTKN 0.210 
TMSB15B -0.217 
 
AFG3L1P 0.155 
 
GCH1 0.210 
DDX60 -0.216 
 
PHTF1 0.155 
 
OLFM2 0.211 
SLC7A5P1 -0.213 
 
PRICKLE4 0.155 
 
ZNF468 0.212 
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MTM1 -0.213 
 
TMCO6 0.155 
 
GMCL1 0.213 
ZNF800 -0.212 
 
HYAL3 0.156 
 
SELS 0.213 
CEPT1 -0.212 
 
TBC1D23 0.156 
 
ZNF585B 0.213 
FAM69A -0.211 
 
TTC26 0.156 
 
ENOX1 0.214 
CXorf23 -0.211 
 
MYO9B 0.156 
 
C9orf116 0.214 
DNAJA4 -0.210 
 
ZNF419 0.157 
 
RGL3 0.216 
NOL11 -0.210 
 
ANXA9 0.157 
 
CAPN10 0.217 
PDE4DIP -0.210 
 
CWC22 0.157 
 
LCORL 0.218 
ZNF451 -0.210 
 
TYW1B 0.157 
 
SETD4 0.218 
CYB5RL -0.210 
 
C1orf115 0.158 
 
FMNL1 0.218 
EDNRB -0.209 
 
ZFYVE26 0.159 
 
RHBDF2 0.218 
IL4I1 -0.209 
 
HMMR 0.159 
 
ATF6B 0.220 
NFATC1 -0.207 
 
FAM162B 0.159 
 
LTB4R2 0.220 
IL24 -0.207 
 
PITPNM2 0.159 
 
EFCAB2 0.221 
TMEM38B -0.207 
 
MED27 0.159 
 
ZSCAN20 0.221 
MGC16121 -0.203 
 
CYB5D1 0.159 
 
FKBP9L 0.222 
SCN2B -0.203 
 
CCZ1B 0.160 
 
MYPN 0.225 
WNT3 -0.201 
 
CRMP1 0.160 
 
GLTSCR1 0.225 
CHUK -0.201 
 
YEATS4 0.160 
 
ACACB 0.227 
CASP9 -0.200 
 
SAMD11 0.161 
 
ZNF616 0.227 
OSGEPL1 -0.199 
 
RGS2 0.161 
 
RNFT1 0.227 
MSH3 -0.199 
 
PAN3 0.161 
 
SLC30A4 0.230 
FAM198B -0.198 
 
CNN2 0.162 
 
PIGZ 0.230 
DNMT3B -0.198 
 
RASIP1 0.162 
 
SLC7A7 0.232 
FAM212A -0.198 
 
CDK20 0.162 
 
TMEM91 0.234 
ZNF490 -0.197 
 
L1CAM 0.162 
 
HLA-C 0.235 
STAC -0.197 
 
PER2 0.162 
 
KDM5B-AS1 0.243 
ZNF280D -0.196 
 
TNIK 0.163 
 
RNASEH2B 0.244 
ZNF14 -0.196 
 
STK11IP 0.163 
 
PGAP2 0.244 
NGEF -0.194 
 
DFFB 0.163 
 
PIK3R4 0.244 
C2orf42 -0.194 
 
NRG1 0.164 
 
FAM179B 0.251 
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PDE4DIP -0.194 
 
KLHL25 0.164 
 
NEFM 0.253 
PDE4DIP -0.193 
 
CDK10 0.164 
 
SLMO1 0.254 
C3orf23 -0.192 
 
TNFRSF10A 0.164 
 
LOC646576 0.254 
C1orf192 -0.189 
 
CROCC 0.165 
 
VAX2 0.255 
TXNIP -0.188 
 
ANXA5 0.165 
 
CGNL1 0.258 
MBD5 -0.187 
 
SPATA7 0.166 
 
TMEM41B 0.259 
SLC29A3 -0.187 
 
RFC1 0.166 
 
MEPCE 0.261 
TEK -0.187 
 
LGMN 0.167 
 
THBS1 0.261 
PMS2 -0.186 
 
CDK20 0.167 
 
MLKL 0.266 
MINPP1 -0.186 
 
PREPL 0.167 
 
GPAM 0.266 
KCNG2 -0.185 
 
EGR1 0.167 
 
RABEP1 0.267 
ZMYM5 -0.184 
 
CTPS 0.168 
 
KIAA1199 0.268 
SEMA6D -0.184 
 
SPON2 0.169 
 
GCC2 0.269 
IL1B -0.181 
 
SYNPO 0.169 
 
METTL7B 0.271 
CTDSPL2 -0.180 
 
AP3D1 0.170 
 
CCDC88B 0.273 
FAM214A -0.177 
 
SETD4 0.171 
 
IFITM3 0.279 
LOC387723 -0.177 
 
ZNF302 0.171 
 
PSPC1 0.284 
IL11RA -0.176 
 
CPT2 0.171 
 
MSANTD2 0.285 
RMND5A -0.175 
 
TMEM180 0.171 
 
GLIS1 0.293 
ZNF619 -0.173 
 
SETD4 0.171 
 
C12orf76 0.295 
SLC33A1 -0.173 
 
ZNF701 0.172 
 
FARP2 0.300 
CEP78 -0.171 
 
AP3D1 0.172 
 
OR7E12P 0.306 
SAV1 -0.171 
 
S100PBP 0.172 
 
SETDB2 0.320 
NEK3 -0.171 
 
PRUNE 0.172 
 
CORO7 0.322 
INPP4B -0.171 
 
ERGIC2 0.172 
 
LOC113230 0.325 
ZKSCAN4 -0.170 
 
VIM 0.173 
 
GAS6 0.327 
CLCC1 -0.170 
 
GON4L 0.173 
 
ARL17B 0.332 
CNTRL -0.169 
 
CDKN1A 0.173 
 
OASL 0.339 
CNRIP1 -0.169 
 
AFG3L1P 0.174 
 
ZNF550 0.371 
SPTLC1 -0.169 
 
LAMP2 0.174 
 
SH3BGR 0.377 
ERMP1 -0.168 
 
COL8A2 0.174 
 
INCA1 0.398 
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PDPN -0.168 
 
GSTM4 0.174 
 
SH3BP1 0.424 
PPAN-P2RY11 -0.168 
 
LOC388242 0.176 
 
HIST2H2BC 0.461 
LOC652276 -0.167 
 
FSTL1 0.177 
 
PLEKHN1 0.464 
OIP5 -0.167 
 
PRICKLE3 0.177 
 
COL1A1 0.467 
YAE1D1 -0.167 
 
LPAR3 0.177 
 
COL1A2 0.469 
C17orf100 -0.167 
 
SUSD3 0.178 
 
PGM5P2 0.480 
BCKDHB -0.167 
 
ZSWIM3 0.178 
 
SGK3 0.510 
 
Table 4.4. Common APA Genes between the NUDT21 KD and the IPF dataset. 
*  all of the genes listed in the table are statistically significant (p < 0.05) 
Gene Name IPF APA PDUI NUDT21 APA PDUI 
C3orf23 -0.19198 -0.42 
RTKN 0.20981 -0.395 
FAM179B 0.25095 -0.355 
RABEP1 0.26666 -0.34 
MSH3 -0.19887 -0.315 
FKTN -0.165576667 -0.315 
CNOT4 -0.15851 -0.305 
BCKDHB -0.166975 -0.295 
C6orf228 0.150206667 -0.295 
PDE4DIP -0.210043333 -0.285 
PDE4DIP -0.1936 -0.285 
PDE4DIP -0.193426667 -0.285 
RWDD2A -0.256806667 -0.27 
KIAA0564 -0.246743333 -0.27 
PCGF6 0.15088 -0.245 
CEP57L1 0.185425 -0.205 
STAU2 0.153646667 -0.165 
MTERFD2 0.178876667 -0.16 
DOHH 0.15117 0.24 
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LOC652276 -0.167486667 0.31 
NAPB -0.31245 0.345 
TYW1B 0.15686 0.35 
NFATC1 -0.20728 0.365 
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DISCUSSION 
IPF is a chronic lung disease with an unclear etiology. Among interstitial lung 
diseases, IPF is the most severe type, with a 5-year survival rate in the range of 20-30% 
(38). This poor patient outcome is largely due to the absence of effective medical 
therapies for IPF. One of the key features of IPF is abnormal fibroblast activation and 
therefore uncontrolled deposition of ECM, which impairs gas exchange across the 
alveolocapillary membrane. Although fibroblasts are one of the major cells that 
overexpress pathological ECM and profibrotic mediators, the mechanisms governing the 
protein expression are still elusive. Our study investigated a novel mechanism for the 
fibrotic gene expression in lung fibroblasts.  
Alternative polyadenylation (APA) has been recognized as a novel post-
transcriptional regulation that affects 3’UTR lengths of transcriptomes and, therefore, 
protein expression of APA target genes. NUDT21, a key protein in the polyadenylation 
machinery, has been associated with various cancer cell lines and tumor growth (190, 
244, 273–275), with previous studies suggesting that APA via NUDT21 reduction 
increases expression of oncogenes contributing to cancer progression (190). However, 
the roles and implications of APA in pathophysiology have been elusive, especially in 
non-cancer diseases. Our previous work demonstrated that IPF is associated with APA 
and NUDT21 reduction, and NUDT21 reduction exacerbates the development of fibrosis 
(201). As a follow up report, our current study identified TGFb1 as a major inducer of 
APA, a post transcriptional regulation, in lung fibroblasts via NUDT21 reduction. We 
demonstrate here that TGFb1, a profibrotic cytokine, downregulates NUDT21 in primary 
human and mouse lung fibroblasts at protein and mRNA levels. Furthermore, it was 
shown that TGFb1 elevates miR203 which targets the 3’UTR of NUDT21 via Smad3 
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phosphorylation in human lung fibroblasts. TGFb1 transgenic mice revealed that TGFb1 
reduces NUDT21 in vivo. In addition, RNA seq data demonstrated that human lung 
fibroblasts treated with TGFb1, as well as IPF patient fibroblasts, exhibited a distinctive 
APA pattern of global shortening and lengthening. Understanding the mechanism driving 
the APA in IPF is important because this novel pathway can be potentially targeted to 
halt pulmonary fibrosis. 
Several studies have demonstrated that initial injuries in alveolar epithelial cells 
are the trigger of pulmonary fibrosis in genetically and environmentally predisposed 
subjects, leading to pathological fibroblast activation (102, 254). In addition to the 
concept of epithelial injury, it has been proposed that fibrotic environments triggered 
initially by epithelial injuries constitute a self-sustaining niche for aggravated fibrotic 
progression, which is independent of epithelial injuries (138, 139). This suggests that 
pulmonary fibrosis may have two distinct phases of pathogenesis that should be 
therapeutically targeted as independent entities: initiation in epithelial cells and 
progression in fibroblasts (254). NUDT21 conditional knockout in fibroblasts does not 
induce spontaneous fibrosis in vivo as previously reported (201), suggesting that 
NUDT21 depletion in fibroblasts does not significantly cause the initial phase of epithelial 
injury or activate resident fibroblasts for pathogenesis at least at age of 6 – 8 weeks in 
mice. Interestingly, NUDT21 conditional knockout mice exhibited significantly worsened 
fibrosis upon bleomycin administration. This result demonstrates that NUDT21 reduction 
in fibroblasts may amplify the severity of fibrosis in the progression phase by 
overexpressing profibrotic mediators and matrix protein, therefore enhancing the 
establishment of a self-sustaining profibrotic niche in the micro-environment (138). 
TGFb1, as a major pro-fibrotic factor, may amplify fibrosis by down-regulating NUDT21 
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and inducing APA. 
 In this project, we reported that NUDT21 reduction is found in lung fibroblasts of 
IPF patients. The subsequent experiments revealed that TGFb1 transcriptionally induces 
miR203 via p-Smad3 to deplete NUDT21 mRNA and, thus, protein leading to APA in 
lung fibroblasts. Interestingly, this robust reduction is not found in type I or II epithelial 
cells of IPF patients as shown in the IHC staining data for NUDT21. It is presumably due 
to the possibilities that TGFb1 does not activate Smad3 pathways at least not as much 
as this molecule does in lung fibroblasts or Smad3 does not target miR203 for 
upregulation in epithelial cells. However, these speculations need to be experimentally 
proven. Interestingly, a recent report on IPF single-cell-seq revealed that NUDT21 is 
elevated in type II epithelial cells (http://ipfcellatlas.com) (276). NUDT21 is known as a 
regulator of stemness and cell fate via APA as previously discussed and a subset of type 
II epithelial cells is a local stem cell which can initiate re-epithelialization which is impaired 
in IPF (234). Therefore, the upregulated NUDT21 may have roles in the pathogenesis of 
IPF in terms of the differentiation of type II epithelial cells. 
NUDT21 is the key regulator of APA in human lung fibroblasts, and the knockdown 
of NUDT21 by siRNA is sufficient to induce global APA enriched for profibrotic mediators 
and is associated with increased protein expression (201). We previously observed a 
unique pattern of APA on the 3’UTR, primarily shortening. However, in this study, the 
human lung fibroblasts challenged with TGFb1 displayed not just shortening, but also 
lengthening of the 3’UTR through APA globally (Figure 4.6 A). This differential APA by 
TGFb1 was presumably due to the fact that TGFb1, as a potent inducer of various 
signaling pathways, regulates multiple regulators of APA, including NUDT21. For 
example, TGFb1 RNA seq data revealed that Fip1, which is another regulator of 3’UTR 
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lengthening by APA, is downregulated (186) (Figure 4.7). In addition to Fip1, TGFb1 
reduces other APA regulators that are associated with 3’UTR shortening, such as 
CFIm68 (172, 277). This unique differential APA pattern is also observed in fibroblasts 
isolated from IPF patients (Figure 4.6 K), suggesting that APA in patients is controlled 
by multiple factors, not just by a single factor. 
 
Figure 4.7. APA regulators in the TGFβ1 fibroblasts 
One of the critical features of IPF is accumulation of pulmonary fibroblasts, 
especially in the areas of fibroblastic foci which are positive for aSMA (215). These 
fibroblasts are resistant to Fas-mediated apoptosis by overexpressing decoy receptor 3 
(DcR3) which antagonizes the action of FasL in immune cells leading to inhibition on the 
clearance of the fibroblasts by effectors cells (278, 279). It has been proposed that the 
enhanced resistance to apoptosis leads to accumulation of fibroblasts. The other 
mechanism which is, in part, responsible for the appearance of accumulated fibroblasts 
in IPF is over-proliferation of the cells (280). Interestingly, there are very few proliferating 
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fibroblasts within fibroblastic foci as indicated by the weak presence of KI67 staining in 
IHC staining of IPF lungs, which weakens the importance of cell proliferation of 
fibroblasts in the pathogenesis of IPF (281). However, it is unclear whether these 
fibroblasts become non-proliferative as a result of preceding over-proliferation and, thus, 
cellular senescence. Moreover, it is possible that the few proliferating fibroblasts within 
fibroblastic foci are sufficient to drive the formation or enlargement of the foci. One of the 
goals of this project is to examine whether NUDT21 reduction promotes cellular 
proliferation of fibroblasts. However, NUDT21 reduction did not lead to cellular 
proliferation. However, considering the fact that the majority of the cells in fibroblastic 
foci shows significant reduction in NUDT21 and is, in fact, less proliferative, NUDT21 
reduction can explain the pathological phenotypes of fibroblasts, such as overexpression 
of pro-fibrotic mediators and ECM proteins. 
Patient care for IPF has been challenging due to the limited therapies for the 
disease. Drug development for IPF has been unsuccessful for decades presumably 
because the clinical drugs target only single molecular pathways associated with IPF and 
thus fail (282). Given the fact that IPF is a heterogeneous disease that has multiple 
pathogenic pathways activated, it has been suggested that drugs developed for IPF 
should target diverse signaling pathways (282). The only drugs that slow down the 
progression of IPF are pirfenidone and nintedanib, and they indeed target multiple 
signaling molecules (79, 83). Nonetheless, a definitive cure remains to be found since 
patients on these medications still show a constant decline in lung function and do not 
have a significantly improved morbidity compared to placebo groups (75, 192–194). The 
APA regulation by NUDT21 is novel and clinically important because this pathway is a 
physiological mechanism that can impact multiple pathways. NUDT21 downregulation, 
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which is also observed in IPF patients, leads to global mRNA shortening, especially 
enriched in important pro-fibrotic pathways such as Wnt, TGFb1, and VEGF signaling, 
suggesting that targeting APA through NUDT21 may be a potential therapeutic approach 
for pulmonary fibrosis. Previously, it was demonstrated that NUDT21 overexpression in 
IPF fibroblasts reduces the protein expression of pro-fibrotic mediators and ECM (201). 
In this study, it was further shown that preventing NUDT21 reduction by antagomiR203, 
an inhibitor of miR203, decreases ECM proteins and inhibits fibroblast activation.  This 
data collectively suggests that targeting APA by NUDT21 overexpression or 
antagomiR203 are potential therapeutic approaches for pulmonary fibrosis. 
In conclusion, our study demonstrated that TGFβ1 downregulates NUDT21 in 
human and mouse lung fibroblasts. The detailed mechanism includes the transcriptional 
induction of miR203 by TGFβ1 through Smad3 activation targeting the 3’UTR of NUDT21. 
In turn, lung fibroblasts challenged with TGFβ1 and fibroblasts isolated from IPF patients 
display differential APA patterns, and the shortening of APA genes was associated with 
increased protein expression. These findings unveil a novel mechanism for APA induced 
by NUDT21 depletion that is associated with deadly diseases, such as IPF and cancer. 
The results of this research will help develop innovative therapies by targeting the 
pathways involved with post-transcriptional regulation of profibrotic mediators and 
pathological genes. 
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CHAPTER FIVE 
SUMMARY, FUTURE DIRECTIONS, AND CONCLUSION 
SUMMARY 
 IPF is a fatal lung disease with a poor prognosis affecting millions of lives in the 
world. The mean survival of the patients after their initial diagnosis is only 2 to 3 years 
due to the limited options for therapies, suggesting an urgent need of innovative 
therapies for IPF (38). The previous work from our lab and collaborators shows that 
alternative polyadenylation (APA) which regulates the lengths of 3’UTRs can affect the 
gene expression of APA target genes. We demonstrated that a reduction in NUDT21, a 
key subunit in the polyadenylation complex, promotes global mRNA shortening via APA 
which stabilizes transcripts and, therefore, enhances protein expression of the genes 
leading to tumor growth of glioblastoma and cell proliferation of cancer cells. In this thesis, 
we elucidated the roles of APA in the pathogenesis of pulmonary fibrosis and the key 
factors which lead to the depletion of NUDT21 in lung fibroblasts.  
 Lung samples from IPF patients revealed that there is a reduction in NUDT21 with 
an increase in fibronectin, a fibrotic marker, suggesting that NUDT21 depletion is 
associated with IPF. We found that the fibroblasts which were positive for αSMA lacked 
signals of NUDT21 although they had DAPI signals from the nuclei and the majority of 
epithelial cells still had signals for NUDT21, indicating that NUDT21 depletion is found in 
fibroblasts. For more quantitative analysis, primary fibroblasts from IPF or health lungs 
were utilized for Western Blot analysis where NUDT21, along other two CFIm complex 
proteins, CFIm59 and CFIm68, was found to be depleted in IPF fibroblasts. The chronic 
i.p. bleomycin-induced fibrosis model revealed that NUDT21 was also significantly 
depleted in the fibroblasts isolated from the mice with bleomycin-induced fibrosis in 
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addition to the reductions in CFIm59 and CFIm68. These results suggest that NUDT21 
reduction in lung fibroblasts is associated with pulmonary fibrosis. 
 In order to investigate the effect of NUDT21 reduction, NUDT21 was depleted by 
siRNA transfection in human lung fibroblasts. NUDT21 depletion increased the 
expression of ECM proteins, such as collagen 1 and fibronectin. Moreover, the reduction 
in NUDT21 promoted 3’UTR shortening in these transcripts as shown by the RT-qPCR-
based PAS usage analysis. This result suggests that NUDT21 reduction causes 3’UTR 
shortening on these ECM proteins leading to an increase in protein expression. To further 
characterize the impact of NUDT21 reduction in APA at a transcriptomic level, we 
performed an RNA-seq, followed by PDUI APA analysis. There was a global mRNA 
shortening where 808 and 29 transcripts were shortened and lengthened respectively. 
APA events were evident in pro-fibrotic pathways, such as VEGF, TGFβ1, Wnt, and 
MAPK signaling pathways. Vma21, a positive control for APA and global shortening, had 
significant APA associated with an increase in protein expression as shown in the 3’UTR 
plot, RT-qPCR-based PAS analysis, and Western Blot. Additionally, TGFβR1, WNT5A, 
and FZD2 were the targets of NUDT21 reduction, and their protein expressions were 
increased upon NUDT21 depletion. These results demonstrate that NUDT21 reduction 
causes 3’UTR shortening via APA and leads to increased protein expression for APA 
target genes.  
 To investigate the causal relationship between NUDT21 reduction and pulmonary 
fibrosis, NUDT21 was conditionally depleted in Col1a1 or Foxd1 positive cells including 
fibroblasts or pericytes, precursor cells of fibroblasts, in mice followed by induction of 
bleomycin-induced fibrosis. NUDT21 reduction in the cells consistently worsened the 
pulmonary fibrosis induced bleomycin in both o.p.a and i.p models as shown by multiple 
markers of fibrosis, including fibronectin, collagen, Ashcroft score, Masson’s trichrome, 
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and sircol assay. Furthermore, similar to the finding in human lung fibroblasts, NUDT21 
reduction caused an increased in protein expression of APA target genes, such as 
TGFβR1, WNT5A, and FZD2. NUDT21 overexpression via electroporation additionally 
demonstrated that NUDT21 reduction contributes to lung fibrosis via APA and 
augmentation of NUDT21 can be a potential therapeutic approach. Granted, further work 
needs to be performed to test the efficacy and safety of the NUDT21 therapy for IPF. 
 To identify the mechanisms which are responsible for the NUDT21 reduction in 
IPF, primary lung fibroblasts were cultured with pro-fibrotic cytokines and growth factors. 
TGFβ1 depleted NUDT21 protein and mRNAs as shown by Western blot analysis and 
RT-qPCR. The observation on a reduction in NUDT21 mRNA following TGFβ1 led to a 
hypothesis that TGFβ1 enhances mRNA degradation of NUDT21. The mRNA 
degradation assay demonstrated that indeed TGFβ1 made NUDT21 mRNA unstable. 
miR203, 23a, and 27b which were predicted to target the 3’UTR of NUDT21 were 
selected for a dual-luciferase assay and transfection experiments and miR203 
consistently targeted the 3’UTR of NUDT21 and lowered the protein expression of 
NUDT21. This miR203 was also significantly elevated in the fibroblasts isolated from IPF 
lungs. These results led to another hypothesis that TGFβ1 depletes NUDT21 via miR203. 
 To test this hypothesis, primary human lung fibroblasts were cultured with TGFβ1. 
TGFβ1 induced miR203 expression in a time dependent manner. The expression of 
miR203 following TGFβ1 was mediated through the phosphorylation of Smad3 which is 
a signaling molecule in the TGFβ1 pathway. SIS3, a specific inhibitor of Smad3, 
decreased the expression of miR203 following TGFβ1 and prevented reductions in 
NUDT21 protein and mRNA by TGFβ1. ChIP-PCR revealed that Smad3 transcriptionally 
induced miR203 by binding to promotor regions of miR203. Dual-luciferase assays and 
GFP reporter assay demonstrated that deletion of miR203 binding sites on the 3’UTR of 
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human NUDT21 prevented the TGFβ1-mediated NUDT21 reduction, suggesting that 
miR203 is responsible for the NUDT21 depletion. We further found that inhibiting miR203 
via antagomir significantly restored the levels of NUDT21 and decreased markers of 
fibrosis, suggesting that antagomir targeting miR203 can be a therapeutic approach for 
fibrosis. These results collectively suggested that TGFβ1 depletes NUDT21 by 
transcriptionally inducing miR203 and targeting the 3’UTR of NUDT21 in human lung 
fibroblasts. 
 The role of TGFβ1 in NUDT21 reduction was investigated in mouse models. The 
primary mouse lung fibroblasts which were cultured with TGFβ1 revealed that TGFβ1 
depleted NUDT21 and increased miR203 in mouse lung fibroblasts similar to the findings 
in human fibroblasts. SIS3 prevented the TGFβ1-mediated NUDT21 reduction, 
suggesting that the TGFβ1-mediated NUDT21 reduction is Smad3 dependent. miR203 
mimic depleted NUDT21 in mouse lung fibroblasts associated with increased markers of 
fibrosis. Antagomir which inhibited miR203 restored NUDT21 at basal levels and 
prevented the TGFβ1-mediated NUDT21 reduction. Furthermore, the TGFβ1 transgenic 
mice which overexpressed TGFβ1 in lungs demonstrated that TGFβ1 depleted NUDT21 
in lung fibroblasts. These results suggest that TGFβ1 depletes NUDT21 via Smad3 and 
miR203 in mouse lung fibroblasts.  
 To examine the impact of TGFβ1-mediated NUDT21 in APA, we cultured primary 
human lung fibroblasts to deplete NUDT21 and performed an RNA-seq for APA analysis. 
TGFβ1 induced differential APA in human lung fibroblasts, both shortening and 
lengthening of transcripts. This unique differential APA was also found in IPF fibroblasts, 
suggesting that differential APA may be a molecular signature of the disease. A several 
pro-fibrotic pathways were the targets of APA, such as PI3K-akt, MAPK, chemokine 
signaling, and ECM pathways. At individual gene levels, FGF14, RICTOR, TMOD2, and 
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UCP5 which were important for the biology of fibroblasts or IPF were the target of APA 
as confirmed by both the RNA-seq and RT-qPCR-based PAS analysis. Moreover, these 
APA target genes had elevated levels of gene expression following TGFβ1 treatment. 
These results revealed that TGFβ1-mediated NUDT21 reduction causes differential APA 
and leads to a robust protein expression of the APA target genes. 
 
Figure 5.1 Working model of NUDT21 reduction in pulmonary fibrosis. IPF patients 
have elevated levels of TGFβ1 in extra cellular space which binds to TGFβ receptors 
phosphorylating Smad3. The phosphorylated Smad3 with other Smad proteins acts as a 
transcription factor to induce expression of miR203 which targets the 3’UTR of NUDT21. 
NUDT21 is reduced due to the miRNA-mediated mRNA degradation leading to a 
reduction in NUDT21 protein. The NUDT21 reduction causes global mRNA shortening 
via APA and enhances translation of the pro-fibrotic pathways which are the targets of 
NUDT21 for APA contributing to pulmonary fibrosis.  
 165 
 This project is innovative in that these findings include the knowledge in 
unforeseen pathways of TGFβ1, which is one of the most critical pathways for IPF. 
Despite the importance of TGFβ1 signaling pathway, this pathway has not been actively 
targeted as a therapy for IPF due to the potential adverse effects, such as auto-immunity 
and inflammation, although these side effects have never been reported in any of the 
previous clinical trials in cancer ((259, 283–285). The data presented in this thesis 
demonstrate that the Smad3-mediated TGFβ1 signaling pathway depletes NUDT21 to 
induce APA on pro-fibrotic genes, including TGFBR1. This pathway is an indirect 
pathway of TGFβ1 which can be potentially targeted as a treatment for IPF to prevent 
activation of fibroblasts. 
This dissertation addresses several gaps in knowledge in the field of fibrosis and 
APA in regard to the contribution of APA in the pathogenesis of pulmonary fibrosis. We 
demonstrate that NUDT21, a key regulator of APA, is depleted in IPF fibroblasts and the 
NUDT21 reduction causes 3’UTR shortening through APA leading to a robust protein 
expression of APA target genes and ultimately amplifying pulmonary fibrosis. We 
subsequently report that TGFβ1, a potent activator of fibroblasts, is responsible for 
NUDT21 reduction in lung fibroblasts. TGFβ1 transcriptionally induces miR203 which 
targets the 3’UTR of NUDT21 via phosphorylation of Smad3 leading to NUDT21 
reduction, differential APA, and increased protein expression of APA target genes. Lastly, 
we demonstrate that overexpression of NUDT21 significantly lowers expression of 
fibrotic markers and augmentation of NUDT21 via antagomiR203 not only decreases 
expression of APA target genes but also reduces production of ECM proteins, suggesting 
that targeting NUDT21 can be a therapeutic option for IPF. 
The findings of this dissertation are innovative in that a novel mechanism of gene 
expression, APA, has been thoroughly investigated. APA by NUDT21 depletion is 
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important for the pathogenesis of pulmonary fibrosis, especially in late stages of the 
disease where fibroblasts and myofibroblasts accumulate and overproduce pro-fibrotic 
mediators for progressive phenotypes. NUDT21 is a potential therapeutic target to halt 
the progression of IPF, and these therapies could significantly improve the prognosis of 
IPF patients by intervening the positive feedback system of the disease. There are a 
several unanswered questions in regard to the roles and impacts of APA in IPF as 
described in the next section. These questions need to be thoroughly investigated before 
the APA therapy is translated to patient care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 167 
FUTURE DIRECTIONS 
 The work reported in this dissertation broadens our understanding of how APA 
caused by NUDT21 reduction contributes to pulmonary fibrosis and how this NUDT21 
can be regulated by TGFβ1 and miR203 at molecular levels. Nonetheless, there are a 
few questions that remain to be answered in order to better understand the impact of 
APA in lung and other diseases.  
 
What are the transcripts significantly impacted by APA for gene expression? 
Conditional deletion of NUDT21 in Col1a1 positive fibroblasts or Foxd1 positive 
pericytes exacerbates the lung fibrosis induced by bleomycin treatment. To understand 
the worsened phenotype of these mice, we primarily focused on the role of NUDT21 
depletion in mRNA shortening and stabilization and chose TGFβ1 and Wnt signaling 
pathways for subsequent validations. However, there might be other unexplored 
pathways and transcripts which are more significantly affected by NUDT21 depletion to 
amplify pulmonary fibrosis. In order to identify the transcripts that are robustly altered by 
NUDT21 reduction, we need to perform additional bio-informatic analyses. A 
comprehensive analysis for miRNA-RNA-APA network needs to be performed because 
APA can alter the RNA network by releasing miRNAs via 3’UTR shortening or absorbing 
miRNAs via 3’UTR lengthening. Especially, there is a recent report that APA might 
modulate the network of competing endogenous RNA via its miRNA sponging effect 
(286). Moreover, more analyses need to be performed especially for the transcripts which 
undergo deletions of AU-rich elements or important binding sites for RNA-binding 
proteins through 3’UTR shortening which can significantly affect the stability of mRNAs. 
 
What role does the lengthening of 3’UTR play in pulmonary fibrosis? 
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 In this dissertation, we mainly investigated the transcripts which had the 3’UTR 
shortening via APA because NUDT21 reduction caused global mRNA shortening with 
very few transcripts lengthened. However, we discovered that IPF fibroblasts and 
fibroblasts which were treated with TGFβ1 treatment had both shortening and 
lengthening of mRNAs, suggesting that 3’UTR lengthening might be also clinically and 
pathologically important in IPF patients. One possible role of the lengthened 3’UTRs is 
to antagonize miRNAs, which interact with the lengthened part of 3’UTR, by binding and 
halting the effect of miRNAs. It is possible that the gene expression of the target gene of 
the miRNAs can increase because miRNAs can no longer inhibit the mRNAs. Another 
possible role of the lengthened 3’UTRs is that gene expression of the lengthened mRNAs 
can decrease as they are now targeted by more miRNAs. Possible candidates for these 
lengthened 3’UTR is anti-fibrotic genes as APA is implicated with more severe fibrosis. 
In order to test these hypotheses, as discussed in the preceding section, a 
comprehensive analysis for a miRNA-RNA-APA network needs to be performed. 
Additionally, anti-fibrotic genes need to be identified and examined to see whether these 
genes undergo a 3’UTR shortening in the dataset. 
 
What are the roles of other APA regulators in pulmonary fibrosis? 
We found that the IPF fibroblasts and fibroblasts treated with TGFb1 had a 
differential APA pattern, both shortening and lengthening of mRNA. This result was 
presumably due to the fact that TGFb1, as a potent inducer of various signaling pathways, 
alters multiple regulators of APA and there are many pathways affecting APA in IPF 
fibroblasts, including NUDT21. For example, we reported that TGFb1 treatment 
decreased Fip1, which is another regulator of 3’UTR lengthening by APA (186). 
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Additionally, TGFb1 depleted other APA regulators for mRNA shortening, including 
CFIm68 (172, 277). In order to identify regulatory points which can be pharmacologically 
targeted for APA therapies, each of these APA regulators might need to be investigated. 
 
Are there other mechanisms governing the NUDT21 depletion? 
In this dissertation, TGFβ1 signaling pathway has been investigated as a key 
mechanism driving the NUDT21 reduction in the pathogenesis of pulmonary fibrosis. 
However, there might be other pathways which impact the NUDT21 depletion. For 
example, our lab found that cellular senescence induced by in vitro passaging or reactive 
oxygen species can significantly decrease NUDT21 in human lung fibroblasts (data not 
shown). This result is in line with the findings that aged mice or elderly human individuals 
had significantly lower NUDT21 as compared to younger mice and humans (data not 
shown). We believe that senescence and aging are critical factors of NUDT21 depletion, 
but these hypotheses need to be further validated. Additionally, we found that hypoxia 
and activation of mTOR signaling pathways can also reduce NUDT21 levels in primary 
human lung fibroblasts. These results indicate that there is more than one pathway by 
which fibroblasts deplete its NUDT21 and that we can pharmacologically intervene to 
restore NUDT21 and to halt the progression of pulmonary fibrosis. 
 
What is the role of APA and NUDT21 in other cell types? 
 The focus of this dissertation was the role of APA in lung fibroblasts because a 
fibroblast is one of the main producers of ECM and pro-fibrotic mediators and APA is a 
newly identified mechanism promoting a robust protein expression. However, there might 
be other cell types where APA plays critical cellular roles for the pathogenesis of 
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pulmonary fibrosis. Alveolar epithelial progenitor cells (AEP) are a small group of SPC 
positive cells which can work as a muti-potent stem cell reconstituting type 2 and type 1 
epithelial cells upon lung injuries (287, 288). There is a proposed role of AEP in 
pulmonary fibrosis that pulmonary fibrosis occurs as a result of failure in re-epithelization 
by AEP during the initial stage of the pathogenesis (287, 288). NUDT21 knockdown in 
stem cells affects cell fate and its stemness (234). Therefore, it is possible that 
dysregulated NUDT21 in AEP affects the initiation of pulmonary fibrosis or modulating 
NUDT21 in AEP can enhance a re-epithelization and wound healing after lung injuries. 
We reported that conditional deletion of NUDT21 in Foxd1 positive cells, a marker of 
pericytes and fibroblast progenitor cells, exacerbates pulmonary fibrosis. However, we 
have not investigated how NUDT21 deletion affects the differentiation of pericytes to 
fibroblasts and to myofibroblasts at molecular levels. In order to examine a role of APA 
in pericytes, the cells can be isolated and can be differentiated to monitor the levels of 
APA in a longitudinal way. Moreover, NUDT21 can be knock-downed to see the effect of 
APA in pericytes in vitro. In addition to these cell types, APA might play important roles 
in other cell types, such as immune cells and vascular smooth muscle cells. For example, 
Dr. Harry Karmouty-Quintana’s group found that NUDT21 reduction in vascular smooth 
muscle cells might exacerbate the progression of pulmonary hypertension (data not 
shown). In order to examine the involvement of APA in other cell types in diseased 
conditions, IHC can be performed where specific markers for cell types and NUDT21 are 
co-stained in tissue sections of patient samples. 
 
Is there any genetic mutation where normal APA is disrupted and therefore the 
risk of IPF is increased? 
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NUDT21 depletion and APA contribute to the pathogenesis of pulmonary fibrosis 
as demonstrated in this dissertation. We mainly focused on NUDT21 reduction in lung 
fibroblasts to investigate the roles of APA in lung fibrosis. However, it is possible that 
dysregulated APA might be implicated in the disease, especially for the cases of familiar 
PF (FIPF). As previously discussed in Chapter 1, there are cases where mutations in 
polyadenylation site (PAS) are associated with genetic predispositions for disease. A 
PAS sequence for FOXP3, a transcriptional regulator for T cells, is mutated from 
AATAAA to AATGAA leading to an aberrant polyadenylation and reduced expression of 
FOXP3. This genetic mutation causes abnormal T cell development and 
immunodeficiency in the patients (176, 177). This type of SNP is found in other diseases, 
including cancer (178), neonatal diabetes (179), α-thalassaemia (180), β-thalassaemia 
(181), and systemic lupus erythematosus (SLE) (182). One common feature of these 
cases is that the loss-of-function mutation in PAS leads to reductions in transcript and 
protein levels of the beneficial genes which significantly increase the risk of the diseases. 
SNP in FIPF has been thoroughly investigated. However, the majority of these studies 
focused on SNP in coding sequences or promotors, not 3’UTR, indicating that the roles 
of genetic mutations in PAS and APA regulating regions for IPF are yet to be discovered. 
To reveal the association between mutations related to APA and FIPF, the published 
dataset which were utilized for SNP analysis can be re-analyzed for mutations in PAS 
and NUDT21 binding sites. 
 
Is there any association of APA with clinical parameters? 
 For every IPF sample used in this project, we randomized the patient samples for 
gender, age, severity of the disease, and the stability of the disease. Despite the 
randomization for sampling, NUDT21 reduction was significantly correlated with an 
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increase in fibronectin, a marker of fibrosis. However, whether NUDT21 reduction is 
correlated with actual clinical parameters, such as DLCO and FVC, is unknown at this 
point. NUDT21 can be used as a predictor of prognosis. NUDT21 reduction is a predictor 
of prognosis in the patients with glioblastoma presumably because the patient with lower 
NUDT21 display more aggressive phenotype and progression, leading to lower survival 
rates (190, 219). Therefore, similarly, it is possible that levels of NUDT21 can be used 
as a predictor for survival or prognosis in IPF patients. Additionally, given the importance 
of NUDT21 levels in protein over-expression, it is important to further investigate whether 
patients with different rates of disease progression might have different levels of NUDT21. 
It is possible that NUDT21 levels in patients explain why some patients experience a fast 
progression of fibrosis whereas others remain stable. Moreover, it would be critical to 
examine levels of NUDT21 in men and women as this knowledge potentially provides an 
answer to the significantly different susceptibility to IPF between two genders. Therefore, 
a comprehensive analysis of clinical parameters and health information along with the 
levels of NUDT21 can be performed to understand how NUDT21 reduction is related to 
the susceptibility, stability, and prognosis of the disease. 
 
Does APA play a role in other lung or fibrotic diseases? 
 NUDT21 depletion in lung fibroblasts worsens the pulmonary fibrosis induced by 
bleomycin treatment. In this dissertation, fibroblasts are the subjects of the investigation 
because this cell type is one of the main producers of ECM proteins which are the main 
component of organ fibrosis. There are other fibrotic diseases where fibroblasts play 
important roles for the pathogenesis, such as kidney fibrosis, pancreatic fibrosis, liver 
fibrosis, and skin fibrosis. Therefore, it is possible that NUDT21 depletion and APA play 
detrimental roles in the progression of these fibrotic diseases. Supporting this hypothesis, 
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our lab discovered that NUDT21 reduction in dermal fibroblasts amplifies skin fibrosis 
following bleomycin treatment (data not shown). This result suggests that NUDT21 
depletion may be a common pathway for fibrotic diseases. Therefore, other fibrotic 
diseases can be investigated for the involvement of APA. Additionally, APA might play 
key roles in other lung diseases. Emerging evidence reports that NUDT21 reduction 
affects stem cell and alters cell fate (234), suggesting that dysregulation in APA might 
be implicated in diseases where stem cells are significantly impaired. Chronic obstructive 
pulmonary disease (COPD) is an epithelial disease in that epithelial cells are severely 
injured and the regeneration of the cells is impaired. Therefore, whether aberrant APA 
impairs the regeneration of epithelial cells in COPD can be investigated. Furthermore, 
enhancing stemness by manipulating NUDT21 can be also examined to halt the 
progression of COPD. 
 
Can APA be targeted as a novel therapeutic method? 
NUDT21 reduction acts as an amplifier of IPF by shortening and stabilizing ECM 
and pro-fibrotic mediators from lung fibroblasts. Therefore, the APA pathways can be 
potentially targeted to halt the progression of the disease. We demonstrated that 
overexpression of NUDT21 via pcDNA3.1 plasmids can lower the expression of pro-
fibrotic proteins and ECM molecules. Additionally, we reported that antagomiR203, an 
inhibitor of miR203, restored NUDT21 proteins and, therefore, significantly decreased 
markers of fibrosis. These data collectively suggest that augmenting levels of NUDT21 
can be a therapeutic method for treatments of IPF. Before translating this method to the 
actual IPF treatment, more preclinical experiments need to be performed to test its safety 
as there are some potential side effects of the NUDT21 therapies. For example, a target 
of NUDT21-mediated APA is methyl CpG binding protein 2 (MeCP2) which is an 
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important regulator of neuronal survival and development (289). Overexpression of 
NUDT21 can lead to an increased susceptibility of neurons to toxin-induced cell death 
(289, 290). As previously demonstrated, miR203 is a promising interventional point 
where NUDT21 can be regulated at molecular levels as miR203 depletes NUDT21 via 
miRNA-mediated mRNA degradation. To increase the specificity of the antagomiR203 
treatment, we can utilize nano particles or lipid-based vesicles which specifically target 
pulmonary fibroblasts (291).  
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CONCLUSION 
 In this project, we found the association of NUDT21 reduction with IPF using lung 
samples from the patients. Furthermore, we utilized established mouse models of 
bleomycin-induced fibrosis along with a number of in vitro systems to elucidate the roles 
and mechanisms of NUDT21 reduction in lung fibroblasts which contributes to pulmonary 
fibrosis. We demonstrated a role of NUDT21 reduction in promoting APA of mRNAs, 
leading to 3’UTR shortening and enhanced protein expression for pro-fibrotic mediators 
in pulmonary fibroblasts. Our knockout mice lacking NUDT21 in fibroblasts revealed that 
NUDT21 depletion is detrimental and worsens the pulmonary fibrosis induced by 
bleomycin, suggesting that NUDT21 reduction in IPF patients contributes to the 
progression of the disease. Moreover, we found that TGFβ1 depleted NUDT21 in lung 
fibroblasts by transcriptionally inducing expression of miR203 which targets the 3’UTR 
of NUDT21. Antagomir treatment which inhibits the activity of miR203 restored the levels 
of NUDT21 and significantly decreased the expression of ECM proteins, suggesting that 
targeting NUDT21 reduction via antagomir can be a potential therapeutic approach for 
IPF. However, additional investigations need to be conducted carefully to validate the 
effect of antagomir treatment to halt the progression of fibrosis in vivo.  
 IPF is the most common type of interstitial lung diseases, but this disease has the 
poorest patient outcome due to limited options for therapies (38). This indicates that there 
is an urgent medical need to develop innovative treatments to attenuate or even reverse 
the progression of pulmonary fibrosis. This thesis project is innovative in that a novel 
mechanism for gene regulation, alternative polyadenylation, is discovered to play a 
critical role in the pathogenesis of pulmonary fibrosis. We found that IPF patients have 
significantly decreased levels of NUDT21 in their fibroblasts, leading to the global 3’UTR 
shortening of mRNAs. A several well-known pro-fibrotic pathways are the target APA 
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which stabilizes the transcripts and enhances the protein expression leading to 
exacerbation of pulmonary fibrosis. A subsequence investigation revealed that TGFβ1 is 
responsible for the NUDT21 reduction as that potent pro-fibrotic mediator 
transcriptionally promote expression of miR203 via Smad3 to target the 3’UTR of 
NUDT21 lowering the transcripts and protein expression and ultimately leading to APA 
and amplification of fibrosis. We discovered that antagomir inhibiting miR203 prevented 
the depletion of NUDT21 by TGFβ1 and lowered the expression of fibrotic markers, 
suggesting that antagomiR203 can be a therapeutic treatment for pulmonary fibrosis. 
This hypothesis needs to be validated in multiple models of fibrosis before conducting a 
clinical trial with the antagomir to understand the specificity, safety, kinetics, and long-
term effects of antagomir-based therapies against APA for treatment of IPF. This project 
broadened our understanding of the role of APA in human disease and can potentially 
benefit other fibrotic or known APA diseases, such as liver fibrosis, scleroderma, kidney 
fibrosis, liver cancer, and glioblastoma.  
 
 
 
 
 
 
 
 
 
 
 
 177 
BIBLIOGRAPHY 
1. Sgalla, G., B. Iovene, M. Calvello, M. Ori, F. Varone, and L. Richeldi. 2018. 
Idiopathic pulmonary fibrosis: Pathogenesis and management. Respir. Res. 19. 
2. Ley, B., and H. R. Collard. 2013. Epidemiology of idiopathic pulmonary fibrosis. Clin. 
Epidemiol. 5: 483–92. 
3. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The 
epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150: 967–972. 
4. Raghu, G., D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster. 2006. Incidence 
and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174: 
810–816. 
5. King, T. E., A. Pardo, and M. Selman. 2011. Idiopathic pulmonary fibrosis. Lancet 
378: 1949–1961. 
6. Raghu, G., S. Y. Chen, Q. Hou, W. S. Yeh, and H. R. Collard. 2016. Incidence and 
prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur. Respir. J. 
48: 179–186. 
7. Strongman, H., I. Kausar, and T. M. Maher. 2018. Incidence, Prevalence, and 
Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Adv. Ther. 35: 724–
736. 
8. Raghu, G., M. Remy-Jardin, J. L. Myers, L. Richeldi, C. J. Ryerson, D. J. Lederer, J. 
Behr, V. Cottin, S. K. Danoff, F. Morell, K. R. Flaherty, A. Wells, F. J. Martinez, A. 
Azuma, T. J. Bice, D. Bouros, K. K. Brown, H. R. Collard, A. Duggal, L. Galvin, Y. 
Inoue, R. Gisli Jenkins, T. Johkoh, E. A. Kazerooni, M. Kitaichi, S. L. Knight, G. 
Mansour, A. G. Nicholson, S. N. J. Pipavath, I. Buendía-Roldán, M. Selman, W. D. 
Travis, S. Walsh, and K. C. Wilson. 2018. Diagnosis of idiopathic pulmonary fibrosis An 
Official ATS/ERS/JRS/ALAT Clinical practice guideline. Am. J. Respir. Crit. Care Med. 
 178 
198: e44–e68. 
9. Nakamura, Y., and T. Suda. 2016. Idiopathic pulmonary fibrosis: Diagnosis and 
clinical manifestations. Clin. Med. Insights Circ. Respir. Pulm. Med. 9: 163–171. 
10. Devaraj, A. 2014. Imaging: How to recognise idiopathic pulmonary fibrosis. Eur. 
Respir. Rev. 23: 215–219. 
11. Orens, J. B., E. A. Kazerooni, F. J. Martinez, J. L. Curtis, B. H. Gross, A. Flint, and 
J. P. Lynch. 1995. The sensitivity of high-resolution CT in detecting idiopathic 
pulmonary fibrosis proved by open lung biopsy: A prospective study. Chest 108: 109–
115. 
12. King, J., U. Costabel, J. F. Cordier, G. A. DoPico, R. M. DuBois, D. Lynch, J. P. 
Lynch, J. Myers, R. Panos, G. Raghu, D. Schwartz, and C. M. Smith. 2000. Idiopathic 
pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement. Am. 
J. Respir. Crit. Care Med. 161: 646–664. 
13. Oh, C. K., L. A. Murray, and N. A. Molfino. 2012. Smoking and idiopathic pulmonary 
fibrosis. Pulm. Med. . 
14. Ryu, J. H., T. V. Colby, T. E. Hartman, and R. Vassallo. 2001. Smoking-related 
interstitial lung diseases: A concise review. Eur. Respir. J. 17: 122–132. 
15. Baumgartner, K. B., J. M. Samet, C. A. Stidley, T. V. Colby, and J. A. Waldron. 
1997. Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. 
Crit. Care Med. 155: 242–248. 
16. Hubbard, R., S. Lewis, K. Richards, I. Johnston, and J. Britton. 1996. Occupational 
exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 
347: 284–289. 
17. Awadalla, N. J., A. Hegazy, R. A. Elmetwally, and I. Wahby. 2012. Occupational 
and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: A multicenter 
 179 
case-control study. Int. J. Occup. Environ. Med. 3: 107–116. 
18. Nogee, L. M., A. E. Dunbar, S. E. Wert, F. Askin, A. Hamvas, and J. A. Whitsett. 
2001. A Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial 
Lung Disease. N. Engl. J. Med. 344: 573–579. 
19. Thomas, A. Q., K. Lane, J. Phillips, M. Prince, C. Markin, M. Speer, D. A. Schwartz, 
R. Gaddipati, A. Marney, J. Johnson, R. Roberts, J. Haines, M. Stahlman, and J. E. 
Loyd. 2002. Heterozygosity for a surfactant protein C gene mutation associated with 
usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one 
kindred. Am. J. Respir. Crit. Care Med. 165: 1322–1328. 
20. Ono, S., T. Tanaka, M. Ishida, A. Kinoshita, J. Fukuoka, M. Takaki, N. Sakamoto, 
Y. Ishimatsu, S. Kohno, T. Hayashi, M. Senba, M. Yasunami, Y. Kubo, L. M. Yoshida, 
H. Kubo, K. Ariyoshi, K. Yoshiura, and K. Morimoto. 2011. Surfactant protein C G100S 
mutation causes familial pulmonary fibrosis in Japanese kindred. Eur. Respir. J. 38: 
861–869. 
21. Wolters, P. J., H. R. Collard, and K. D. Jones. 2014. Pathogenesis of Idiopathic 
Pulmonary Fibrosis. Annu. Rev. Pathol. Mech. Dis. 9: 157–179. 
22. Romero, F., and R. Summer. 2017. Protein folding and the challenges of 
maintaining endoplasmic reticulum proteostasis in idiopathic pulmonary fibrosis. Ann. 
Am. Thorac. Soc. 14: S410–S413. 
23. Willander, H., G. Askarieh, M. Landreh, P. Westermark, K. Nordling, H. Keränen, E. 
Hermansson, A. Hamvas, L. M. Noge, T. Bergman, A. Saenz, C. Casals, J. Åqvist, H. 
Jörnvall, H. Berglund, J. Presto, S. D. Knight, and J. Johansson. 2012. High-resolution 
structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity 
on lung surfactant protein C. Proc. Natl. Acad. Sci. U. S. A. 109: 2325–2329. 
24. Markart, P., C. Ruppert, M. Wygrecka, R. Schmidt, M. Korfei, H. Harbach, I. 
 180 
Theruvath, U. Pison, W. Seeger, A. Guenther, and H. Witt. 2007. Surfactant protein C 
mutations in sporadic forms of idiopathic interstitial pneumonias. Eur. Respir. J. 29: 
134–137. 
25. Lawson, W. E., S. W. Grant, V. Ambrosini, K. E. Womble, E. P. Dawson, K. B. 
Lane, C. Markin, E. Renzoni, P. Lympany, A. Q. Thomas, J. Roldan, T. A. Scott, T. S. 
Blackwell, J. A. Phillips, J. E. Loyd, and R. M. Du Bois. 2004. Genetic mutations in 
surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 59: 977–980. 
26. Wang, Y., P. J. Kuan, C. Xing, J. T. Cronkhite, F. Torres, R. L. Rosenblatt, J. M. 
DiMaio, L. N. Kinch, N. V. Grishin, and C. K. Garcia. 2009. Genetic Defects in 
Surfactant Protein A2 Are Associated with Pulmonary Fibrosis and Lung Cancer. Am. 
J. Hum. Genet. 84: 52–59. 
27. Greene, K. E., J. E. King, Y. Kuroki, B. Bucher-Bartelson, G. W. Hunninghake, L. S. 
Newman, H. Nagae, and R. J. Mason. 2002. Serum surfactant proteins-A and -D as 
biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 19: 439–446. 
28. Tsakiri, K. D., J. T. Cronkhite, P. J. Kuan, C. Xing, G. Raghu, J. C. Weissler, R. L. 
Rosenblatt, J. W. Shay, and C. K. Garcia. 2007. Adult-onset pulmonary fibrosis caused 
by mutations in telomerase. Proc. Natl. Acad. Sci. U. S. A. 104: 7552–7557. 
29. Armanios, M. Y., J. J. L. Chen, J. D. Cogan, J. K. Alder, R. G. Ingersoll, C. Markin, 
W. E. Lawson, M. Xie, I. Vulto, J. A. Phillips, P. M. Lansdorp, C. W. Greider, and J. E. 
Loyd. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. 
Engl. J. Med. 356: 1317–1326. 
30. Cronkhite, J. T., C. Xing, G. Raghu, K. M. Chin, F. Torres, R. L. Rosenblatt, and C. 
K. Garcia. 2008. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. 
J. Respir. Crit. Care Med. 178: 729–737. 
31. Alder, J. K., J. J. L. Chen, L. Lancaster, S. Danoff, S. C. Su, J. D. Cogan, I. Vulto, 
 181 
M. Xie, X. Qi, R. M. Tuder, J. A. Phillips, P. M. Lansdorp, J. E. Loyd, and M. Y. 
Armanios. 2008. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. 
Proc. Natl. Acad. Sci. U. S. A. 105: 13051–13056. 
32. Seibold, M. A., A. L. Wise, M. C. Speer, M. P. Steele, K. K. Brown, J. E. Loyd, T. E. 
Fingerlin, W. Zhang, G. Gudmundsson, S. D. Groshong, C. M. Evans, S. Garantziotis, 
K. B. Adler, B. F. Dickey, R. M. Du Bois, I. V. Yang, A. Herron, D. Kervitsky, J. L. 
Talbert, C. Markin, J. Park, A. L. Crews, S. H. Slifer, S. Auerbach, M. G. Roy, J. Lin, C. 
E. Hennessy, M. I. Schwarz, and D. A. Schwartz. 2011. A common MUC5B promoter 
polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364: 1503–1512. 
33. Raghu, G., T. D. Freudenberger, S. Yang, J. R. Curtis, C. Spada, J. Hayes, J. K. 
Sillery, C. E. Pope, and C. A. Pellegrini. 2006. High prevalence of abnormal acid 
gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 27: 136–142. 
34. Oldham, J. M., and H. R. Collard. 2017. Comorbid conditions in idiopathic 
pulmonary fibrosis: Recognition and management. Front. Med. 4. 
35. Cano-Jiménez, E., F. Hernández González, and G. Peloche. 2018. Comorbidities 
and Complications in Idiopathic Pulmonary Fibrosis. Med. Sci. 6: 71. 
36. Daniels, C. E., E. S. Yi, and J. H. Ryu. 2008. Autopsy findings in 42 consecutive 
patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 32: 170–174. 
37. Raghu, G., H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr, K. K. Brown, T. V. 
Colby, J. F. Cordier, K. R. Flaherty, J. A. Lasky, D. A. Lynch, J. H. Ryu, J. J. Swigris, A. 
U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D. M. Hansell, 
T. Johkoh, D. S. Kim, T. E. King, Y. Kondoh, J. Myers, N. L. Müller, A. G. Nicholson, L. 
Richeldi, M. Selman, R. F. Dudden, B. S. Griss, S. L. Protzko, and H. J. Schünemann. 
2011. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: 
Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care 
 182 
Med. 183: 788–824. 
38. Ley, B., H. R. Collard, and T. E. King. 2011. Clinical course and prediction of 
survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183: 431–440. 
39. Juarez, M. M., A. L. Chan, A. G. Norris, B. M. Morrissey, and T. E. Albertson. 2015. 
Acute exacerbation of idiopathic pulmonary fibrosis-A review of current and novel 
pharmacotherapies. J. Thorac. Dis. 7: 499–519. 
40. Olson, A. L., J. J. Swigris, D. C. Lezotte, J. M. Norris, C. G. Wilson, and K. K. 
Brown. 2007. Mortality from pulmonary fibrosis increased in the United States from 
1992 to 2003. Am. J. Respir. Crit. Care Med. 176: 277–284. 
41. Kong, X., M. H. Cho, W. Anderson, H. O. Coxson, N. Muller, G. Washko, E. A. 
Hoffman, P. Bakke, A. Gulsvik, D. A. Lomas, E. K. Silverman, and S. G. Pillai. 2011. 
Genome-wide association study identifies BICD1 as a susceptibility gene for 
emphysema. Am. J. Respir. Crit. Care Med. 183: 43–49. 
42. Collard, H. R., B. B. Moore, K. R. Flaherty, K. K. Brown, R. J. Kaner, and T. E. 
King. 2007. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. 
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176. 
43. Collard, H. R., B. B. Moore, K. R. Flaherty, K. K. Brown, R. J. Kaner, T. E. King, J. 
A. Lasky, J. E. Loyd, I. Noth, M. A. Olman, G. Raghu, J. Roman, J. H. Ryu, D. A. 
Zisman, G. W. Hunninghake, T. V Colby, J. J. Egan, D. M. Hansell, T. Johkoh, N. 
Kaminski, D. S. Kim, Y. Kondoh, D. A. Lynch, J. Müller-Quernheim, J. L. Myers, A. G. 
Nicholson, M. Selman, G. B. Toews, A. U. Wells, F. J. Martinez, and Idiopathic 
Pulmonary Fibrosis Clinical Research Network Investigators. 2007. Acute 
exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176: 
636–43. 
44. Song, J. W., S. B. Hong, C. M. Lim, Y. Koh, and D. S. Kim. 2011. Acute 
 183 
exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur. 
Respir. J. 37: 356–363. 
45. Kondoh, Y., H. Taniguchi, T. Katsuta, K. Kataoka, T. Kimura, O. Nishiyama, K. 
Sakamoto, T. Johkoh, M. Nishimura, K. Ono, and M. Kitaichi. 2010. Risk factors of 
acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffus. Lung Dis. 
27: 103–110. 
46. Hubbard, R., I. Johnston, and J. Britton. 1998. Survival in patients with cryptogenic 
fibrosing alveolitis: A population-based cohort study. Chest 113: 396–400. 
47. Kim, H. J., D. Perlman, and R. Tomic. 2015. Natural history of idiopathic pulmonary 
fibrosis. Respir. Med. 109: 661–670. 
48. Raghu, G. 2017. Idiopathic pulmonary fibrosis: lessons from clinical trials over the 
past 25 years. Eur. Respir. J. 50. 
49. Raghu, G., W. J. Depaso, K. Cain, S. P. Hammar, C. E. Wetzel, D. F. Dreis, J. 
Hutchinson, N. E. Pardee, and R. H. Winterbauer. 1991. Azathioprine combined with 
prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-
blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144: 291–296. 
50. Behr, J., K. Maier, B. Degenkolb, F. Krombach, and C. Vogelmeier. 1997. 
Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. 
Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 
156: 1897–1901. 
51. Demedts, M., J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H. M. Jansen, W. 
MacNee, M. Thomeer, B. Wallaert, F. Laurent, A. G. Nicholson, E. K. Verbeken, J. 
Verschakelen, C. D. R. Flower, F. Capron, S. Petruzzelli, P. De Vuyst, J. M. M. Van 
Den Bosch, E. Rodriguez-Becerra, G. Corvasce, I. Lankhorst, M. Sardina, and M. 
Montanari. 2005. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. 
 184 
Med. 353: 2229–2242. 
52. Martinez, F. J., J. A. De Andrade, K. J. Anstrom, T. E. King, and G. Raghu. 2014. 
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 
370: 2093–2101. 
53. Ziesche, R., E. Hofbauer, K. Wittmann, V. Petkov, and L. H. Block. 1999. A 
preliminary study of long-term treatment with interferon gamma-1b and low-dose 
prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341: 1264–
1269. 
54. King, T. E., C. Albera, W. Z. Bradford, U. Costabel, P. Hormel, L. Lancaster, P. W. 
Noble, S. A. Sahn, J. Szwarcberg, M. Thomeer, D. Valeyre, and R. M. du Bois. 2009. 
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis 
(INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222–228. 
55. Raghu, G., K. K. Brown, W. Z. Bradford, K. Starko, P. W. Noble, D. A. Schwartz, 
and T. E. King. 2004. A Placebo-Controlled Trial of Interferon Gamma-1b in Patients 
with Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 350: 125–133. 
56. Imokawa, S., A. Sato, H. Hayakawa, M. Kotani, T. Urano, and A. Takada. 1997. 
Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic 
pulmonary fibrosis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 156: 631–
636. 
57. Kotani, I., A. Sato, H. Hayakawa, T. Urano, Y. Takada, and A. Takada. 1995. 
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic 
pulmonary fibrosis. Thromb. Res. 77: 493–504. 
58. Kubo, H., K. Nakayama, M. Yanai, T. Suzuki, M. Yamaya, M. Watanabe, and H. 
Sasaki. 2005. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 
1475–1482. 
 185 
59. Noth, I., K. J. Anstrom, S. B. Calvert, J. De Andrade, K. R. Flaherty, C. Glazer, R. J. 
Kaner, and M. A. Olman. 2012. A placebo-controlled randomized trial of warfarin in 
idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 186: 88–95. 
60. Raghu, G., B. Rochwerg, Y. Zhang, C. A. C. Garcia, A. Azuma, J. Behr, J. L. 
Brozek, H. R. Collard, W. Cunningham, S. Homma, T. Johkoh, F. J. Martinez, J. Myers, 
S. L. Protzko, L. Richeldi, D. Rind, M. Selman, A. Theodore, A. U. Wells, H. 
Hoogsteden, H. J. Schünemann, ATS, ERS, and JRS. 2015. An official 
ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary 
fibrosis: An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care 
Med. 192: e3–e19. 
61. Kreuter, M., M. S. Wijsenbeek, M. Vasakova, P. Spagnolo, M. Kolb, U. Costabel, D. 
Weycker, K. U. Kirchgaessler, and T. M. Maher. 2016. Unfavourable effects of 
medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur. 
Respir. J. 47: 1776–1784. 
62. Jain, R., P. W. Shaul, Z. Borok, and B. C. Willis. 2007. Endothelin-1 induces 
alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated 
production of TGF-β1. Am. J. Respir. Cell Mol. Biol. 37: 38–47. 
63. King, T. E., K. K. Brown, G. Raghu, R. M. Du Bois, D. A. Lynch, F. Martinez, D. 
Valeyre, I. Leconte, A. Morganti, S. Roux, and J. Behr. 2011. BUILD-3: A randomized, 
controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care 
Med. 184: 92–99. 
64. King, T. E., J. Behr, K. K. Brown, R. M. Du Bois, L. Lancaster, J. A. De Andrade, G. 
Stähler, I. Leconte, S. Roux, and G. Raghu. 2008. BUILD-1: A randomized placebo-
controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care 
Med. 177: 75–81. 
 186 
65. Raghu, G., R. Million-Rousseau, A. Morganti, L. Perchenet, J. Behr, N. Goh, A. 
Glanville, M. Musk, P. Hopkins, D. C. Lien, C. Chan, J. D. Rolf, P. Wilcox, P. G. Cox, H. 
Manganas, V. Cottin, D. Valeyre, B. Walleart, S. Andreas, C. Neurohr, A. Guenther, N. 
Schönfeld, A. Koch, M. Kramer, R. Breuer, I. Ben-Dov, G. Fink, Y. Schwarz, C. Albera, 
M. Confalonieri, C. Saltini, S. Harari, M. Flezar, M. Greenblatt, G. J. Ras, F. Morell, J. 
L. Alvarez-Sala, A. Xaubet, A. Sueiro, M. J. Linares, M. Sköld, O. Kayacan, N. 
Mogulkoc, A. Chan, J. Chapman, J. Parambil, N. Ettinger, J. Golden, K. C. Meyer, J. J. 
Swigris, G. L. Yung, D. Antin-Ozerkis, P. K. Mohabir, L. J. Wesselius, J. De Andrade, F. 
Cordova, Z. Safdar, and M. Wencel. 2013. Macitentan for the treatment of idiopathic 
pulmonary fibrosis: The randomised controlled MUSIC trial. Eur. Respir. J. 42: 1622–
1632. 
66. Ghofrani, H. A., R. Wiedemann, F. Rose, R. T. Schermuly, H. Olschewski, N. 
Weissmann, A. Gunther, D. Walmrath, W. Seeger, and F. Grimminger. 2002. Sildenafil 
for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled 
trial. Lancet 360: 895–900. 
67. Kleinsasser, A., A. Loeckinger, C. Hoermann, F. Puehringer, N. Mutz, G. Bartsch, 
and K. H. Lindner. 2001. Sildenafil modulates hemodynamics and pulmonary gas 
exchange. Am. J. Respir. Crit. Care Med. 163: 339–343. 
68. Zisman, D. A., M. Schwarz, K. J. Anstrom, H. R. Collard, K. R. Flaherty, G. W. 
Hunninghake, J. de Andrade, S. Frankel, R. Kaplan, L. Lancaster, G. Raghu, J. P. Utz, 
S. R. White, D. A. Zisman, K. K. Brown, J. de Andrade, R. J. Kaner, T. E. King, J. A. 
Lasky, J. E. Loyd, F. J. Martinez, G. Raghu, J. Roman, J. H. Ryu, I. Noth, D. A. Zisman, 
J. Chapman, M. Olman, S. Lubell, L. D. Morrison, M. P. Steele, T. Haram, J. Roman, R. 
Perez, T. Perez, J. P. Utz, A. H. Limper, C. E. Daniels, K. Meiras, S. Walsh, K. K. 
Brown, S. Frankel, D. Kervitsky, J. A. Lasky, S. Ditta, J. de Andrade, V. J. Thannickal, 
 187 
M. Stewart, D. A. Zisman, J. P. Lynch, E. Calahan, P. Lopez, T. E. King, J. A. Golden, 
P. J. Wolters, R. Jeffrey, I. Noth, D. K. Hogarth, N. Sandbo, M. E. Strek, S. R. White, C. 
Brown, I. Garic, S. Maleckar, F. J. Martinez, M. L. Han, B. Moore, G. B. Toews, D. 
Dahlgren, G. Raghu, J. Hayes, M. Snyder, J. E. Loyd, L. Lancaster, W. Lawson, R. 
Greer, W. Mason, R. J. Kaner, V. Monroy, M. Wang, D. Lynch, T. Colby, R. C. Becker, 
E. L. Eisenstein, N. R. MacIntyre, L. D. Morrison, J. Rochon, M. P. Steele, J. S. Sundy, 
L. Davidson-Ray, P. Dignacco, R. Edwards, R. Anderson, R. Beci, S. Calvert, K. Cain, 
T. Gentry-Bumpass, D. Hill, M. Ingham, E. Kagan, J. Kaur, C. Matti, J. McClelland, A. 
Meredith, T. Nguyen, J. Pesarchick, R. S. Roberts, W. Tate, T. Thomas, J. Walker, D. 
Whelan, J. Winsor, Q. Yang, E. Yow, H. Y. Reynolds, X. Tian, and J. Kiley. 2010. A 
controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 
363: 620–628. 
69. Schaefer, C. J., D. W. Ruhrmund, L. Pan, S. D. Seiwert, and K. Kossen. 2011. 
Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20: 85–97. 
70. Liu, H., P. Drew, A. C. Gaugler, Y. Cheng, and G. A. Visner. 2005. Pirfenidone 
inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am. J. Transplant. 
5: 1256–1263. 
71. Card, J. W., W. J. Racz, J. F. Brien, S. B. Margolin, and T. E. Massey. 2003. 
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the 
hamster model of amiodarone-induced pulmonary toxicity. Toxicol. Sci. 75: 169–180. 
72. Oku, H., T. Shimizu, T. Kawabata, M. Nagira, I. Hikita, A. Ueyama, S. Matsushima, 
M. Torii, and A. Arimura. 2008. Antifibrotic action of pirfenidone and prednisolone: 
Different effects on pulmonary cytokines and growth factors in bleomycin-induced 
murine pulmonary fibrosis. Eur. J. Pharmacol. 590: 400–408. 
73. Kakugawa, T., H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, H. Oku, M. Miyazaki, 
 188 
J. Kadota, and S. Kohno. 2004. Pirfenidone attenuates expression of HSP47 in murine 
bleomycin-induced pulmonary fibrosis. Eur. Respir. J. 24: 57–65. 
74. Raghu, G., W. C. Johnson, D. Lockhart, and Y. Mageto. 1999. Treatment of 
idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a 
prospective, open-label phase II study. Am. J. Respir. Crit. Care Med. 159: 1061–1069. 
75. King, T. E., W. Z. Bradford, S. Castro-Bernardini, E. A. Fagan, I. Glaspole, M. K. 
Glassberg, E. Gorina, P. M. Hopkins, D. Kardatzke, L. Lancaster, D. J. Lederer, S. D. 
Nathan, C. A. Pereira, S. A. Sahn, R. Sussman, J. J. Swigris, and P. W. Noble. 2014. A 
phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. 
Med. 370: 2083–2092. 
76. Noble, P. W., C. Albera, W. Z. Bradford, U. Costabel, R. M. D. Bois, E. A. Fagan, R. 
S. Fishman, I. Glaspole, M. K. Glassberg, L. Lancaster, D. J. Lederer, J. A. Leff, S. D. 
Nathan, C. A. Pereira, J. J. Swigris, D. Valeyre, and T. E. King. 2016. Pirfenidone for 
idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 
trials. Eur. Respir. J. 47: 243–253. 
77. Wollin, L., I. Maillet, V. Quesniaux, A. Holweg, and B. Ryffel. 2014. Antifibrotic and 
anti-inflammatory activity of the Tyrosine Kinase inhibitor Nintedanib in Experimental 
Models Of Lung Fibrosiss. J. Pharmacol. Exp. Ther. 349: 209–220. 
78. Hilberg, F., G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-
Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, and W. J. Rettig. 
2008. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and 
good antitumor efficacy. Cancer Res. 68: 4774–4782. 
79. Wollin, L., E. Wex, A. Pautsch, G. Schnapp, K. E. Hostettler, S. Stowasser, and M. 
Kolb. 2015. Mode of action of nintedanib in the treatment of idiopathic pulmonary 
fibrosis. Eur. Respir. J. 45: 1434–1445. 
 189 
80. Richeldi, L., U. Costabel, M. Selman, D. S. Kim, D. M. Hansell, A. G. Nicholson, K. 
K. Brown, K. R. Flaherty, P. W. Noble, G. Raghu, M. Brun, A. Gupta, N. Juhel, M. 
Klüglich, and R. M. Du Bois. 2011. Efficacy of a tyrosine kinase inhibitor in idiopathic 
pulmonary fibrosis. N. Engl. J. Med. 365: 1079–1087. 
81. Richeldi, L., R. M. Du Bois, G. Raghu, A. Azuma, K. K. Brown, U. Costabel, V. 
Cottin, K. R. Flaherty, D. M. Hansell, Y. Inoue, D. S. Kim, M. Kolb, A. G. Nicholson, P. 
W. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard, S. Stowasser, R. 
Schlenker-Herceg, B. Disse, and H. R. Collard. 2014. Efficacy and safety of nintedanib 
in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370: 2071–2082. 
82. Cottin, V., and T. Maher. 2015. Long-term clinical and real-world experience with 
pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 24: 58–
64. 
83. Margaritopoulos, G. A., E. Vasarmidi, and K. M. Antoniou. 2016. Pirfenidone in the 
treatment of idiopathic pulmonary fibrosis: An evidence-based review of its place in 
therapy. Core Evid. 11: 11–22. 
84. Kato, M., S. Sasaki, T. Nakamura, K. Kurokawa, T. Yamada, Y. Ochi, H. Ihara, F. 
Takahashi, and K. Takahashi. 2019. Gastrointestinal adverse effects of nintedanib and 
the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci. Rep. 9. 
85. Mason, D. P., M. E. Brizzio, J. M. Alster, A. M. McNeill, S. C. Murthy, M. M. Budev, 
A. C. Mehta, O. A. Minai, G. B. Pettersson, and E. H. Blackstone. 2007. Lung 
Transplantation for Idiopathic Pulmonary Fibrosis. Ann. Thorac. Surg. 84: 1121–1128. 
86. Richeldi, L., E. R. Fernández Pérez, U. Costabel, C. Albera, D. J. Lederer, K. R. 
Flaherty, N. Ettinger, R. Perez, M. B. Scholand, J. Goldin, K.-H. Peony Yu, T. Neff, S. 
Porter, M. Zhong, E. Gorina, E. Kouchakji, and G. Raghu. 2019. Pamrevlumab, an anti-
connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a 
 190 
phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. . 
87. Maher, T. M., E. M. van der Aar, O. Van de Steen, L. Allamassey, J. Desrivot, S. 
Dupont, L. Fagard, P. Ford, A. Fieuw, and W. Wuyts. 2018. Safety, tolerability, 
pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to 
treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled 
trial. Lancet Respir. Med. 6: 627–635. 
88. Kohberg, C., C. U. Andersen, and E. Bendstrup. 2016. Opioids: an unexplored 
option for treatment of dyspnea in IPF. Eur. Clin. Respir. J. 3: 30629. 
89. Cortes-Telles, A., L. Forker, D. E. O’Donnell, and O. Morań-Mendoza. 2014. 
Idiopathic pulmonary fibrosis: New insights to functional characteristics at diagnosis. 
Can. Respir. J. 21. 
90. Ley, B., C. J. Ryerson, E. Vittinghoff, J. H. Ryu, S. Tomassetti, J. S. Lee, V. Poletti, 
M. Buccioli, B. M. Elicker, K. D. Jones, T. E. King, and H. R. Collard. 2012. A 
multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. 
Intern. Med. 156: 684–695. 
91. Du Bois, R. M., D. Weycker, C. Albera, W. Z. Bradford, U. Costabel, A. Kartashov, 
L. Lancaster, P. W. Noble, G. Raghu, S. A. Sahn, J. Szwarcberg, M. Thomeer, D. 
Valeyre, and T. E. King. 2011. Ascertainment of individual risk of mortality for patients 
with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 184: 459–466. 
92. Richeldi, L., C. J. Ryerson, J. S. Lee, P. J. Wolters, L. L. Koth, B. Ley, B. M. Elicker, 
K. D. Jones, T. E. King, J. H. Ryu, and H. R. Collard. 2012. Relative versus absolute 
change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 67: 407–411. 
93. Flaherty, K. R., J. A. Mumford, S. Murray, E. A. Kazerooni, B. H. Gross, T. V. 
Colby, W. D. Travis, A. Flint, G. B. Toews, J. P. Lynch, and F. J. Martinez. 2003. 
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial 
 191 
pneumonia. Am. J. Respir. Crit. Care Med. 168: 543–548. 
94. Flaherty, K. R., A. C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. 
Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, and F. J. Martinez. 2006. Idiopathic 
pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. 
Am. J. Respir. Crit. Care Med. 174: 803–809. 
95. Du Bois, R. M., C. Albera, W. Z. Bradford, U. Costabel, J. A. Leff, P. W. Noble, S. 
A. Sahn, D. Valeyre, D. Weycker, and T. E. King. 2014. 6-minute walk distance is an 
independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur. 
Respir. J. 43: 1421–1429. 
96. Lama, V. N., K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, Q. Long, S. 
Murray, E. A. Kazerooni, B. H. Gross, J. P. Lynch, and F. J. Martinez. 2003. Prognostic 
Value of Desaturation during a 6 Minute Walk Test in Idiopathic Interstitial Pneumonia. 
Am. J. Respir. Crit. Care Med. 168: 1084–1090. 
97. Nadrous, H. F., P. A. Pellikka, M. J. Krowka, K. L. Swanson, N. Chaowalit, P. A. 
Decker, and J. H. Ryu. 2005. Pulmonary hypertension in patients with idiopathic 
pulmonary fibrosis. Chest 128: 2393–9. 
98. Shorr, A. F., J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan. 2007. 
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. 
Eur. Respir. J. 30: 715–721. 
99. Nathan, S. D., O. A. Shlobin, S. D. Barnett, R. Saggar, J. A. Belperio, D. J. Ross, S. 
Ahmad, R. Saggar, E. Libre, J. P. Lynch, and D. A. Zisman. 2008. Right ventricular 
systolic pressure by echocardiography as a predictor of pulmonary hypertension in 
idiopathic pulmonary fibrosis. Respir. Med. 102: 1305–1310. 
100. Moore, B. B., and C. M. Hogaboam. 2008. Murine models of pulmonary fibrosis. 
Am. J. Physiol. - Lung Cell. Mol. Physiol. 294. 
 192 
101. Baron, R. M., A. J. S. Choi, C. A. Owen, and A. M. K. Choi. 2012. Genetically 
manipulated mouse models of lung disease: Potential and pitfalls. Am. J. Physiol. - 
Lung Cell. Mol. Physiol. 302. 
102. Selman, M., and A. Pardo. 2006. Role of epithelial cells in idiopathic pulmonary 
fibrosis: From innocent targets to serial killers. Proc. Am. Thorac. Soc. 3: 364–372. 
103. Maeyama, T., K. Kuwano, M. Kawasaki, R. Kunitake, N. Hagimoto, T. Matsuba, 
M. Yoshimi, I. Inoshima, K. Yoshida, and N. Hara. 2001. Upregulation of Fas-signalling 
molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur. 
Respir. J. 17: 180–189. 
104. Waghray, M., Z. Cui, J. C. Horowitz, I. M. Subramanian, F. J. Martinez, G. B. 
Toews, and V. J. Thannickal. 2005. Hydrogen peroxide is a diffusible paracrine signal 
for the induction of epithelial cell death by activated myofibroblasts. FASEB J. 19: 854–
856. 
105. Walter, P., and D. Ron. 2011. The unfolded protein response: From stress 
pathway to homeostatic regulation. Science (80-. ). 334: 1081–1086. 
106. Tanjore, H., T. S. Blackwell, and W. E. Lawson. 2012. Emerging evidence for 
endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. 
J. Physiol. - Lung Cell. Mol. Physiol. 302. 
107. Korfei, M., C. Ruppert, P. Mahavadi, I. Henneke, P. Markart, M. Koch, G. Lang, L. 
Fink, R. M. Bohle, W. Seeger, T. E. Weaver, and A. Guenther. 2008. Epithelial 
endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. 
Am. J. Respir. Crit. Care Med. 178: 838–846. 
108. Lawson, W. E., P. F. Crossno, V. V. Polosukhin, J. Roldan, D. S. Cheng, K. B. 
Lane, T. R. Blackwell, C. Xu, C. Markin, L. B. Ware, G. G. Miller, J. E. Loyd, and T. S. 
Blackwell. 2008. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in 
 193 
IPF: Association with altered surfactant protein processing and herpesvirus infection. 
Am. J. Physiol. - Lung Cell. Mol. Physiol. 294. 
109. Cha, S. I., C. J. Ryerson, J. S. Lee, J. Kukreja, S. S. Barry, K. D. Jones, B. M. 
Elicker, D. S. Kim, F. R. Papa, H. R. Collard, and P. J. Wolters. 2012. Cleaved 
cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary 
fibrosis. Respir. Res. 13. 
110. Bridges, J. P., Y. Xu, C. L. Na, H. R. Wong, and T. E. Weaver. 2006. Adaptation 
and increased susceptibility to infection associated with constitutive expression of 
misfolded SP-C. J. Cell Biol. 172: 395–407. 
111. Lawson, W. E., D. S. Cheng, A. L. Degryse, H. Tanjore, V. V. Polosukhin, X. C. 
Xu, D. C. Newcomb, B. R. Jones, J. Roldan, K. B. Lane, E. E. Morrisey, M. F. Beers, F. 
E. Yull, and T. S. Blackwell. 2011. Endoplasmic reticulum stress enhances fibrotic 
remodeling in the lungs. Proc. Natl. Acad. Sci. U. S. A. 108: 10562–10567. 
112. Tanjore, H., D. S. Cheng, A. L. Degryse, D. F. Zoz, R. Abdolrasulnia, W. E. 
Lawson, and T. S. Blackwell. 2011. Alveolar epithelial cells undergo epithelial-to-
mesenchymal transition in response to endoplasmic reticulum stress. J. Biol. Chem. 
286: 30972–30980. 
113. Khalil, N., R. N. O’Connor, K. C. Flanders, and H. Unruh. 1996. TGF-β1, but Not 
TGF-β2 or TGF-β3, Is Differentially Present in Epithelial Cells of Advanced Pulmonary 
Fibrosis: An Immunohistochemical Study. Am. J. Respir. Cell Mol. Biol. 14: 131–138. 
114. Annes, J. P., J. S. Munger, and D. B. Rifkin. 2003. Making sense of latent TGFβ 
activation. J. Cell Sci. 116: 217–224. 
115. Horan, G. S., S. Wood, V. Ona, J. L. Dan, M. E. Lukashev, P. H. Weinreb, K. J. 
Simon, K. Hahm, N. E. Allaire, N. J. Rinaldi, J. Goyal, C. A. Feghali-Bostwick, E. L. 
Matteson, C. O’Hara, R. Lafyatis, G. S. Davis, X. Huang, D. Sheppard, and S. M. 
 194 
Violette. 2008. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without 
exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177: 56–65. 
116. Giacomini, M. M., M. A. Travis, M. Kudo, and D. Sheppard. 2012. Epithelial cells 
utilize cortical actin/myosin to activate latent TGF-β through integrin αvβ6-dependent 
physical force. Exp. Cell Res. 318: 716–722. 
117. Jenkins, R. G., X. Su, G. Su, C. J. Scotton, E. Camerer, G. J. Laurent, G. E. 
Davis, R. C. Chambers, M. A. Matthay, and D. Sheppard. 2006. Ligation of protease-
activated receptor 1 enhances α vβ6 integrin-dependent TGF-β activation and 
promotes acute lung injury. J. Clin. Invest. 116: 1606–1614. 
118. Xu, M. Y., J. Porte, A. J. Knox, P. H. Weinreb, T. M. Maher, S. M. Violette, R. J. 
McAnulty, D. Sheppard, and G. Jenkins. 2009. Lysophosphatidic acid induces αvβ36 
integrin-mediated TGF-β activation via the LPA2 receptor and the small G protein Gαq. 
Am. J. Pathol. 174: 1264–1279. 
119. Kim, K. K., M. C. Kugler, P. J. Wolters, L. Robillard, M. G. Galvez, A. M. Brumwell, 
D. Sheppard, and H. A. Chapman. 2006. Alveolar epithelial cell mesenchymal transition 
develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. 
Proc. Natl. Acad. Sci. U. S. A. 103: 13180–13185. 
120. Scotton, C. J., and R. C. Chambers. 2007. Molecular targets in pulmonary fibrosis: 
The myofibroblast in focus. Chest 132: 1311–1321. 
121. Desmoulière, A., I. A. Darby, and G. Gabbiani. 2003. Normal and Pathologic Soft 
Tissue Remodeling: Role of the Myofibroblast, with Special Emphasis on Liver and 
Kidney Fibrosis. Lab. Investig. 83: 1689–1707. 
122. Gabbiani, G., G. B. Ryan, and G. Majno. 1971. Presence of modified fibroblasts in 
granulation tissue and their possible role in wound contraction. Experientia 27: 549–
550. 
 195 
123. Li, B., and J. H. C. Wang. 2011. Fibroblasts and myofibroblasts in wound healing: 
Force generation and measurement. J. Tissue Viability 20: 108–120. 
124. Hinz, B. 2007. Formation and function of the myofibroblast during tissue repair. J. 
Invest. Dermatol. 127: 526–537. 
125. Tomasek, J. J., G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown. 2002. 
Myofibroblasts and mechano: Regulation of connective tissue remodelling. Nat. Rev. 
Mol. Cell Biol. 3: 349–363. 
126. Hinz, B., S. H. Phan, V. J. Thannickal, A. Galli, M. L. Bochaton-Piallat, and G. 
Gabbiani. 2007. The myofibroblast: One function, multiple origins. Am. J. Pathol. 170: 
1807–1816. 
127. Powell, D. W., R. C. Mifflin, J. D. Valentich, S. E. Crowe, J. I. Saada, and A. B. 
West. 1999. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. 
Physiol. - Cell Physiol. 277. 
128. Brewster, C. E., P. H. Howarth, R. Djukanovic, J. Wilson, S. T. Holgate, and W. R. 
Roche. 1990. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am. J. 
Respir. Cell Mol. Biol. 3: 507–511. 
129. Uhal, B. D., I. Joshi, W. F. Hughes, C. Ramos, A. Pardo, and M. Selman. 1998. 
Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic 
human lung. Am. J. Physiol. - Lung Cell. Mol. Physiol. 275. 
130. Howat, W. J., S. T. Holgate, and P. M. Lackie. 2002. TGF-β isoform release and 
activation during in vitro bronchial epithelial wound repair. Am. J. Physiol. - Lung Cell. 
Mol. Physiol. 282. 
131. Morishima, Y., A. Nomura, Y. Uchida, Y. Noguchi, T. Sakamoto, Y. Ishii, Y. Goto, 
K. Masuyama, M. J. Zhang, K. Hirano, M. Mochizuki, M. Ohtsuka, and K. Sekizawa. 
2001. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial 
 196 
shedding. Am. J. Respir. Cell Mol. Biol. 24: 1–11. 
132. Urase, K., T. Mukasa, H. Igarashi, Y. Ishii, S. Yasugi, M. Y. Momoi, and T. Momoi. 
1996. Spatial expression of Sonic hedgehog in the lung epithelium during branching 
morphogenesis. Biochem. Biophys. Res. Commun. 225: 161–166. 
133. Pan, L. H., K. Yamauchi, M. Uzuki, T. Nakanishi, M. Takigawa, H. Inoue, and T. 
Sawai. 2001. Type II alveolar epithelial cells and interstitial fibroblasts express 
connective tissue growth factor in IPF. Eur. Respir. J. 17: 1220–1227. 
134. Noble, P. W., C. E. Barkauskas, and D. Jiang. 2012. Pulmonary fibrosis: Patterns 
and perpetrators. J. Clin. Invest. 122: 2756–2762. 
135. Flaherty, K. R., T. V. Colby, W. D. Travis, G. B. Toews, J. Mumford, S. Murray, V. 
J. Thannickal, E. A. Kazerooni, B. H. Gross, J. P. Lynch, and F. J. Martinez. 2003. 
Fibroblastic foci in usual interstitial pneumonia: Idiopathic versus collagen vascular 
disease. Am. J. Respir. Crit. Care Med. 167: 1410–1415. 
136. Cool, C. D., S. D. Groshong, P. R. Rai, P. M. Henson, J. S. Stewart, and K. K. 
Brown. 2006. Fibroblast foci are not discrete sites of lung injury or repair: The fibroblast 
reticulum. Am. J. Respir. Crit. Care Med. 174: 654–658. 
137. Walraven, M., and B. Hinz. 2018. Therapeutic approaches to control tissue repair 
and fibrosis: Extracellular matrix as a game changer. Matrix Biol. 71–72: 205–224. 
138. Herrera, J., C. A. Henke, and P. B. Bitterman. 2018. Extracellular matrix as a 
driver of progressive fibrosis. J. Clin. Invest. 128: 45–53. 
139. Kristensen, J. H., M. A. Karsdal, F. Genovese, S. Johnson, B. Svensson, S. 
Jacobsen, P. Hägglund, and D. J. Leeming. 2014. The role of extracellular matrix 
quality in pulmonary fibrosis. Respiration 88: 487–499. 
140. Rahman, I., and W. MacNee. 1998. Role of transcription factors in inflammatory 
lung diseases. Thorax 53: 601–612. 
 197 
141. López-Maury, L., S. Marguerat, and J. Bähler. 2008. Tuning gene expression to 
changing environments: From rapid responses to evolutionary adaptation. Nat. Rev. 
Genet. 9: 583–593. 
142. Hocine, S., R. H. Singer, and D. Grünwald. 2010. RNA processing and export. 
Cold Spring Harb. Perspect. Biol. 2. 
143. Bentley, D. L. 2014. Coupling mRNA processing with transcription in time and 
space. Nat. Rev. Genet. 15: 163–175. 
144. Proudfoot, N. J., A. Furger, and M. J. Dye. 2002. Integrating mRNA processing 
with transcription. Cell 108: 501–512. 
145. Tian, B., and J. L. Manley. 2016. Alternative polyadenylation of mRNA precursors. 
Nat. Rev. Mol. Cell Biol. 18: 18–30. 
146. Chen, M., G. Lyu, M. Han, H. Nie, T. Shen, W. Chen, Y. Niu, Y. Song, X. Li, H. Li, 
X. Chen, Z. Wang, Z. Xia, W. Li, X. L. Tian, C. Ding, J. Gu, Y. Zheng, X. Liu, J. Hu, G. 
Wei, W. Tao, and T. Ni. 2018. 3′ UTR lengthening as a novel mechanism in regulating 
cellular senescence. Genome Res. 28: 285–294. 
147. Moore, M. J. 2005. From birth to death: The complex lives of eukaryotic mRNAs. 
Science (80-. ). 309: 1514–1518. 
148. Vlasova-St. Louis, I., and P. R. Bohjanen. 2014. Post-transcriptional regulation of 
cytokine signaling by AU-rich and GU-rich elements. J. Interf. Cytokine Res. 34: 233–
241. 
149. Chen, C. Y. A., and A. Bin Shyu. 1995. AU-rich elements: characterization and 
importance in mRNA degradation. Trends Biochem. Sci. 20: 465–470. 
150. Friedman, R. C., K. K. H. Farh, C. B. Burge, and D. P. Bartel. 2009. Most 
mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19: 92–105. 
151. Farazi, T. A., J. I. Spitzer, P. Morozov, and T. Tuschl. 2011. miRNAs in human 
 198 
cancer. J. Pathol. 223: 102–115. 
152. Guo, H., N. T. Ingolia, J. S. Weissman, and D. P. Bartel. 2010. Mammalian 
microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835–840. 
153. Baek, D., J. Villén, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel. 2008. 
The impact of microRNAs on protein output. Nature 455: 64–71. 
154. Griffiths-Jones, S., H. K. Saini, S. Van Dongen, and A. J. Enright. 2008. miRBase: 
Tools for microRNA genomics. Nucleic Acids Res. 36. 
155. Bartel, D. P. 2009. MicroRNAs: Target Recognition and Regulatory Functions. Cell 
136: 215–233. 
156. Graber, J. H., C. R. Cantor, S. C. Mohr, and T. F. Smith. 1999. In silico detection 
of control signals: MRNA 3′-end-processing sequences in diverse species. Proc. Natl. 
Acad. Sci. U. S. A. 96: 14055–14060. 
157. Proudfoot, N. J., and G. G. Brownlee. 1976. 3′ Non-coding region sequences in 
eukaryotic messenger RNA. Nature 263: 211–214. 
158. Shi, Y., D. C. Di Giammartino, D. Taylor, A. Sarkeshik, W. J. Rice, J. R. Yates, J. 
Frank, and J. L. Manley. 2009. Molecular Architecture of the Human Pre-mRNA 3′ 
Processing Complex. Mol. Cell 33: 365–376. 
159. Murthy, K. G. K., and J. L. Manley. 1995. The 160-kD subunit of human cleavage-
polyadenylation specificity factor coordinates pre-mRNA 3’-end formation. Genes Dev. 
9: 2672–2683. 
160. Ryan, K., O. Calvo, and J. L. Manley. 2004. Evidence that polyadenylation factor 
CPSF-73 is the mRNA 3′ processing endonuclease. RNA 10: 565–573. 
161. Mandel, C. R., S. Kaneko, H. Zhang, D. Gebauer, V. Vethantham, J. L. Manley, 
and L. Tong. 2006. Polyadenylation factor CPSF-73 is the pre-mRNA 3′-end-
processing endonuclease. Nature 444: 953–956. 
 199 
162. Callebaut, I. 2002. Metallo-beta-lactamase fold within nucleic acids processing 
enzymes: the beta-CASP family. Nucleic Acids Res. 30: 3592–3601. 
163. Barabino, S. M. L., M. Ohnacker, and W. Keller. 2000. Distinct roles of two Yth1p 
domains in 3’-end cleavage and polyadenylation of yeast pre-mRNAs. EMBO J. 19: 
3778–3787. 
164. Kaufmann, I., G. Martin, A. Friedlein, H. Langen, and W. Keller. 2004. Human Fip1 
is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) 
polymerase. EMBO J. 23: 616–626. 
165. Barnard, D. C., K. Ryan, J. L. Manley, and J. D. Richter. 2004. Symplekin and 
xGLD-2 are required for CPEB-mediated cytoplasmic polyadenylation. Cell 119: 641–
651. 
166. Takagaki, Y., L. C. Ryner, and J. L. Manley. 1989. Four factors are required for 3’-
end cleavage of pre-mRNAs. Genes Dev. 3: 1711–1724. 
167. Brown, K. M., and G. M. Gilmartin. 2003. A Mechanism for the Regulation of Pre-
mRNA 3′ Processing by Human Cleavage Factor Im. Mol. Cell 12: 1467–1476. 
168. de Vries, H. 2000. Human pre-mRNA cleavage factor IIm contains homologs of 
yeast proteins and bridges two other cleavage factors. EMBO J. 19: 5895–5904. 
169. Meyer, S., C. Urbanke, and E. Wahle. 2002. Equilibrium studies on the 
association of the nuclear poly(A) binding protein with poly(A) of different lengths. 
Biochemistry 41: 6082–6089. 
170. Tian, B., J. Hu, H. Zhang, and C. S. Lutz. 2005. A large-scale analysis of mRNA 
polyadenylation of human and mouse genes. Nucleic Acids Res. 33: 201–212. 
171. Lin, Y., Z. Li, F. Ozsolak, S. W. Kim, G. Arango-Argoty, T. T. Liu, S. A. 
Tenenbaum, T. Bailey, A. P. Monaghan, P. M. Milos, and B. John. 2012. An in-depth 
map of polyadenylation sites in cancer. Nucleic Acids Res. 40: 8460–8471. 
 200 
172. Shi, Y. 2012. Alternative polyadenylation: New insights from global analyses. RNA 
18: 2105–2117. 
173. Malka, Y., A. Steiman-Shimony, E. Rosenthal, L. Argaman, L. Cohen-Daniel, E. 
Arbib, H. Margalit, T. Kaplan, and M. Berger. 2017. Post-transcriptional 3´-UTR 
cleavage of mRNA transcripts generates thousands of stable uncapped autonomous 
RNA fragments. Nat. Commun. 8: 2029. 
174. Chang, J. W., H. S. Yeh, and J. Yong. 2017. Alternative polyadenylation in human 
diseases. Endocrinol. Metab. 32: 413–421. 
175. Curinha, A., S. O. Braz, I. Pereira-Castro, A. Cruz, and A. Moreira. 2014. 
Implications of polyadenylation in health and disease. Nucleus 5: 508–519. 
176. Rosenwasser, L. J. 2001. A rare polyadenylation signal mutation of the FOXP3 
gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics 53: 435–
439. 
177. Bacchetta, R., F. Barzaghi, and M. G. Roncarolo. 2016. From IPEX syndrome to 
FOXP3 mutation: A lesson on immune dysregulation. Ann. N. Y. Acad. Sci. 1417: 5–22. 
178. Stacey, S. N., P. Sulem, A. Jonasdottir, G. Masson, J. Gudmundsson, D. F. 
Gudbjartsson, O. T. Magnusson, S. A. Gudjonsson, B. Sigurgeirsson, K. Thorisdottir, 
R. Ragnarsson, K. R. Benediktsdottir, B. A. Nexø, A. Tjønneland, K. Overvad, P. 
Rudnai, E. Gurzau, K. Koppova, K. Hemminki, C. Corredera, V. Fuentelsaz, P. Grasa, 
S. Navarrete, F. Fuertes, M. D. García-Prats, E. Sanambrosio, A. Panadero, A. De 
Juan, A. Garcia, F. Rivera, D. Planelles, V. Soriano, C. Requena, K. K. Aben, M. M. 
Van Rossum, R. G. H. M. Cremers, I. M. Van Oort, D. J. Van Spronsen, J. A. Schalken, 
W. H. M. Peters, B. T. Helfand, J. L. Donovan, F. C. Hamdy, D. Badescu, O. Codreanu, 
M. Jinga, I. E. Csiki, V. Constantinescu, P. Badea, I. N. Mates, D. E. Dinu, A. 
Constantin, D. Mates, S. Kristjansdottir, B. A. Agnarsson, E. Jonsson, R. B. 
 201 
Barkardottir, G. V. Einarsson, F. Sigurdsson, P. H. Moller, T. Stefansson, T. 
Valdimarsson, O. T. Johannsson, H. Sigurdsson, T. Jonsson, J. G. Jonasson, L. 
Tryggvadottir, T. Rice, H. M. Hansen, Y. Xiao, D. H. Lachance, B. P. O’Neill, M. L. 
Kosel, P. A. Decker, G. Thorleifsson, H. Johannsdottir, H. T. Helgadottir, A. 
Sigurdsson, V. Steinthorsdottir, A. Lindblom, R. S. Sandler, T. O. Keku, K. Banasik, T. 
Jørgensen, D. R. Witte, T. Hansen, O. Pedersen, V. Jinga, D. E. Neal, W. J. Catalona, 
M. Wrensch, J. Wiencke, R. B. Jenkins, E. Nagore, U. Vogel, L. A. Kiemeney, R. 
Kumar, J. I. Mayordomo, J. H. Olafsson, A. Kong, U. Thorsteinsdottir, T. Rafnar, and K. 
Stefansson. 2011. A germline variant in the TP53 polyadenylation signal confers 
cancer susceptibility. Nat. Genet. 43: 1098–1103. 
179. Garin, I., E. L. Edghill, I. Akerman, O. Rubio-Cabezas, I. Rica, J. M. Locke, M. A. 
Maestro, A. Alshaikh, R. Bundak, G. Del Castillo, A. Deeb, D. Deiss, J. M. Fernandez, 
K. Godbole, K. Hussain, M. O’Connell, T. Klupa, S. Kolouskova, F. Mohsin, K. Perlman, 
Z. Sumnik, J. M. Rial, E. Ugarte, T. Vasanthi, K. Johnstone, S. E. Flanagan, R. 
Martínez, C. Castaño, A. M. Patch, E. Fernández-Rebollo, K. Raile, N. Morgan, L. W. 
Harries, L. Castaño, S. Ellard, J. Ferrer, G. P. De Nanclares, A. T. Hattersley, F. Bas, 
O. Cinek, M. Malecki, and M. Rachmiel. 2010. Recessive mutations in the INS gene 
result in neonatal diabetes through reduced insulin biosynthesis. Proc. Natl. Acad. Sci. 
U. S. A. 107: 3105–3110. 
180. Higgs, D. R., S. E. Y. Goodbourn, J. Lamb, J. B. Clegg, D. J. Weatherall, and N. J. 
Proudfoot. 1983. α-Thalassaemia caused by a polyadenylation signal mutation. Nature 
306: 398–400. 
181. Orkin, S. H., T. C. Cheng, S. E. Antonarakis, and H. H. Kazazian. 1985. 
Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human 
beta-globin gene. EMBO J. 4: 453–456. 
 202 
182. Hellquist, A., M. Zucchelli, K. Kivinen, U. Saarialho-Kere, S. Koskenmies, E. 
Widen, H. Julkunen, A. Wong, M. L. Karjalainen-Lindsberg, T. Skoog, J. Vendelin, D. S. 
Cunninghame-Graham, T. J. Vyse, J. Kere, and C. M. Lindgren. 2007. The human 
GIMAP5 gene has a common polyadenylation polymorphism increasing risk to 
systemic lupus erythematosus. J. Med. Genet. 44: 314–321. 
183. Graham, R. R., C. Kyogoku, S. Sigurdsson, I. A. Vlasova, L. R. L. Davies, E. C. 
Baechler, R. M. Plenge, T. Koeuth, W. A. Ortmann, G. Hom, J. W. Bauer, C. Gillett, N. 
Burtt, D. S. C. Graham, R. Onofrio, M. Petri, I. Gunnarsson, E. Svenungsson, L. 
Rönnblom, G. Nordmark, P. K. Gregersen, K. Moser, P. M. Gaffney, L. A. Criswell, T. J. 
Vyse, A. C. Syvänen, P. R. Bohjanen, M. J. Daly, T. W. Behrens, and D. Altshuler. 
2007. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and 
protective haplotypes for human lupus. Proc. Natl. Acad. Sci. U. S. A. 104: 6758–6763. 
184. Kocabas, A., T. Duarte, S. Kumar, and M. A. Hynes. 2015. Widespread 
Differential Expression of Coding Region and 3’ UTR Sequences in Neurons and Other 
Tissues. Neuron 88: 1149–1156. 
185. Jereb, S., H. W. Hwang, E. van Otterloo, E. E. Govek, J. J. Fak, Y. Yuan, M. E. 
Hatten, and R. B. Darnell. 2018. Differential 3’ processing of specific transcripts 
expands regulatory and protein diversity across neuronal cell types. Elife 7. 
186. Xia, Z., L. A. Donehower, T. A. Cooper, J. R. Neilson, D. A. Wheeler, E. J. 
Wagner, and W. Li. 2014. Dynamic analyses of alternative polyadenylation from RNA-
seq reveal a 3’2-UTR landscape across seven tumour types. Nat. Commun. 5. 
187. Sandberg, R., J. Neilson, A. Sarma, P. Sharp, and C. Burge. 2008. Proliferating 
cells express mRNAs with shortened 3′ untranslated regions and fewer MicroRNA 
target sites. Chemtracts 21: 217–219. 
188. Wiestner, A., M. Tehrani, M. Chiorazzi, G. Wright, F. Gibellini, K. Nakayama, H. 
 203 
Liu, A. Rosenwald, H. K. Muller-Hermelink, G. Ott, W. C. Chan, T. C. Greiner, D. D. 
Weisenburger, J. Vose, J. O. Armitage, R. D. Gascoyne, J. M. Connors, E. Campo, E. 
Montserrat, F. Bosch, E. B. Smeland, S. Kvaloy, H. Holte, J. Delabie, R. I. Fisher, T. M. 
Grogan, T. P. Miller, W. H. Wilson, E. S. Jaffe, and L. M. Staudt. 2007. Point mutations 
and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are 
associated with increased proliferation rate and shorter survival. Blood 109: 4599–
4606. 
189. Morris, A. R., A. Bos, B. Diosdado, K. Rooijers, R. Elkon, A. S. Bolijn, B. Carvalho, 
G. A. Meijer, and R. Agami. 2012. Alternative cleavage and polyadenylation during 
colorectal cancer development. Clin. Cancer Res. 18: 5256–5266. 
190. Masamha, C. P., Z. Xia, J. Yang, T. R. Albrecht, M. Li, A. Bin Shyu, W. Li, and E. 
J. Wagner. 2014. CFIm25 links alternative polyadenylation to glioblastoma tumour 
suppression. Nature 510: 412–416. 
191. Sun, M., J. Ding, D. Li, G. Yang, Z. Cheng, and Q. Zhu. 2017. NUDT21 regulates 
3′-UTR length and microRNA-mediated gene silencing in hepatocellular carcinoma. 
Cancer Lett. 410: 158–168. 
192. Richeldi, L., V. Cottin, R. M. du Bois, M. Selman, T. Kimura, Z. Bailes, R. 
Schlenker-Herceg, S. Stowasser, and K. K. Brown. 2016. Nintedanib in patients with 
idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and 
INPULSIS® trials. Respir. Med. 113: 74–79. 
193. Tzouvelekis, A., F. Bonella, and P. Spagnolo. 2015. Update on therapeutic 
management of idiopathic pulmonary fibrosis. Ther. Clin. Risk Manag. 11: 359–370. 
194. Raghu, G., and M. Selman. 2015. Nintedanib and pirfenidone: New antifibrotic 
treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. 
Am. J. Respir. Crit. Care Med. 191: 252–254. 
 204 
195. Moore, M. W., and E. L. Herzog. 2013. Regulation and Relevance of Myofibroblast 
Responses in Idiopathic Pulmonary Fibrosis. Curr. Pathobiol. Rep. 1: 199–208. 
196. Phan, S. H. 2002. The myofibroblast in pulmonary fibrosis. In Chest vol. 122. 
American College of Chest Physicians. 286S-289S. 
197. Willis, B. C., R. M. DuBois, and Z. Borok. 2006. Epithelial origin of myofibroblasts 
during fibrosis in the lung. Proc. Am. Thorac. Soc. 3: 377–382. 
198. Boutet, S. C., T. H. Cheung, N. L. Quach, L. Liu, S. L. Prescott, A. Edalati, K. Iori, 
and T. A. Rando. 2012. Alternative polyadenylation mediates microRNA regulation of 
muscle stem cell function. Cell Stem Cell 10: 327–336. 
199. Liaw, H. H., C. C. Lin, H. F. Juan, and H. C. Huang. 2013. Differential MicroRNA 
Regulation Correlates with Alternative Polyadenylation Pattern between Breast Cancer 
and Normal Cells. PLoS One 8. 
200. Ballester, B., J. Milara, and J. Cortijo. 2019. Idiopathic pulmonary fibrosis and lung 
cancer: Mechanisms and molecular targets. Int. J. Mol. Sci. 20. 
201. Weng, T., J. Ko, C. P. Masamha, Z. Xia, Y. Xiang, N. yuan Chen, J. G. Molina, S. 
Collum, T. C. Mertens, F. Luo, K. Philip, J. Davies, J. Huang, C. Wilson, R. A. 
Thandavarayan, B. A. Bruckner, S. S. K. Jyothula, K. A. Volcik, L. Li, L. Han, W. Li, S. 
Assassi, H. Karmouty-Quintana, E. J. Wagner, and M. R. Blackburn. 2019. Cleavage 
factor 25 deregulation contributes to pulmonary fibrosis through alternative 
polyadenylation. J. Clin. Invest. 129: 1984–1999. 
202. Kang, H. R., J. C. Soo, G. L. Chun, R. J. Homer, and J. A. Elias. 2007. 
Transforming Growth Factor (TGF)-β 1 stimulates pulmonary fibrosis and inflammation 
via a Bax-dependent, Bid-activated pathway that involves matrix metalloproteinase-12. 
J. Biol. Chem. 282: 7723–7732. 
203. Elias, J. A., T. Zheng, C. G. Lee, R. J. Homer, Q. Chen, B. Ma, M. Blackburn, and 
 205 
Z. Zhu. 2003. Transgenic modeling of interleukin-13 in the lung. Chest 123: 339S–45S. 
204. Nalysnyk, L., J. Cid-Ruzafa, P. Rotella, and D. Esser. 2012. Incidence and 
prevalence of idiopathic pulmonary fibrosis: Review of the literature. Eur. Respir. Rev. 
21: 355–361. 
205. Redente, E. F., K. M. Jacobsen, J. J. Solomon, A. R. Lara, S. Faubel, R. C. Keith, 
P. M. Henson, G. P. Downey, and D. W. H. Riches. 2011. Age and sex dimorphisms 
contribute to the severity of bleomycin-induced lung injury and fibrosis. Am. J. Physiol. - 
Lung Cell. Mol. Physiol. 301. 
206. De Vooght, V., J. A. J. Vanoirbeek, S. Haenen, E. Verbeken, B. Nemery, and P. 
H. M. Hoet. 2009. Oropharyngeal aspiration: An alternative route for challenging in a 
mouse model of chemical-induced asthma. Toxicology 259: 84–89. 
207. Hübner, R. H., W. Gitter, N. E. El Mokhtari, M. Mathiak, M. Both, H. Bolte, S. 
Freitag-Wolf, and B. Bewig. 2008. Standardized quantification of pulmonary fibrosis in 
histological samples. Biotechniques 44: 507–517. 
208. Ashcroft, T., J. M. Simpson, and V. Timbrell. 1988. Simple method of estimating 
severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41: 467–470. 
209. Jinnin, M., H. Ihn, and K. Tamaki. 2006. Characterization of SIS3, a novel specific 
inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular 
matrix expression. Mol. Pharmacol. 69: 597–607. 
210. Le, T.-T. T., H. Karmouty-Quintana, E. Melicoff, T.-T. T. Le, T. Weng, N.-Y. Chen, 
M. Pedroza, Y. Zhou, J. Davies, K. Philip, J. Molina, F. Luo, A. T. George, L. J. Garcia-
Morales, R. R. Bunge, B. A. Bruckner, M. Loebe, H. Seethamraju, S. K. Agarwal, and 
M. R. Blackburn. 2014.  Blockade of IL-6 Trans Signaling Attenuates Pulmonary 
Fibrosis . J. Immunol. 193: 3755–3768. 
211. Allen, J. T., and M. A. Spiteri. 2002. Growth factors in idiopathic pulmonary 
 206 
fibrosis: relative roles. Respir. Res. 3: 13. 
212. Chun Geun Lee, R. J. Homer, Z. Zhu, S. Lanone, X. Wang, V. Koteliansky, J. M. 
Shipley, P. Gotwals, P. Noble, Q. Chen, R. M. Senior, and J. A. Elias. 2001. Interleukin-
13 induces tissue fibrosis by selectively stimulating and activating transforming growth 
factor β1. J. Exp. Med. 194: 809–821. 
213. Agarwal, V., G. W. Bell, J. W. Nam, and D. P. Bartel. 2015. Predicting effective 
microRNA target sites in mammalian mRNAs. Elife 4. 
214. Schwartz, D. A. 2018. Idiopathic pulmonary fibrosis is a genetic disease involving 
mucus and the peripheral airways. In Annals of the American Thoracic Society vol. 15. 
American Thoracic Society. S192–S197. 
215. Sakai, N., and A. M. Tager. 2013. Fibrosis of two: Epithelial cell-fibroblast 
interactions in pulmonary fibrosis. Biochim. Biophys. Acta - Mol. Basis Dis. 1832: 911–
921. 
216. Parker, M. W., D. Rossi, M. Peterson, K. Smith, K. Sikström, E. S. White, J. E. 
Connett, C. A. Henke, O. Larsson, and P. B. Bitterman. 2014. Fibrotic extracellular 
matrix activates a profibrotic positive feedback loop. J. Clin. Invest. 124: 1622–35. 
217. Kendall, R. T., and C. A. Feghali-Bostwick. 2014. Fibroblasts in fibrosis: Novel 
roles and mediators. Front. Pharmacol. 5 MAY. 
218. Di Giammartino, D. C., K. Nishida, and J. L. Manley. 2011. Mechanisms and 
Consequences of Alternative Polyadenylation. Mol. Cell 43: 853–866. 
219. Chu, Y., N. Elrod, C. Wang, L. Li, T. Chen, A. Routh, Z. Xia, W. Li, E. J. Wagner, 
and P. Ji. 2019. Nudt21 regulates the alternative polyadenylation of Pak1 and is 
predictive in the prognosis of glioblastoma patients. Oncogene 38: 4154–4168. 
220. Park, H. J., P. Ji, S. Kim, Z. Xia, B. Rodriguez, L. Li, J. Su, K. Chen, C. P. 
Masamha, D. Baillat, C. R. Fontes-Garfias, A. Bin Shyu, J. R. Neilson, E. J. Wagner, 
 207 
and W. Li. 2018. 3′ UTR shortening represses tumor-suppressor genes in trans by 
disrupting ceRNA crosstalk. Nat. Genet. 50: 783–789. 
221. Wang, Y., J. Yella, J. Chen, F. X. McCormack, S. K. Madala, and A. G. Jegga. 
2017. Unsupervised gene expression analyses identify IPF-severity correlated 
signatures, associated genes and biomarkers. BMC Pulm. Med. 17. 
222. Dacic, S., I. Kalajzic, D. Visnjic, A. C. Lichtler, and D. W. Rowe. 2001. Col1a1-
driven transgenic markers of osteoblast lineage progression. J. Bone Miner. Res. 16: 
1228–1236. 
223. Goodwin, J., H. Choi, M.-H. Hsieh, M. L. Neugent, J.-M. Ahn, H. N. Hayenga, P. 
K. Singh, D. B. Shackelford, I.-K. Lee, V. Shulaev, S. Dhar, N. Takeda, and J.-W. Kim. 
2018. Targeting Hypoxia-Inducible Factor-1α/Pyruvate Dehydrogenase Kinase 1 Axis 
by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis. Am. J. Respir. 
Cell Mol. Biol. 58: 216–231. 
224. Baran, C. P., J. M. Opalek, S. McMaken, C. A. Newland, J. M. O’Brien, M. G. 
Hunter, B. D. Bringardner, M. M. Monick, D. R. Brigstock, P. C. Stromberg, G. W. 
Hunninghake, and C. B. Marsh. 2007. Important roles for macrophage colony-
stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the 
pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176: 78–89. 
225. Luo, F., N. B. Le, T. Mills, N. Y. Chen, H. Karmouty-Quintana, J. G. Molina, J. 
Davies, K. Philip, K. A. Volcik, H. Liu, Y. Xia, H. K. Eltzschig, and M. R. Blackburn. 
2016. Extracellular adenosine levels are associated with the progression and 
exacerbation of pulmonary fibrosis. FASEB J. 30: 874–883. 
226. Hung, C., G. Linn, Y. H. Chow, A. Kobayashi, K. Mittelsteadt, W. A. Altemeier, S. 
A. Gharib, L. M. Schnapp, and J. S. Duffield. 2013. Role of lung Pericytes and resident 
fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 
 208 
188: 820–830. 
227. Nance, T., K. S. Smith, V. Anaya, R. Richardson, L. Ho, M. Pala, S. Mostafavi, A. 
Battle, C. Feghali-Bostwick, G. Rosen, and S. B. Montgomery. 2014. Transcriptome 
analysis reveals differential splicing events in IPF lung tissue. PLoS One 9: e97550. 
228. Deng, N., C. G. Sanchez, J. A. Lasky, and D. Zhu. 2013. Detecting Splicing 
Variants in Idiopathic Pulmonary Fibrosis from Non-Differentially Expressed Genes. 
PLoS One 8. 
229. Elkon, R., A. P. Ugalde, and R. Agami. 2013. Alternative cleavage and 
polyadenylation: Extent, regulation and function. Nat. Rev. Genet. 14: 496–506. 
230. Martin, J., R. H. Jenkins, R. Bennagi, A. Krupa, A. O. Phillips, T. Bowen, and D. J. 
Fraser. 2011. Post-transcriptional regulation of transforming growth factor beta-1 by 
microRNA-744. PLoS One 6. 
231. Sommer, J., C. Garbers, J. Wolf, A. Trad, J. M. Moll, M. Sack, R. Fischer, J. 
Grötzinger, G. H. Waetzig, D. M. Floss, and J. Scheller. 2014. Alternative intronic 
polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10. J. 
Biol. Chem. 289: 22140–22150. 
232. Dirks, R. P. H., and H. P. J. Bloemers. 1995. Signals controlling the expression of 
PDGF. Mol. Biol. Reports An Int. J. Mol. Cell. Biol. 22: 1–24. 
233. Kubo, T., T. Wada, Y. Yamaguchi, A. Shimizu, and H. Handa. 2006. Knock-down 
of 25 kDa subunit of cleavage factor Im in Hela cells alters alternative polyadenylation 
within 3′-UTRs. Nucleic Acids Res. 34: 6264–6271. 
234. Brumbaugh, J., B. Di Stefano, X. Wang, M. Borkent, E. Forouzmand, K. J. 
Clowers, F. Ji, B. A. Schwarz, M. Kalocsay, S. J. Elledge, Y. Chen, R. I. Sadreyev, S. 
P. Gygi, G. Hu, Y. Shi, and K. Hochedlinger. 2018. Nudt21 Controls Cell Fate by 
Connecting Alternative Polyadenylation to Chromatin Signaling. Cell 172: 106-120.e21. 
 209 
235. Gujral, T. S., M. Chan, L. Peshkin, P. K. Sorger, M. W. Kirschner, and G. 
Macbeath. 2014. A noncanonical frizzled2 pathway regulates epithelial-mesenchymal 
transition and metastasis. Cell 159: 844–856. 
236. Kim, J. E., K. Nakashima, and B. De Crombrugghe. 2004. Transgenic mice 
expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: A new 
tool to examine physiology and disease of postnatal bone and tooth. Am. J. Pathol. 
165: 1875–1882. 
237. Sun, Y., Y. Fu, Y. Li, and A. Xu. 2012. Genome-wide alternative polyadenylation in 
animals: insights from high-throughput technologies. J. Mol. Cell Biol. 4: 352–61. 
238. Yeh, H. S., and J. Yong. 2016. Alternative polyadenylation of mRNAs: 3’-
untranslated region matters in gene expression. Mol. Cells 39: 281–285. 
239. Lembo, A., F. Di Cunto, and P. Provero. 2012. Shortening of 3′UTRs correlates 
with poor prognosis in breast and lung cancer. PLoS One 7. 
240. Singh, P., T. L. Alley, S. M. Wright, S. Kamdar, W. Schott, R. Y. Wilpan, K. D. 
Mills, and J. H. Graber. 2009. Global changes in processing of mRNA 3′ untranslated 
regions characterize clinically distinct cancer subtypes. Cancer Res. 69: 9422–9430. 
241. Ji, Z., J. Y. Lee, Z. Pan, B. Jiang, and B. Tian. 2009. Progressive lengthening of 3′ 
untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic 
development. Proc. Natl. Acad. Sci. U. S. A. 106: 7028–7033. 
242. Hilgers, V., M. W. Perry, D. Hendrix, A. Stark, M. Levine, and B. Haley. 2011. 
Neural-specific elongation of 3′ UTRs during Drosophila development. Proc. Natl. Acad. 
Sci. U. S. A. 108: 15864–15869. 
243. Bartkova, J., N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L. V. F. 
Vassiliou, E. Kolettas, K. Niforou, V. C. Zoumpourlis, M. Takaoka, H. Nakagawa, F. 
Tort, K. Fugger, F. Johansson, M. Sehested, C. L. Andersen, L. Dyrskjot, T. Ørntoft, J. 
 210 
Lukas, C. Kittas, T. Helleday, T. D. Halazonetis, J. Bartek, and V. G. Gorgoulis. 2006. 
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA 
damage checkpoints. Nature 444: 633–637. 
244. Xiang, Y., Y. Ye, Y. Lou, Y. Yang, C. Cai, Z. Zhang, T. Mills, N. Y. Chen, Y. Kim, 
F. M. Ozguc, L. Diao, H. Karmouty-Quintana, Y. Xia, R. E. Kellems, Z. Chen, M. R. 
Blackburn, S. H. Yoo, A. Bin Shyu, G. B. Mills, and L. Han. 2018. Comprehensive 
characterization of alternative polyadenylation in human cancer. J. Natl. Cancer Inst. 
110: 379–389. 
245. Takagaki, Y., and J. L. Manley. 1998. Levels of polyadenylation factor CstF-64 
control IgM heavy chain mRNA accumulation and other events associated with B cell 
differentiation. Mol. Cell 2: 761–771. 
246. Shell, S. A., C. Hesse, S. M. Morris, and C. Milcarek. 2005. Elevated levels of the 
64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated 
macrophages influence gene expression and induce alternative poly(A) site selection. 
J. Biol. Chem. 280: 39950–39961. 
247. Gawande, B., M. D. Robida, A. Rahn, and R. Singh. 2006. Drosophila sex-lethal 
protein mediates polyadenylation switching in the female germline. EMBO J. 25: 1263–
1272. 
248. Castelo-Branco, P., A. Furger, M. Wollerton, C. Smith, A. Moreira, and N. 
Proudfoot. 2004. Polypyrimidine Tract Binding Protein Modulates Efficiency of 
Polyadenylation. Mol. Cell. Biol. 24: 4174–4183. 
249. Dai, W., G. Zhang, and E. V. Makeyev. 2012. RNA-binding protein HuR 
autoregulates its expression by promoting alternative polyadenylation site usage. 
Nucleic Acids Res. 40: 787–800. 
250. Li, W., B. You, M. Hoque, D. Zheng, W. Luo, Z. Ji, J. Y. Park, S. I. Gunderson, A. 
 211 
Kalsotra, J. L. Manley, and B. Tian. 2015. Systematic Profiling of Poly(A)+ Transcripts 
Modulated by Core 3’ End Processing and Splicing Factors Reveals Regulatory Rules 
of Alternative Cleavage and Polyadenylation. PLoS Genet. 11. 
251. Matoulkova, E., E. Michalova, B. Vojtesek, and R. Hrstka. 2012. The role of the 3′ 
untranslated region in post-transcriptional regulation of protein expression in 
mammalian cells. RNA Biol. 9: 563–576. 
252. Szostak, E., and F. Gebauer. 2013. Translational control by 3’-UTR-binding 
proteins. Brief. Funct. Genomics 12: 58–65. 
253. Gupta, I., S. Clauder-Münster, B. Klaus, A. I. Järvelin, R. S. Aiyar, V. Benes, S. 
Wilkening, W. Huber, V. Pelechano, and L. M. Steinmetz. 2014. Alternative 
polyadenylation diversifies post-transcriptional regulation by selective RNA-protein 
interactions. Mol. Syst. Biol. 10. 
254. Chambers, R. C., and P. F. Mercer. 2015. Mechanisms of alveolar epithelial injury, 
repair, and fibrosis. In Annals of the American Thoracic Society vol. 12. American 
Thoracic Society. S16–S20. 
255. Hata, A., and Y. G. Chen. 2016. TGF-β signaling from receptors to smads. Cold 
Spring Harb. Perspect. Biol. 8. 
256. Thannickal, V. J., D. Y. Lee, E. S. White, Z. Cui, J. M. Larios, R. Chacon, J. C. 
Horowitz, R. M. Day, and P. E. Thomas. 2003. Myofibroblast differentiation by 
transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via 
focal adhesion kinase. J. Biol. Chem. 278: 12384–12389. 
257. Clark, R. A., G. A. McCoy, J. M. Folkvord, and J. M. McPherson. 1997. TGF-beta 
1 stimulates cultured human fibroblasts to proliferate and produce tissue-like 
fibroplasia: a fibronectin matrix-dependent event. J. Cell. Physiol. 170: 69–80. 
258. Xiao, L., Y. Du, Y. Shen, Y. He, H. Zhao, and Z. Li. 2011. TGF-beta 1 induced 
 212 
fibroblast proliferation is mediated by the FGF-2/ERK pathway. Front. Biosci. 17: 2667–
2674. 
259. Varga, J., and B. Pasche. 2008. Antitransforming growth factor-β therapy in 
fibrosis: Recent progress and implications for systemic sclerosis. Curr. Opin. 
Rheumatol. 20: 720–728. 
260. Györfi, A. H., A. E. Matei, and J. H. W. Distler. 2018. Targeting TGF-β signaling 
for the treatment of fibrosis. Matrix Biol. 68–69: 8–27. 
261. Wang, J., Y. Wang, Y. Wang, Y. Ma, Y. Lan, and X. Yang. 2013. Transforming 
growth factor β-regulated microrna-29a promotes angiogenesis through targeting the 
phosphatase and tensin homolog in endothelium. J. Biol. Chem. 288: 10418–10426. 
262. Kong, W., H. Yang, L. He, J. -j. Zhao, D. Coppola, W. S. Dalton, and J. Q. Cheng. 
2008. MicroRNA-155 Is Regulated by the Transforming Growth Factor  /Smad Pathway 
and Contributes to Epithelial Cell Plasticity by Targeting RhoA. Mol. Cell. Biol. 28: 
6773–6784. 
263. Redshaw, N., C. Camps, V. Sharma, M. Motallebipour, M. Guzman-Ayala, S. 
Oikonomopoulos, E. Thymiakou, J. Ragoussis, and V. Episkopou. 2013. TGF-
β/Smad2/3 Signaling Directly Regulates Several miRNAs in Mouse ES Cells and Early 
Embryos. PLoS One 8. 
264. Biernacka, A., M. Dobaczewski, and N. G. Frangogiannis. 2011. TGF-β signaling 
in fibrosis. Growth Factors 29: 196–202. 
265. Zhang, Y., D. Handley, T. Kaplan, H. Yu, A. S. Bais, T. Richards, K. V. Pandit, Q. 
Zeng, P. V. Benos, N. Friedman, O. Eickelberg, and N. Kaminski. 2011. High 
throughput determination of TGFβ1/SMAD3 targets in A549 lung epithelial cells. PLoS 
One 6. 
266. Kim, K. K., T. H. Sisson, and J. C. Horowitz. 2017. Fibroblast growth factors and 
 213 
pulmonary fibrosis: it’s more complex than it sounds. J. Pathol. 241: 6–9. 
267. Li, J., J. Ren, X. Liu, L. Jiang, W. He, W. Yuan, J. Yang, and C. Dai. 2015. 
Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney 
fibrosis. Kidney Int. 88: 515–527. 
268. Chang, W., K. Wei, L. Ho, G. J. Berry, S. S. Jacobs, C. H. Chang, and G. D. 
Rosen. 2014. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One 9. 
269. Walker, N. M., E. A. Belloli, L. Stuckey, K. M. Chan, J. Lin, W. Lynch, A. Chang, S. 
M. Mazzoni, D. C. Fingar, and V. N. Lama. 2016. Mechanistic Target of Rapamycin 
Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal 
Cell Activation. J. Biol. Chem. 291: 6262–6271. 
270. Senapedis, W. T., C. J. Kennedy, P. M. Boyle, and P. A. Silver. 2011. Whole 
genome siRNA cell-based screen links mitochondria to Akt signaling network through 
uncoupling of electron transport chain. Mol. Biol. Cell 22: 1791–1805. 
271. Weber, A., C. R. Pennise, G. G. Babcock, and V. M. Fowler. 1994. Tropomodulin 
caps the pointed ends of actin filaments. J. Cell Biol. 127: 1627–1635. 
272. Rao, J. N., Y. Madasu, and R. Dominguez. 2014. Mechanism of actin filament 
pointed-end capping by tropomodulin. Science (80-. ). 345: 463–467. 
273. Tan, S., H. Li, W. Zhang, Y. Shao, Y. Liu, H. Guan, J. Wu, Y. Kang, J. Zhao, Q. 
Yu, Y. Gu, K. Ding, M. Zhang, W. Qian, Y. Zhu, H. Cai, C. Chen, P. E. Lobie, X. Zhao, 
J. Sun, and T. Zhu. 2018. NUDT21 negatively regulates PSMB2 and CXXC5 by 
alternative polyadenylation and contributes to hepatocellular carcinoma suppression. 
Oncogene 37: 4887–4900. 
274. Huang, J., T. Weng, J. Ko, N. yuan Chen, Y. Xiang, K. Volcik, L. Han, M. R. 
Blackburn, and X. Lu. 2018. Suppression of cleavage factor Im 25 promotes the 
proliferation of lung cancer cells through alternative polyadenylation. Biochem. Biophys. 
 214 
Res. Commun. 503: 856–862. 
275. Wang, Y., Y. Xu, W. Yan, P. Han, J. Liu, J. Gong, D. Li, X. Ding, H. Wang, Z. Lin, 
D. Tian, and J. Liao. 2018. CFIm25 inhibits hepatocellular carcinoma metastasis by 
suppressing the p38 and JNK/c-Jun signaling pathways. Oncotarget 9: 11783–11793. 
276. Adams, T. S., J. C. Schupp, S. Poli, E. A. Ayaub, N. Neumark, F. Ahangari, S. G. 
Chu, B. A. Raby, G. DeIuliis, M. Januszyk, Q. Duan, H. A. Arnett, A. Siddiqui, G. R. 
Washko, R. Homer, X. Yan, I. O. Rosas, and N. Kaminski. 2019. Single Cell RNA-seq 
reveals ectopic and aberrant lung resident cell populations in Idiopathic Pulmonary 
Fibrosis. bioRxiv 759902. 
277. Turner, R. E., A. D. Pattison, and T. H. Beilharz. 2018. Alternative polyadenylation 
in the regulation and dysregulation of gene expression. Semin. Cell Dev. Biol. 75: 61–
69. 
278. Im, J., K. Kim, P. Hergert, and R. S. Nho. 2016. Idiopathic pulmonary fibrosis 
fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of 
decoy receptor 3. J. Pathol. 240: 25–37. 
279. Predescu, S. A., J. Zhang, C. Bardita, M. Patel, V. Godbole, and D. N. Predescu. 
2017. Mouse lung fibroblast resistance to Fas-mediated apoptosis is dependent on the 
baculoviral inhibitor of apoptosis protein 4 and the cellular FLICE-inhibitory protein. 
Front. Physiol. 8. 
280. Habiel, D. M., and C. Hogaboam. 2014. Heterogeneity in fibroblast proliferation 
and survival in idiopathic pulmonary fibrosis. Front. Pharmacol. 5. 
281. Cha, S. I., S. D. Groshong, S. K. Frankel, B. L. Edelman, G. P. Cosgrove, J. L. 
Terry-Powers, L. K. Remigio, D. Curran-Everett, K. K. Brown, C. D. Cool, and D. W. H. 
Riches. 2010. Compartmentalized expression of c-FLIP in lung tissues of patients with 
idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 42: 140–148. 
 215 
282. Rafii, R., M. M. Juarez, T. E. Albertson, and A. L. Chan. 2013. A review of current 
and novel therapies for idiopathic pulmonary fibrosis. J. Thorac. Dis. 5: 48–73. 
283. Connolly, E. C., J. Freimuth, and R. J. Akhurst. 2012. Complexities of TGF-β 
targeted cancer therapy. Int. J. Biol. Sci. 8. 
284. Löffek, S. 2018. Transforming of the Tumor Microenvironment: Implications for 
TGF-β Inhibition in the Context of Immune-Checkpoint Therapy. J. Oncol. 2018. 
285. Varga, J., and B. Pasche. 2009. Transforming growth factor β as a therapeutic 
target in systemic sclerosis. Nat. Rev. Rheumatol. 5: 200–206. 
286. Cai, Y., and J. Wan. 2018. Competing Endogenous RNA Regulations in 
Neurodegenerative Disorders: Current Challenges and Emerging Insights. Front. Mol. 
Neurosci. 11. 
287. Hoffman, A. M., and E. P. Ingenito. 2012. Alveolar epithelial stem and progenitor 
cells: emerging evidence for their role in lung regeneration. Curr. Med. Chem. 19: 
6003–8. 
288. Olajuyin, A. M., X. Zhang, and H. L. Ji. 2019. Alveolar type 2 progenitor cells for 
lung injury repair. Cell Death Discov. 5. 
289. Gennarino, V. A., C. E. Alcott, C. A. Chen, A. Chaudhury, M. A. Gillentine, J. A. 
Rosenfeld, S. Parikh, J. W. Wheless, E. R. Roeder, D. D. G. Horovitz, E. K. Roney, J. 
L. Smith, S. W. Cheung, W. Li, J. R. Neilson, C. P. Schaaf, and H. Y. Zoghbi. 2015. 
NUDT21-spanning CNVs lead to neuropsychiatric disease and altered MeCP2 
abundance via alternative polyadenylation. Elife 4. 
290. Russell, J. C., M. E. Blue, M. V. Johnston, S. Naidu, and M. A. Hossain. 2007. 
Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to 
excitotoxicity and hypoxia. Neuroscience 150: 563–574. 
291. Yoon, P. O., J. W. Park, C.-M. Lee, S. H. Kim, H.-N. Kim, Y. Ko, S. J. Bae, S. Yun, 
 216 
J. H. Park, T. Kwon, W. S. Kim, J. Lee, Q. Lu, H.-R. Kang, W.-K. Cho, J. A. Elias, J.-S. 
Yang, H.-O. Park, K. Lee, and C. G. Lee. 2016. Self-assembled Micelle Interfering RNA 
for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis. J. Biol. 
Chem. 291: 6433–46. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 217 
VITA 
 
 Junsuk Ko was born in Seoul, Republic of Korea, the son of Jaesup Ko and 
Youngshin Lim. After completing his work in high school, Republic of Korea, he decided 
to pursue an undergraduate degree in the United States. He received the degree of 
Bachelor of Science (Sc.B.) in biochemistry and molecular biology with honors from 
Brown University in May 2015. While he was at Brown, he worked in Dr. Qing Lu’s Brown 
Vascular Laboratory for his honors project investigating the mechanisms of cigarette 
smoke-induced acute lung injury (ALI). After graduation from Brown, he joined the Ph.D. 
program at the University of Texas MD Anderson Cancer Center UTHealth Graduate 
School of Biomedical Sciences in Aug 2015. 
